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   “Reductionism was the driving force behind much of the twentieth century’s research. To 
comprehend nature, it tells us, we first must decipher its components. [: : :] Divide and 
conquer; the devil is in the details. [: : :] Now we are close to knowing just about everything 
there is to know about the pieces. But we are as far as we have ever been from understanding 
nature as a whole. [: : :] The reason is simple: Rising reductionism, we run into the hard wall 
of complexity. We have learned that nature is not a well-designed puzzle with only one way 
to put it back together. [: : :] It [Nature] does so by exploiting the all-encompassing laws 
of self-organization, whose roots are still largely a mystery to us. Today we increasingly 
recognize that nothing happens in isolation. [: : :] We have come to see that we live in a 
small world, where everything is linked to everything else. We are witnessing a revolution 
in the making as scientists from all different disciplines discover that complexity has a strict 










The Apolipoprotein E isoform E4 (ApoE4) is consistently associated with an elevated risk of 
developing late-onset Alzheimer's Disease (AD). However, little is known about his potential 
genetic modulation on the structural covariance brain networks during prodromal stages like 
Mild Cognitive Impairment (MCI). The covariance phenomenon is based on the observation 
that regions correlating in morphometric descriptors are often part of the same brain system. 
In a first study, I assessed the ApoE4-related changes on the brain network topology in 256 
MCI patients, using the regional cortical thickness to define the covariance network. The cross-
sectional sample selected from the ADNI database was subdivided into ApoE4-positive 
(Carriers) and negative (non-Carriers). At the group-level, the results showed a significant 
decrease in characteristic path length, clustering index, local efficiency, global connectivity, 
modularity, and increased global efficiency for Carriers compared to non-Carriers. Overall, I 
found that ApoE4 in MCI shaped the topological organization of cortical thickness covariance 
networks. 
In the second project, I investigated the impact of ApoE4 on the single-subject gray matter 
networks in a sample of 200 MCI from the ADNI database. The patients were classified based 
on clinical outcome (stable MCI versus converters to AD) and ApoE4 status (Carriers versus 
non-Carriers). The effects of ApoE4 and disease progression on the network measures at 
baseline and rate of change were explored. The topological network attributes were correlated 
with AD biomarkers. The main findings showed that gray matter network topology is affected 
independently by ApoE4 and the disease progression (to AD) in late-MCI. The network 
measures alterations showed a more random organization in Carriers compared to non-Carriers. 
Finally, as additional research, I investigated whether a network-based approach combined 
with the graph theory is able to detect cerebrovascular reactivity (CVR) changes in MCI. Our 
findings suggest that this experimental approach is more sensitive to identifying subtle 
cerebrovascular alterations than the classical experimental designs. This study paves the way 
for a future investigation on the ApoE4-cerebrovascular interaction effects on the brain 
networks during AD progression. 
In summary, my thesis results provide evidence of the value of the structural covariance brain 
network measures to capture subtle neurodegenerative changes associated with ApoE4 in MCI. 
Together with other biomarkers, these variables may help predict disease progression, 






L’isophorme E4 de l’Apolipoprotéine E (ApoE4) est systématiquement associé avec un risqué 
élevé de développer la maladie d’Alzheimer (MA) à début tardif. Cependant, on connait peu 
sa modulation génétique potentielle sur les réseaux cérébraux de covariance structurelle durant 
la phase prodromique, telle que les troubles cognitifs légers (MCI). Le phénomène de 
covariance est basé sur l’observation que les régions corrélant des descripteurs 
morphométriques font souvent parti des mêmes systèmes cérébraux. 
Dans une première étude, j’ai évalué les changements liés à ApoE4 sur la topologie des réseaux 
cérébraux chez 256 patients MCI, en utilisant l’épaisseur corticale régionale pour définir les 
réseaux de covariance. L’échantillon transversal sélectionné à partir de la base de données 
ADNI a été divisé en ApoE4-positif (Porteurs) et négatif (non-Porteurs). Au niveau des 
analyses de groupe, les résultats ont montré une diminution significative des caractéristiques 
«longueur de chemin», «index de cluster», «efficience locale», «connectivité globale», 
«modularité»; et une augmentation de l’«efficience globale» chez les Porteurs comparés aux 
non-Porteurs. 
Dans l’ensemble, j’ai trouvé que ApoE4 dans les MCI modèle l’organisation topologique des 
réseaux de covariance de l’épaisseur corticale. Dans un second projet, j’ai étudié l’impact 
d’ApoE4 sur les réseaux de matière grise au niveau de chaque sujet, dans un échantillon de 200 
MCI issu de la base de données ADNI. Les patients étaient classés sur la base de critère clinique 
(MCI stable versus en conversion vers la MA) et du statut ApoE4 (Porteurs versus non-
Porteurs). Les effets d’ApoE4 et de l’évolution de la maladie sur les réseaux cérébraux ont été 
examinés au point de référence ainsi que leur taux de changement. Les attributs des réseaux 
topologiques étaient corrélés avec des biomarqueurs établis de la MA. Les principales 
conclusions ont montré que la topologie des réseaux de matière grise est affectée 
indépendamment par ApoE4 et par l’évolution de la maladie (vers la MA) dans les MCI à début 
tardif. Les altérations des mesures de réseaux ont montré une organisation plus aléatoire chez 
les Porteurs comparés aux non-Porteurs. 
Finalement, comme recherche additionnelle, j’ai étudié si une approche basée sur les réseaux 
associée à la théorie des graphes peut permettre de détecter les changements de réactivité 
cérébro-vasculaire (RCV) dans les MCI. Nos conclusions suggèrent que cette approche 
expérimentale est beaucoup plus sensible pour identifier les altérations cérébro-vasculaires 
subtiles que les designs expérimentaux classiques. Cette étude ouvre la voie à une investigation 
future des effets d’interaction entre ApoE4 et la réactivité cérébro-vasculaire sur les réseaux 
cérébraux durant la progression de la MA. 
En résumé, les résultats de ma thèse prouvent la valeur des mesures de réseaux cérébraux de 
covariance structurelle pour saisir les changements neurodégénératifs subtils associés à ApoE4 
dans les MCI. Associées à d’autres biomarqueurs, ces variables devraient aider à prédire la 






LIST OF ABBREVIATIONS 
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MCI  Mild Cognitive Impairment 
ApoE  Apolipoprotein E  
ApoE4  Apolipoprotein E ε4 allele 
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E2 Allele 2  
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ADNI  Alzheimer Disease Neuroimaging Initiative 
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T-Tau  Total tau proteins 
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NFT  Neurofibrillary tangles 
sMRI  Structural Magnetic Resonance Imaging 
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CBF  Cerebral Blood Flow 
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DTI  Diffusion tensor imaging  
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HC  Healthy Controls 
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MMSE Mini Mental-State Examination 
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FSC  Functional Connectivity Strength 
PHF-Tau Hyperphosphorylated tau protein 
NC Normal Controls 
CVR Cerebrovascular reactivity 
PCC Posterior cingulate cortex 
NBC Normalized Betweenness Centrality 
ADNI-MEM Alzheimer Disease Neuroimaging Initiative Composite measures of executive 
function and memory 
ACZ Acetazolamide 
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1.1 Context and Motivation 
Dementia constitutes a prevailing public health crisis nowadays, and it is considered a 
pandemic by the International Federation of Alzheimer's Associations. The World Alzheimer 
Report 2019 estimates that over 50 million people are living with dementia globally. As the 
demographic shifts toward older ages and increases in health and longevity globally, this 
number is predicted to reach 75 million in 2030 (Prince et al., 2015), causing an ever-increasing 
percentage of the population with dementia, an enormous burden on caregivers and health 
systems. Late-onset Alzheimer's Disease (AD) is the most common cause of dementia, 
accounting for 60% to 80% of cases (Hardy, 1997). It is a progressive condition causing 
behavioral changes, memory loss, and a decline in learning capacity (McKhann et al., 2011). 
There are no disease-modifying treatments currently available for Alzheimer's. In the past 
decade, clinical drug trials have had a 99.6% failure rate (Cummings et al., 2014). The general 
postulate is that one contributor to this negative result is that brain pathology begins years 
before the onset of objective cognitive symptoms and maybe irreversible by the diagnosis time. 
It is now recognized that; AD is best conceptualized as a biological and clinical continuum 
covering both the preclinical (clinically asymptomatic individuals with evidence of AD 
pathology) and clinical (symptomatic phases: Mild cognitive impairment (MCI) and AD 
dementia)) (Aisen et al., 2017).  In this spectrum, MCI represents this transitional zone between 
the cognitive changes of aging and early AD (Ronald C. Petersen et al., 1999; Petersen, 2004) 
and a "window" in which it may be possible to intervene and delay dementia progression. 
Numerous international population-based studies have been conducted to document the 
frequency of MCI, estimating its prevalence to be between 15% and 20% in persons 60 years 
and older, with an annual rate of progression to dementia between 8% and 15% per year, 
implying that it is an essential condition to identify and treat (Petersen, 2016; Petersen and 
O’Brien, 2006). 
Although multiple risk factors are involved in AD pathogenesis, the E4 allele of the 
Apolipoprotein E (ApoE4) gene is recognized as the most potent genetic risk factor for late-
onset AD (Bu, 2009; Corder et al., 1993; Liu et al., 2013). The presence of the ApoE4 has been 
associated with an increased risk of progression from MCI to AD-type dementia (Elias-




question of why some MCI ApoE4 Carriers develop the disease while others seem not to be 
affected. 
There is an emerging consensus in neuroscience that most major psychiatric disorders, 
including AD, arise from the dysfunction of spatially distributed, interconnected neural 
systems (Deco and Kringelbach, 2014; Fornito et al., 2015). Advances in the application of 
network science and graph theory have permitted detailed descriptions of diverse disease 
processes based on the highly complex brain network organization (Fornito et al., 2016; 
Newman, 2010). The resulting network properties can be examined as "intermediate 
phenotypes" that are situated in this thesis, between the genetic domain (ApoE4) and the 
behavior (diagnosis, disease progression, cognitive measurements), offering an opportunity for 
a clinical research strategy. The complex etiology and multiple pathogenesis associated with 
the MCI progression into AD call for a development of a system-level biomarker. In this 
context a network-based approach will provide key insights to fully understand the network 
degeneration hypothesis and its association with the disease risk factors. From the brain 
imaging biomarker research there is clear evidence that the risk of disease progression in MCI 
evolve at the system level. As such a network based-biomarker can be used as an indicator of 
normal biological change (including aging adaptative mechanisms), pathogenesis processes, or 
pharmacological responses. In particular a network approach provides quantitative 
characterization of the brain and integrate heterogenic data in a general mathematical body 
paving the way for a predictive, preventive, and personalized medicine. 
Like many other approaches before, there is a challenging open question regarding the MCI 
population: how can we identify those patients at high risk for AD progression? Which ApoE4 
Carriers are going to be more affected by the disease? Ongoing clinical trials use either the 
increased genetic risk or positive amyloid biomarkers as useful strategies to predict 
progression. However, cerebral amyloid-beta deposition is a necessary yet insufficient 
condition for late-onset AD (Karran et al., 2011), while the genetic is neither necessary nor 
sufficient (Bertram and Tanzi, 2012; Goldman et al., 2011). 
In this thesis, I considered a different methodological approach that focuses on studying the 
network-level brain integrity in MCI, considering the ApoE4 as a risk factor. From this 
perspective, I may identify network attributes that predict risk for AD progression, providing 
an opportunity for intervention efforts. A better understanding of how the pathological changes 
in AD affect brain networks and how they respond to accumulating pathology might offer 




However, AD's overt clinical phenotype is complex and comprises neurocognitive, 
neurobehavioral, and psychiatric symptoms (McKhann et al., 2011). Given this complexity, it 
is challenging to link AD's end clinical phenotype to specific genetic underpinnings like ApoE4 
in the MCI phase. Using endophenotypes, or intermediate phenotypes, like brain network 
properties, I hope to fill in the gaps between genetic risk variability and higher-level behavioral 
MCI phenotypes (Gottesman and Gould, 2003). 
1.2 Mild Cognitive Impairment as an intermediate phase in Alzheimer's Disease. 
During AD progression, there are three broad phases: preclinical AD, MCI, and possible or 
probable AD (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011). AD spectrum is 
defined as a progressive and irreversible neurodegenerative disorder characterized by memory 
loss and cognitive decline that impair a person's ability to function in daily life (Masters et al., 
2006) along with evidence of AD-related brain changes of accumulation of extracellular 
amyloid β in the form of plaques (Aβ) and the intracellular accumulation of 
hyperphosphorylated tau proteins as neurofibrillary tangles (NFTs) (Hyman et al., 2012; 
Montine et al., 2012). The length of each phase on the AD continuum is influenced by age, 
genetics, gender, and other factors (Vermunt et al., 2019). A definitive diagnosis of AD can 
only be made postmortem through an autopsy, which shows the occurrence of Aβ and NFTs 
pathology in the brain (McKhann et al., 1984). 
Following the 2011 Alzheimer's Association published revised guidelines (NIA-AA), the 
concept of "MCI due to AD" is used to identify those symptomatic but non-demented 
individuals whose primary underlying pathophysiology is AD (Albert et al., 2011). Like AD 
dementia, MCI due to AD cannot be currently diagnosed by a laboratory test but requires a 
clinician's judgment. Also, similar to AD dementia, other pathophysiological processes may 
coexist in an individual who meets the criteria for MCI due to AD. MCI patients report a 
subjective memory concern either autonomously or via an informant or clinician. However, 
daily living activities are essentially preserved, there are no significant impairment levels in 
other cognitive domains, and no signs of dementia exist. Levels of MCI (early or late) are 
determined using a memory test like the Wechsler Memory Scale Logical Memory II. 
Diagnostic and research criteria for MCI have been suggested by Petersen (2004), who 
proposed two clinical subtypes of MCI amnestic and non-amnestic. In most of the studies, the 
criteria have focused on the amnestic form of MCI (Ronald C. Petersen et al., 1999; Petersen, 
2004).  The two major subtypes, amnestic and non-amnestic, can be further subdivided into 




of amnestic MCI lead to AD at a high rate (Lopez et al., 2003; Petersen, 2004).  Though MCI 
does not always lead to AD, some patients remain stable or revert to a normal state (up to 44%)  
while others progress to different brain pathologies (15-41%) (Grundman et al., 2004; 
Hänninen et al., 2002). Identifying which MCI are more likely to develop AD or other 
dementias is a major goal of biomarker's current research. 
In terms of clinical diagnosis is essential to clarify that this thesis follows the NIA-AA's 
guidelines (Sperling et al., 2011). The patient's samples were selected from ADNI, an open 
public database, that applies this criterium (http://adni.loni.usc.edu/). Here, AD will refer to the 
late-onset (non-familiar) disease form. MCI term (amnesic subtype) is considered due to AD 
under ADNI clinical protocol (For ADNI clinical protocols, see http://adni.loni.usc.edu/wp-
content/themes/freshnews-dev-v2/documents/clinical/ADNI-1_Protocol.pdf).  
In particular, ADNI I project criteria for these patients are as follows: MMSE scores between 
24-30 (inclusive), a memory complaint, have objective memory loss measured by education 
adjusted scores on Wechsler Memory Scale Logical Memory II, a CDR of 0.5, absence of 
significant levels of impairment in other cognitive domains, essentially preserved activities of 
daily living, and an absence of dementia (R C Petersen et al., 1999; Petersen, 2003). The 
clinical performance characteristics of these subjects are intermediate between normal control 
subjects and subjects with very mild AD. 
1.2.1 Pathogenesis of MCI  
Despite the scientific community's effort, we still do not fully understand the cause and 
pathology of MCI. Previous studies showed that persons with MCI often meet the minimal 
pathologic criteria for AD (Bennett et al., 2005; Galvin et al., 2005; Markesbery et al., 2006; 
Saito and Murayama, 2007). Their AD brain pathology is typically intermediate between 
persons with and without clinical AD (Bennett et al., 2005; Markesbery et al., 2006; Petersen 
and O’Brien, 2006; Sabbagh et al., 2006). Nevertheless, MCI is a heterogeneous disorder; 
autopsy studies confirmed this heterogeneity with individual cases demonstrating non-AD 
pathology, such as hippocampal sclerosis, infarcts, or subcortical ischemic vascular disease, 
despite similar cognitive characterization (Jicha et al., 2006; Petersen and Morris, 2005). As an 
intermediate state, MCI shares, to a certain degree, the histopathological hallmarks of AD: the 
extracellular aggregates of Aβ plaques and intracellular aggregations of neurofibrillary tangles 
(NFTs) (Crews et al., 2010; Iqbal and Grundke-Iqbal, 2002; Mandelkow and Mandelkow, 




The leading Amyloid hypothesis (Hardy and Higgins, 1992) proposed a model where an 
imbalance between production and clearance of Aβ is an initiating factor of AD. Amyloid 
pathogenesis starts with altered cleavage of APP to produce insoluble Aβ fibrils. Aβ then 
oligomerizes, interfering with synaptic signaling. The Aβ40 and Aβ42 are two main types of Aβ 
polymers that directly affect plaque formation and induced neurotoxicity. In this hypothesis, 
increased levels of Aβ causes aggregation of hyperphosphorylated tau (P-tau) protein and NFTs 
(Hardy and Higgins, 1992), the second neuropathological hallmark in AD (Braak and Braak, 
1991; Braak and Del Trecidi, 2015; Hyman and Gomez-Isla, 1994). When the tau protein 
gets hyperphosphorylated, this leads to its being oligomerized. The tubule gets unstable and 
aggregate into NFTs. These NFTs lead to abnormal loss of communication between neurons 
and, finally, apoptosis. These pathological processes' downstream consequences include 
neurodegeneration with synaptic and neuronal loss leading to macroscopic atrophy (Serrano-
Pozo et al., 2011). 
1.3 ApoE4 as a genetic risk factor for MCI and AD progression  
The Apolipoprotein E ε4 allele (ApoE4) is the most prominent risk factor in late-onset AD 
(Bekris et al., 2010; Bookheimer and Burggren, 2009; Liu et al., 2013). As we can see in Figure 
1, the lipoprotein is a carrier of cholesterol produced in ApoE alleles (ε2, ε3, ε4), which 
combine to generate five possible genotypes listed in order of increasing risk for AD: ε 2/2, ε 
2/3, ε 3/3, ε 2/4, ε 3/4 and ε 4/4 (Kauwe et al., 2009) by a factor 3 (heterozygous) to 12 
(Homozygous) (Corder et al., 1993; Farrer et al., 1997).  ApoE is essential for normal lipid 
homeostasis in the brain (Bu, 2009; Holtzman and Herz, 2012). There is growing evidence that 
ApoE4 genotype influences multiple physiological pathways in AD (Mahley et al., 2006). 
Mechanistically, ApoE4 has been linked to virtually every AD-relevant pathogenic process 
both directly through Aβ binding and indirectly through Aβ-independent pathways (lipid 
transfer, cell metabolism, repair of neuronal injury, ischemia, inflammation, amyloid-β peptide 
accumulation) (Liu et al., 2013; Shi et al., 2017; Teter et al., 2002; Tiraboschi et al., 2004). 
Relative to the common ε3 allele, possession of at least one ε4 allele increases the risk of AD 
progression of three to 15 times and earlier age on onset by 10 to 20 years as compared to non-
Carriers (Farrer et al., 1997; Raber et al., 2004; Roses, 1996; Thal et al., 2006). In general, 
epidemiological studies have shown that members of the general population are at an 




degree relative who has AD have a 2- to 4-fold increase in risk (Plassman et al., 2007; Slooter 
et al., 1998). 
 
 
Fig 1 | ApoE isoforms and structural differences A) Structural conformation differences between Apolipoprotein 
E (ApoE) 3 and 4 B) ApoE gene structure, polymorphism of ApoE isoforms, and the different changes of the 
nucleotides and aminoacids of each isoform. Modified from (Yamazaki et al., 2016) and (Mahley and Huang, 
2012). 
 
Likewise, ApoE4 prevalence is substantially higher in MCI than in control individuals (Elias-
Sonnenschein et al., 2011; Fleisher et al., 2007; Grundman et al., 2004). A meta-analysis 
revealed that the ApoE4 allele was associated with more than double the risk of progressing 
from MCI to AD across studies (Elias-Sonnenschein et al., 2011; Fei and Jianhua, 2013). 
During this time, ApoE4 interacts with other pathological factors to drive and shape this 
process. The well-documented ability of ApoE4 to accelerate and possibly induce amyloid 
accumulation is the most likely mechanism (Braak and Braak, 1997). Subtle pre-symptomatic 
changes in brain myelination, brain morphology, and cognitive functions may render ApoE4 
Carriers more vulnerable (Bartzokis, 2011). A "second hit" by another age-associated 
pathological factor must be present in addition to amyloid accumulation (Mahley and Huang, 
2009). This factor may be unrelated to the ApoE genotype or only weakly associated (e.g. 
tauopathy), such as any process placing increasing demand on neuronal repair during the MCI 
phase.  
Additionally, the E4 genotype combines synergistically with other risk factors such as 
atherosclerosis, peripheral vascular disease, and type 2 diabetes contributing to an increased 
risk of AD progression (Haan et al., 1999; Peila et al., 2002). The allele is a risk factor for 
cardiovascular disease, suggesting that it might have compounding effects on cognitive decline 




interacts with peripheral cardiovascular risk factors to impact cognition, and these factors share 
common downstream pathogenic properties: atherosclerosis, stroke, and Blood-Brain Barrier 
dysfunction (Tai et al., 2016). ApoE modulates Cerebral Blood Flow (CBF) when assessed 
using PET or SPECT. The higher CBF in MCI patients who are ApoE4 positive may indicate 
compensatory mechanisms in response to stress or of an ongoing pathogenic response affecting 
the vasculature. However, CBF is elevated in posterior brain regions with one risk factor such 
as ApoE4 or MCI, the presence of both results in decreased CBF and a greater likelihood of 
conversion to dementia.  
In this direction, there is evidence that ApoE4 has effects on brain structure and function that 
are not in themselves pathological but appear to make the brain more susceptible to age-
associated pathological mechanisms and environmental factors like diet. Diabetes, another 
well-known risk factor for AD, is strongly associated with disease progression among ApoE4 
Carriers (Matsuzaki et al., 2010; Peila et al., 2002). Patients with diabetes who are carriers of 
ApoE4 have more neuritic plaques and neurofibrillary tangles than noncarriers (Peila et al., 
2002)(Peila et al., 2002). Additionally, researchers have identified a close link between this 
allele and the cerebral iron-burden (Ayton et al., 2017, 2015). The authors' findings raise the 
possibility that ApoE4 confers susceptibility to AD via brain iron accumulation. Starting 
decades before a positive AD diagnosis, the iron influences beta-amyloid aggregation, tau and 
promotes neurotoxicity in the brain (Bartzokis et al., 2007; Ward et al., 2014).  
Finally, it is important to clarify that AD's genetics is more complex and not limited to ApoE4. 
Current thinking holds that the disease's susceptibility is conferred by numerous genetic risk 
factors of relatively high frequency but low penetrance and, therefore, small effect size (Karch 
and Goate, 2015). The genome-wide association studies identified more than 20 genetic loci 
associated with AD's risk (e.g., BIN1, CLU, CR1, and PICALM). These genes are implicated 
in the immune system and inflammatory responses, cholesterol, lipid metabolism, and 
endosomal-vesicle recycling (Guerreiro and Hardy, 2014). However, modern-day genetic 
studies showed that the link between an increased risk for AD and ApoE4 continues to be the 
lead association finding (Bertram et al., 2010; Scheltens et al., 2016). Still, environmental and 
epigenetic factors likely make an important contribution in determining an individual’s risk.  
1.3.1 Impact of ApoE4 on brain and cognition in MCI. Biomarkers 
Even though the presence of ApoE4 does not guarantee disease progression, several cognitive 




MCI and AD patients (Fig. 2).  Across studies, the more salient associations with the ApoE4 
are: (1) Carriers exhibit worse cognitive performance and accelerated cognitive decline in MCI 
and AD subjects (Bookheimer and Burggren, 2009; Cosentino et al., 2008; Farlow et al., 2004; 
Ramakers et al., 2008) (2) increased hippocampal, amygdala and cerebral atrophy (particularly 
in the temporal lobe) (Farlow et al., 2004; Jack et al., 1999; Rusinek et al., 2003) (3) decreased 
cerebral blood flow and glucose metabolism (frontal, temporal, parietal and occipital lobes) 
(Brandon et al., 2018; Haxby et al., 1990; Small et al., 2000) (4) asymmetric atrophy effects 
(right hippocampus and right temporal lobe) and decreased blood flow and glucose metabolism 
mostly in the left hemisphere (Drzezga et al., 2005; Mosconi et al., 2004) (5) more significant 
Aβ deposition in the brains (Fleisher et al., 2013; Mishra et al., 2018; Murphy et al., 2013). 
 
 
Fig 2 | The role of ApoE4 during Alzheimer disease progression. Key functional differences between ApoE4 and 
ApoE3 are illustrated. Abbreviations: Aβ, amyloid-β; ApoE, apolipoprotein E. Figure from (Liu et al., 2013). 
 
Evaluating the extent of AD brain pathology using biomarkers in MCI patients may provide 
clues regarding the biological mechanisms underlying progression. Specifically, impairments 
in delayed free-recall measures from episodic memory tasks (Gomar et al., 2011; Landau et al., 
2010), reduced hippocampal volumes (Devanand et al., 2007; Prestia et al., 2013; Vos et al., 
2013), decreased CSF levels of Aβ42 and elevations in T-tau and P-tau protein  (Buchhave et 
al., 2012; Dickerson and Wolk, 2013; Hansson et al., 2006; Mattsson et al., 2009; Toledo et 
al., 2014; Vos et al., 2013) are the best established predictive biomarkers of AD progression in 





Jack C.R et al. (2013, 2010) proposed a temporal ordering for the biomarkers mentioned above. 
Figure 3 shows an initial point of the development and accumulation of Aβ identified by CSF 
Aβ42 or PET amyloid imaging (Jack et al., 2013, 2010). 
Neuronal injury and dysfunction are identified by CSF tau or FDG-PET and neurodegenerative 
atrophy by sMRI. In MCI, genetic variation in the ApoE gene may shift the amyloid-beta (Aβ) 
and neurodegeneration curves, with individuals positive for ApoE4 showing a pathology 
occurring at an earlier age (Risacher and Saykin, 2013). 
 
Fig 3 | A) Revised dynamic biomarkers of the AD pathological cascade model – 2012. Aβ amyloid is identified 
by CSF Aβ42 (purple) or PET amyloid imaging (red). Elevated CSF tau (blue). FDG PET and structural MRI 
measure neurodegeneration, respectively, drawn concordantly (orange). The horizontal axis of disease progression 
is expressed as time. The cognitive response is illustrated as a zone (green filled area) with low and high-risk 
boarders. B) Panels show the modulation of biomarker curves by ApoE genotype. C) ApoE genotype and amyloid 
positivity. Estimated probabilities of amyloid positivity according to ApoE genotype, plotted against age in mild 
cognitive impairment (MCI). Shaded areas represent 95% CIs. ApoE4 individuals are more likely to be positive 
for amyloid pathology than individuals with any other genotype. Also, note that ApoE4 is a strong driver of Aβ 
positivity irrespective of ApoE2 or ApoE3. Modified from (Jack et al., 2013), (Risacher and Saykin, 2013) and 
(Yamazaki et al., 2019). 
 
Recently, Jack et al. (2016) proposed a fully biomarker-based diagnostic system for research: 
the AT(N) system. It is a binary system in which a patient, that is, e.g., A+T−N− has amyloid 
pathology (amyloid positive), normal tau levels (tau negative), and no abnormal 
neurodegeneration (Jack et al., 2018). However, the authors point out that this biomarker-based 
system should not be considered a template for all research; instead, it should be applied to fit 




Nevertheless, recent multifactorial data-driven analysis in AD have shown a different tentative 
temporal ordering of disease progression. The authors suggest that intra-brain vascular 
dysregulation is an early pathological event during disease progression (Iturria-Medina et al., 
2017, 2016). 
During the disease course, an incremental spread of pathophysiological hallmarks between 
brain regions is observed, suggesting the presence of a disconnection syndrome that disrupts 
brain networks (Brier et al., 2014; Delbeuck et al., 2007, 2003; Pievani et al., 2011; Selkoe, 
2002). However, it remains unclear which factors induce such dysfunction from a local site by 
interplaying adaptive and maladaptive mechanisms (Carrera and Tononi, 2014; Fornito et al., 
2015; Klupp et al., 2014). 
This hypothesis implies the necessary application of a brain network-based approach in MCI 
research because local disruptions in such complex networks may have unpredictable and 
widespread effects (Gratton et al., 2012). 
 
1.4 Network neurosciences and Graph Theory to study brain networks in MCI and 
AD 
1.4.1 Networks of structural covariance 
In the Network neuroscience context, a network is conformed by two essential ingredients: (a) 
a structure (or graph, topology) that can be associated with "hardware" and (b) a function (or 
process, related to "software"). This approach addresses a fundamental limitation to univariate 
and many standard multivariate techniques that do not always represent the complex 
relationships between neural systems, genes, and behaviors (Bassett and Sporns, 2017; Mišić 
et al., 2016). The human connectome is a comprehensible map of the brain's circuitry, 
consisting of brain areas, structural connections, and functional interactions (Hagmann, 2005; 
Sporns et al., 2005). The connectome can be explored with various neuroimaging techniques, 
but sMRI has a prevalent use due to its near-ubiquity, non-invasiveness, high resolution, and 
broad applicability in clinical settings (Craddock et al., 2013). Depending on the neuroimaging 
technique, at least three different brain network classes can be studied (Friston, 1994; Sporns, 
2011): functional, structural (axonal), and networks of structural covariance.  
The structural covariance networks represent the statistical interdependencies of morphological 
features between different brain regions, as is shown in figure 3 (Bassett et al., 2008; He et al., 
2007; Lerch et al., 2006; Sanabria-Diaz et al., 2010). The coordinated variations of brain 




found in many sMRI studies (Andrews et al., 1997; Bullmore et al., 1998; Lerch et al., 2006; 
Mechelli et al., 2005; Wright et al., 1999; Zielinski et al., 2010). 
It has been demonstrated that brain regions that are highly correlated in size are often part of 
systems subserving particular behavioral or cognitive functions. The spatial proximity between 
brain regions is suggestive of the presence of white matter tracts (Honey et al., 2009; Kaiser 
and Hilgetag, 2006), a coupling of their intrinsic functional activity (A. F. Alexander-Bloch et 
al., 2013; Honey et al., 2009; Salvador et al., 2005) and implies higher-than-average structural 
covariance. These relationships are, in turn, influenced by direct white matter connections and 
functional coactivation and probably also by other genetic and environmental factors (for a 
review, see (A. Alexander-Bloch et al., 2013). 
The studies that address the structural covariance brain networks use one out of three 
experimental approaches: seed analysis, principal component analysis, or graph theory 
framework. This thesis focuses on the last method. 
1.4.2 Graph theory formalism to study the topological organization of brain networks. 
Graph theory– a branch of mathematics concerned with modeling systems of interacting 
elements – provides a unifying and robust framework for characterizing the human 
connectome. In general, a complex network can be represented as a graph G=[N,K], the 
components of this system are called nodes (N), and the relations or connections between them 
are called edges (K) (Boccaletti et al., 2006). The nodes anatomical location in a given network 
is referred to as topography, and the architecture of their connections, referred to as a topology. 
In addition to the type of connectivity being examined, networks can also be differentiated into 
binary versus weighted. A specific threshold is applied to the connections in binary networks, 
resulting in either present or absent edges. In weighted networks, on the other hand, edges also 
contain information about connection strength. Directed versus undirected is another 
classification of networks. Connections (edges) of an undirected network do not include any 
direction contrary to directed graphs that contain some direction information. Once the nodes 
and edges have been defined, all information can be summarized in the connectivity or adjacent 
matrix. In such matrices, rows and columns represent nodes, while matrix entries denote links. 
A network's topological properties can be examined by a rich array of graph metrics based on 
the connectivity matrix. In this thesis, the structural covariance analysis corresponds to a binary 




Graph metrics can be classified mainly into measures covering segregation, integration, and 
centrality properties in the network (for a review, see (Rubinov and Sporns, 2010)). 
'Segregation' refers to the ability for specialized processing to occur within densely 
interconnected groups of brain regions. For example, the 'clustering coefficient' of a node is an 
essential measure of segregation, quantifying the number of connections that exist between the 
direct neighbors of a node as a proportion of the maximum number of possible connections 
(Watts and Strogatz, 1998). The average clustering coefficient across all network nodes is the 
clustering index of the network. Modularity is another measure of segregation, which describes 
densely interconnected nodes (Girvan and Newman, 2002; Guimerà and Amaral, 2005). 
'Integration,' on the other hand, relates to the network's capacity to rapidly combine specialized 
information from distributed brain regions. Measures of integration are commonly based on 
the path lengths representing the number of steps between two nodes. Hence, shorter paths 
implying a stronger potential for integration. At the network level, it is translated to the 
'characteristic path length' of the network, calculated as the average shortest path length 
between all pairs of nodes. A related measure is 'global efficiency' (Latora and Marchiori, 
2001), defined as the average inverse shortest path length. 
'Centrality' measures describe the importance of network nodes and edges to network 
functioning. The most straightforward index of centrality is the node 'degree,' the number of 
links connected to a given node. Another measure of importance is 'betweenness centrality,' 
defined as the fraction of all shortest paths in the network that pass through a given node (edge). 
Both measurements are critical in global information integration between different network 
parts, so-called 'hubs' (Sporns et al., 2007). Network robustness is then typically assessed by 
measuring the graph's ability not to fragment into subgraphs when elements of the graph are 
removed (Kaiser et al., 2007; Sporns et al., 2004). To calculate the networks' resilience, two 
types of attacks are commonly investigated (Bullmore and Sporns, 2009): random deletion of 
nodes/edges and targeted attack of nodes/edges based on their centrality. 
Finally, to examine Small-world (σ), the values of characteristic path length and clustering 
index are compared with the same metrics estimated in random networks with the same number 
of nodes, average degree (average of the degree over all node, where the degree of a node 
corresponds to the number of connections to that node), and degree distribution (the probability 
that a randomly selected node has k connection) as the network of interest (Achard et al., 2006; 
Watts and Strogatz, 1998). A small-world network is characterized by a clustering coefficient 
greater than that of an equivalent random network, yet it has approximately the same 




network topology is commonly thought to reflect an optimal balance between segregation and 
integration (Watts and Strogatz, 1998). There is mounting evidence that healthy structural and 
functional brain networks also show this kind of organization across various modalities (Stam, 
2010). 
1.4.3 Networks of structural covariance: Group and single-subject-based workflows 
Group level approach: It has been used in most previous studies of structural covariance brain 
networks in MCI and AD (Melie-Garcia et al., 2013; Sanabria-Diaz et al., 2013, 2010; Sánchez-
Catasús et al., 2017). Here the morphometric properties in multiple subjects have the same 
statistical role for structural covariance analysis as brain activations measured at multiple time 
points for functional connectivity analysis. This group-based approach does not allow 
correlation analyses to be performed with individual clinical despite providing useful 
information measures (Fig.4). 
The workflow comprises two main steps: 
Step 1. Computation of morphometric descriptor matrices: Briefly, the cortical 
reconstruction and volumetric segmentation are performed using dedicated software (i.e., 
Freesurfer). The parcellation of the cerebral cortex based on a reference atlas (i.e., 
Destrieux sulci-gyral-based atlas) allows the calculation of the regional mean value 
descriptor (i.e., cortical thickness) for each cortical structure. The outputs are used to 
construct a data matrix for each group. The number of rows corresponds to the number of 
subjects, while the number of columns corresponds to the number of structures (For details, 
see Study 1, Fig 1). 
Step 2. Networks of structural covariance construction: Here, the connectivity matrices are 
computed. First, a connection is defined as the statistical associations between each pair of 
brain regions for an anatomical brain parcellation scheme defined in Step 1. The 
synchronized changes in the morphometric descriptor between two regions are computed 
using an association measure (i.e., Pearson’s or Partial correlation) across subjects. Thus, 
the interregional correlation matrix (N×N, N is the number of brain regions) of such 
connections is obtained using all pairs of anatomical structures. Self-connections are 
excluded implying zeros in the diagonal of the symmetric matrix. Before the correlation 
analysis, linear regression is performed in every region to remove confounding effects such 
as age, gender, age-gender interaction, and cerebral mean morphometric values (For details, 
see Study 1, Fig 2). In order to calculate the AUC network measure values a range of 




each connectivity matrices) are calculated to obtain different matrix sparsity denote as 
‘sparsity degree’. A sparsity degree of 0.9 means that 90% of the connectivity matrix is off, 
and only the highest 10% of the connectivity values were taking into account. The sparsity 
degrees are computed for sparsity degrees ranging from 0.5 to 0.9, in step of 0.02. This 
procedure normalizes the networks to have the same number of nodes and edges, allowing 
the examination of the relative network properties and morphometric descriptor obtained 
for each group. The range of sparsity degree was chosen to allow for all network properties 
to be properly estimated and the number of spurious edges in each network minimized as 
indicated in previous studies (Achard and Bullmore, 2007; He et al., 2007; Sanabria-Diaz 
et al., 2013).  
 
 
Fig 4 | Flowchart of structural covariance analysis. (A) Choice of brain atlas and computation of cortical measures. 
(B) Multiple subjects in one data set. (C) Data matrix construction with brain region of all subjects. Typically at 
this point, a confounding effects correction is performed. (D) Computation of the correlation between all pairs of 
brain regions. (E) Gathering all correlations in a matrix termed ‘structural covariance connectivity matrix’. 
 
Study 1 applies this approach using cortical thickness as a morphometric descriptor. Cortical 
thickness has been proposed as a more stable parameter for AD diagnosis than volume/density 




used in various studies as markers to separate AD patients from healthy controls and MCI 
subjects (Chételat et al., 2005; Desikan et al., 2009; Hutton et al., 2008; Singh et al., 2006). 
Besides, attempts to distinguish progressive-MCI from stable-MCI by analyzing the baseline 
cortical thickness have also been reported (Querbes et al., 2009). 
 
Single-subject-based approach: Figure 5 illustrates the flowchart of the automated method 
used to construct the single-subject gray matter networks, which has been described previously 
(Batalle et al., 2013; Dicks et al., 2018, 2020; Rimkus et al., 2019; Tijms et al., 2013a, 2014, 
2018). It is overcome the group level approach's main limitation by providing a method that 
can create individual structural covariance networks. 
 
Fig 5 | Schematic overview of the pipeline to extract single-subject gray matter networks. The resulting gray 
matter segmentation is divided into voxel cubes (1). The similarity between all cubes is computed with the 
correlation coefficient (2), and the maximum similarity value over multiple rotations is stored in a similarity 
matrix (3). This matrix is then thresholded to include similarity values that crossed the significance threshold of 
0.05, corrected for multiple comparisons. For each binarized graph, random graphs are generated that kept intact 
the size and degree distribution (4). For all graphs, the network attributes are computed (5). Finally, are determined 
across subjects the correlation between the network properties and other measures (6). Figure modified from 
(Tijms et al., 2014). 
 
The workflow is composed of two main steps: 
Step 1. Image acquisition and preprocessing: Anatomical images are segmented into gray 
matter, white matter, and cerebrospinal fluid. In the native space gray matter segmentation 
of each subject, anatomical areas are identified based on an automated anatomical labeling 
atlas (i.e., AAL; (Tzourio-Mazoyer et al., 2002)). 
Step 2. Single-subject gray matter network computation: the network's nodes are defined 
as small regions of interest of N x N x N voxel cubes (e.g., 3 x 3 x 3) in the native space 
gray matter segmentations. The correlation coefficient expresses the similarity between 
nodes in the network. Given that the cortex is a curved object, two similar cubes could be 
located at an angle from each other, decreasing their similarity value. Therefore, the 
maximum correlation value is computed over different rotations of the seed cube. Regions 




undefined. Next, the similarity matrices are binarised to construct unweighted and 
undirected graphs after determining each graph's threshold correcting for multiple 
comparisons. Finally, network attributes are assessed (Rubinov and Sporns, 2010). 
 
Study 2 applies this approach using gray matter volume similarity extracted from sMRI (Tijms 
et al., 2012). Intracortical similarity has been associated with coordinated growth patterns, 
functional coactivation, and axonal connectivity (A. Alexander-Bloch et al., 2013; Gong et al., 
2012). Previous studies have shown that gray matter networks are disrupted in AD (Pereira et 
al., 2016; Tijms et al., 2013a; Yao et al., 2010), associated with cognitive impairment (Tijms 
et al., 2013a, 2014) and related to faster disease progression and cognitive decline in the 
predementia stage of AD (Dicks et al., 2018; Tijms et al., 2018; Verfaillie et al., 2018). 
Furthermore, disrupted gray matter network organization has been associated with aggregating 
amyloid in cognitively normal individuals (ten Kate et al., 2018; Tijms et al., 2016) and before 
overt atrophy is evident (Voevodskaya et al., 2018). 
1.5 ApoE4 impact on the brain networks in MCI and AD 
1.5.1 Previous studies of the networks of structural covariance in MCI and AD using graph 
theory 
Table 1 shows preceding studies demonstrating that MCI and AD patients have aberrant 
structural covariance network topology showing greater segregation and disrupted integration. 
(Tijms et al., 2013b; Xie and He, 2012). In AD compared to controls, the results indicated a 
higher characteristic path length, a reduced global efficiency as well as higher local clustering 
index (He et al., 2008; Lo et al., 2010). Additionally, patients showed a loss of balance between 
segregation and integration reflected in the small-world attribute and a redistribution of hub 
regions (Y He et al., 2009; Sanabria-Diaz et al., 2013; Sanz-Arigita et al., 2010; Stam et al., 
2009; Supekar et al., 2008; Yao et al., 2010).  In particular, MCI's network showed intermediate 
topological attributes supporting the view of MCI as a transitional stage between normal aging 
and AD (Dai and He, 2014; Tijms et al., 2013b; Xie and He, 2012). 
It could be hypothesized that these network alterations are related to pathological disease 
features (amyloid-beta (Aβ) plaques and neurofibrillary tangles) in one region of the brain. 
It may capture the earliest neurodegenerative changes in MCI, predicting future atrophy in 
more distant brain areas. In this way, regions that covaried in their cortical thickness e.g., will 




both regions atrophy uniformly. Increasing evidence indicates that network topology changes 
during AD progression (Pereira et al., 2016; Yao et al., 2010) already start at early, preclinical 
stages (Tijms et al., 2016). 
Therefore, brain network measures might have promise as prognostic biomarkers for future 
cognitive decline in MCI. However, it needs to be noted that no previous studies were exploring 
the ApoE4-related effects on the structural covariance brain networks in MCI using sMRI. 
Such analysis could provide important clues into which network topology changes mark the 
transition to AD and improve our understanding of how the ApoE4 and the disease progression 
affect the brain networks.  
 
Table 1. Previous studies using sMRI and graph theory approach to explore the Networks of 
structural covariance in MCI and AD. 
Study N Network Properties Main Findings 
 He et al., 2008 97 NC 
92 AD 
 
Cp, Lp, SW, BC, TA, 
hubs 
Cp (AD>NC); Lp (AD>NC) 
BW (AD<NC); TA (AD>NC)  
MCI intermediate topology 
Yao et al., 2010 98 NC 
113 MCI 
91 AD 
Cp, Lp, SW, BC, hubs Cp (AD>NC), Lp (AD>NC)  
BW (AD, MCI<NC) 
MCI intermediate topology 
Tijms et al., 2013 38 NC 
38 AD 
Dg, Cp, Lp, SW, BC 
(regional and global), 
hubs  
Cp (AD<NC); Lp (AD<NC) 
SW(AD<NC); BC (AD<NC)  
MMSE scores associated with Lp in AD 




Cp Cp (< pMCI in time) 
 Cp< olfactory cortex region in AD  
Indicates degenerated wiring efficiency of the brain 
network due to AD 
Dicks et al., 2018 258 MCI 
(100 sMCI; 
115 pMCI)  
Cd, Dg, Cp, Lp, SW,  
BC, hubs.  
SW (pMCI<sMCI) 
Lower SW associated with cognitve decline. 
Lower BC correlated with a faster decline in MMSE. 
Disrupted network properties were related to worse 
cognitive impairment. 






Cp, Lp, SW, M, Ts, 
Cp-n, BC, w-MDg, Pc 
Cp (lMCIc, eMCIc, and AD<NC)  
Ts (patients<NC), M (patients>NC)  
BC ( sMCI, lMCIc, eMCI,  AD <NC) 
 M (4 NC, 3 sMCI, lMCIc, and eMCIc ; 5 modules AD) 
Prodromal and clinical stages of AD are associated with 
an abnormal network topology 
Dicks et al., 2020 71 NC 
110 pAD 
Ns, Cd, Cp, Lp, nCp, 
nLp, SW 
 SW (AD<NC) 
 Ns and Cd (AD>NC): associated with progression 
low Cp and high Lp: associated with early amyloid 
accumulating.  
Gray matter network measures may have use for 
identifying those individuals with preclinical AD who 
will show disease progression before overt atrophy 
Legend:sMCI: stable MCI; pMCI: progressive MCI; lMCI: late MCI; eMCI: early MCI; nLp: nodal characteristic ptah length; Cp: clustering 
index; Lp: characteristic path length; SW: small world; BC: betweenness centrality; TA: target attack; Ns: network size; Cd: connectivity 
density; Dg: degree; M: modularity; Ts: transitivity; nCP: clustering index nodal; w-MDg: within module degree; Pc: participation coefficient; 







1.5.2 Previous studies of ApoE4 effects on the brain networks in AD using graph theory. 
Despite the interest in assessing the network of structural covariance in MCI, the inclusion of 
the ApoE4 in previous studies has been scarce to date, limited to healthy aging subjects and 
AD patients (Brown et al., 2011; Goryawala et al., 2015; Seo et al., 2013; Wang et al., 2015; 
Yao et al., 2015; Zhao et al., 2012). I summarized the few previous studies' main results in 
Table 2. It is essential to highlight that there is one used sMRI in a healthy aging sample  
(Goryawala et al., 2015), while Yao et al. (Yao et al., 2015) included, for the first time, MCI 
patients to explore the metabolic networks in Carriers and non-Carriers. However, they mixed 
the healthy, MCI, and AD subjects, challenging interpreting the ApoE4 effects on MCI. 
 
Table 2. Previous studies on the ApoE4-related effects on the brain networks in NC, MCI, and 
AD using graph theory  




Brown et al., 
2011 
DTI 30 NC non-
Carriers 
25 NC Carriers 
Lc, Gi, SW 
 
mean Lc (Carriers<non-Carriers)  
SW (Carriers<non-Carriers) 
loss in MCT (Carriers>non-Carriers)  
Carriers: negative correlations of age and 
performance on two episodic memory 
tasks 




28 NC Carriers 
 
Cp, Lp, SW, BC 
 
Cp (Carriers<non-Carriers)  
Lp (Carriers<non-Carriers) 
Hubs (Carriers<non-Carriers)  
BC-Hippocampus (Carriers<non-Carriers)  
BC- Precuneus (Carriers> non-Carriers) 
Regional cerebral glucose metabolism 
(Carriers< non-Carriers)  
Goryawala et al., 
2015 
sMRI 106 NC non-
Carriers 
41 NC Carriers  




interregional correlation coefficients 
(Carriers> non-Carriers) (precentral, 
superior frontal and inferior temporal 
regions) 
Cp (Carriers>non-Carriers) 
Lp (Carriers>non-Carriers)  
BC (non-Carriers> Carriers) (several 
regions middle temporal, para-
hippocampal gyrus, posterior cingulate and 
insula)  
Yao et al., 2015 rsFDG-
PET 
NC, MCI, AD 
mixed in 
165 Carriers  
165 non-Carriers 




Cp (Carriers<non-Carriers)   
BC (Carriers<non-Carriers) (left insula, 
right insula, right anterior 
cingulate, right paracingulate gyri, left 
cuneus) 
Local short distance interregional 
Correlations (Carriers>non-Carriers)  
Carriers: disrupted long distance 
interregional correlations 
Wang et al., 2015 rsfMRI 26 AD non- 
Carriers 
16 AD Carriers 
 








 Eloc, Eglob, M (Carriers<non-Carriers)  
DMN connectivity (Carriers<non-Carriers)  





Zhu et al., 2018 rsfMRI 28 aMCI Carriers  
38 aMCI non-
Carriers 
FCs  ε4-related FCs increases in the right 
HIP/PHG 
Carriers: lower or higher FCs between the 
right HIP/PHG and MPFC or the occipital 
cortex 
Carriers: FCs values in the right HIP/PHG 
and lower HIP/PHG-RSFCs with the 
bilateral MPFC correlated with the 
impairment of episodic memory  
Executive function in the HIP/PHG-FCs 
with MPFC predicted aMCI-conversion to 
AD 
Li Y et al., 2019 PHF-Tau-
PET 










Cp, Lp, M, BC 
 
Non-Carriers T− showed significant 
differences in Cp, Lp, M compared with 
the other 3 groups. 
Carriers T+ < Cp  
Carriers T− < Cp, Lp and Q 
Non-Carriers T+ < Cp, Lp, M 
BC showed significant differences in some 
regions for the Carriers T+ compared with 
the non-Carriers T−  
Compared with ApoE4−T− group, the 
other three groups showed significant 
regional differences in nodal properties 
Legend: MCI: Mild Cognitive Impairment; AD: Alzheimer Disease; NC: healthy controls; aMCI: amnesic Mild Cognitive Impairment; Cp: 
clustering index; Lp: characteristic path length; SW: small world; BC: betweenness centrality; M: modularity; Ns: nodal strength; Lc: Local 
interconnectivity; Gi: Global integration; Eglob: global efficiency; Eloc: local efficiency; MTC: mean cortical thickness; FCs: functional 
connectivity strength; HIP: hippocampus; PHG: parahippocampal gyrus; T+ CSF T-Tau pathology positive; T-: CSF T-Tau pathology 
negative; DTI: diffusion imaging; rsFDG-PET: resting-state fluorodeoxyglucose Positron emission tomography; rsfMRI: resting-state 
functional magnetic imaging; PHF-Tau-PET: PHF-Tau Positron Emission Tomography 
 
These findings suggest that the ApoE4 allele modulate the large-scale brain network in AD, 
indicating disease-related disconnection mechanisms (Delbeuck et al., 2003; Filippi and 
Agosta, 2011; Yong He et al., 2009). Moreover, they provided new insights into the 
understanding of AD's biological mechanism that could lead to using a network-based imaging 
biomarker for disease diagnosis and monitoring. 
1.6 Thesis Aims 
Based on the evidence above, to my best knowledge, there are no previous studies focused on 
how ApoE4 affects the topological organization of the covariance brain networks in MCI. 
Significantly, has still not been explored the interaction effect between ApoE4 and AD 
progression on these networks. Therefore, the aims of this thesis are the following: 
 
1. To investigate the effect of ApoE4 on the structural covariance brain networks in MCI 
patients (ApoE4 Carriers versus non-Carriers). 
This aim is addressed in Study 1. I investigated the ApoE4-related modulation of the 
topological organization of cortical thickness covariance brain networks in MCI through sMRI 
using a graph-theory approach. The identification of these subtle alterations at the network 




I examined different features of the structural brain topology:1) regional cortical thickness, 2) 
global network attributes (clustering index, characteristic path length, local and global 
efficiency, global connectivity, and homologous region connectivity) 3) nodal properties 
(normalized betweenness centrality, hubs) 4) network community detection (modularity) and 
resilience to insults (target attack). 
 
2. To investigate the ApoE4-related changes on the single-subject structural covariance brain 
network associated with AD progression (stable MCI versus Converters into AD). 
3. To examine how the network properties alter with AD biomarkers of Aβ42, tau, 
neurodegeneration, and memory deficits in MCI associated with the ApoE4. 
These two aims were tackled in Study 2. I analyzed how ApoE4 affects the single-subject gray 
matter network's in MCI. Moreover, I evaluated the ApoE4 and disease progression interaction 
effects on these networks' topological properties. Such longitudinal follow-ups are required to 
reveal changes associated with the genetic risk allele per se and to be able to identify possible 
network properties alterations related to subsequent progression into AD. Additionally, the 
ApoE4 modulation on the association between the network topology and other 
neuropathological AD biomarkers (i.e., CSF Aβ42 and total tau levels) were explored. 
 
4. To investigate whether the topological network measures can detect vasodilatory-induced 
changes in the cerebral blood flow network in MCI. 
In this additional research, I investigated whether a network-based approach combined with 
the graph theory is able to detect cerebrovascular reactivity (CVR) changes in MCI. The 
findings suggest that this experimental approach is more sensitive to identifying subtle 
cerebrovascular alterations than the classical experimental designs. Notably, this study paves 
the way for my next investigation on the ApoE4- cerebrovascular interaction effects on the 
brain networks during AD progression. 
1.7 Thesis Outline 
In the previous sections of this Chapter, I provide a background of MCI and AD, and brain 
networks. The first subsection reviews the literature about MCI and AD regarding diagnostic, 
pathophysiology, and biomarkers. The second subsection is dedicated to describing the ApoE4 
as a major genetic risk for AD. The main concepts of the brain network framework and the 




AD are presented in the last subsection. Also, a review of previous studies focus on the impact 
of ApoE4 on the structural covariance brain networks topology in MCI and AD is introduced. 
The Studies 1 and 2, as well as additional research, are presented in Chapter 2. Study 1 (section 
2.1, Annex 6.1) explores the impact of ApoE4 on the brain networks of structural covariance 
in a cross-sectional MCI sample divided into ApoE4-positive ('Carriers') and ApoE4-negative 
('non-Carriers') selected from the Alzheimer Disease Neuroimaging Initiative (ADNI) 
database. I estimated the cortical thickness from sMRI to calculate the correlation among 
anatomical regions across subjects and build the cortical thickness covariance networks. At the 
group level, the topological network properties were described through the graph theory 
approach. 
In Study 2 (section 2.2, Annex 6.2) I investigated the influence of ApoE4 and the risk of AD 
progression on the brain network topology in MCI. This study used a single-subject-based 
approach to construct gray matter networks to investigate whether network properties at 
baseline predict disease progression. I also explored the association between the network 
topological properties, AD biomarkers (Aβ42, tau), and cognitive measurements. 
At the end of this Chapter is enclosed a brief presentation of an additional research study 
(section 2.3, Annex 6.3) developed during this thesis. This project proposed a new approach to 
investigate Cerebrovascular reactivity in MCI based on graph theoretical analysis of brain 
perfusion SPECT data. 
The thesis finalizes with a general discussion of my findings, the principal limitations, 





2 SUMMARY OF THE RESULTS 
2.1 Apolipoprotein E4 effects on Topological Brain Network Organization in Mild 
Cognitive Impairment 
2.1.1 Context 
This section is based on the article ‘Apolipoprotein E4 effects on Topological Brain Network 
Organization in Mild Cognitive Impairment’, Gretel Sanabria-Diaz, Lester Melie-Garcia, 
Bogdan Draganski, Jean-Francois Demonet, Ferath Kherif. (2021). Scientific Reports, volume 
11, 845. https://doi.org/10.1038/s41598-020-80909-7 (Annex 6.1).  
2.1.2 Summary of findings 
My findings revealed a decrease in global and homologous connectivity strength, clustering 
index, characteristic path length, local efficiency, modularity, and increased global efficiency 
in MCI Carriers compared to non-Carriers. MCI Carriers showed lower Normalized 
Betweenness Centrality (NBC) values in several brain regions. Together they indicate a 
topological organization more like a random network in this group of patients, a structure 
previously reported in MCI and AD subjects (Pereira et al., 2016; Tijms et al., 2013a, 2018).  
I found a decrease in global connectivity strength- an aggregate measure of the correlation 
values between all possible pairwise anatomical structures- in MCI Carriers relative to non-
Carriers. Previous studies did not report on this network property (Ma et al., 2017; Wang et al., 
2017; Yao et al., 2015).  
The nodal properties results allowed me to generate hypotheses about the ApoE4 impact on 
brain network integration and segregation in MCI. My findings showed agreements with 
previous studies in AD neurodegeneration. The fact that crucial structures like Posterior 
Cingulate Cortex (PCC) and the Precuneus showed lower NBC values in the Carriers group 
suggests that regional topological properties may capture disease-related effects that can be 
further explored in association with the risk of AD progression. Notably, for all detected hubs, 
regions considered critical for the brain's information flux, lower NBC values were found in 
Carriers than non-Carriers. Some of these structures belong to the Default Mode Network 
(DMN) involved in self-referential functions such as episodic memory (Buckner et al., 2008) 
affected by AD.  ApoE4, considered a disrupted metabolic factor (Liu et al., 2013), may 





Additionally, I observed a decreased modularity in Carriers as compared with non-Carriers. A 
less modular network implies fewer connections within modules and more connections to other 
modules. The increase of interconnectedness between modules can lead to disease pathological 
markers' rapid spreading and loss of specialization (Salathé and Jones, 2010). Summarizing, 
these findings concur with the evidence that ApoE4 is associated with an aberrant brain 
network topology in MCI. On the other hand, the changes were not detectable with the standard 
univariate approach based on the brain regional cortical thickness.  
 
Reference: Apolipoprotein E4 effects on Topological Brain Network Organization in Mild 
Cognitive Impairment. Author: Gretel Sanabria-Diaz, Lester Melie-Garcia, Bogdan 
Draganski, Jean-Francois Demonet, Ferath Kherif. (2021). Scientific Reports, volume 11, 845. 
https://doi.org/10.1038/s41598-020-80909-7.  
Contribution: elaborated study design, analyzed data, wrote the paper. 
Abstract: The Apolipoprotein E isoform E4 (ApoE4) is consistently associated with an elevated 
risk of developing late-onset Alzheimer's Disease (AD); however, less is known about the 
potential genetic modulation of the brain networks organization during prodromal stages like 
Mild Cognitive Impairment (MCI). To investigate this issue during this critical stage, we used 
a dataset with a cross-sectional sample of 253 MCI patients divided into ApoE4-positive 
(‛Carriers') and ApoE4-negative ('non-Carriers'). We estimated the cortical thickness (CT) 
from high-resolution T1-weighted structural magnetic images to calculate the correlation 
among anatomical regions across subjects and build the CT covariance networks (CT-Nets). 
The topological properties of CT-Nets were described through the graph theory approach. 
Specifically, our results showed a significant decrease in characteristic path length, clustering 
index, local efficiency, global connectivity, modularity, and increased global efficiency for 
Carriers compared to non-Carriers. Overall, we found that ApoE4 in MCI shaped the 
topological organization of CT-Nets. Our results suggest that in the MCI stage, the ApoE4 
disrupting the CT correlation between regions may be due to adaptive mechanisms to sustain 
the information transmission across distant brain regions to maintain the cognitive and 







2.2 Apolipoprotein E allele 4 effects on Single-Subject Gray Matter Networks in Mild 
Cognitive Impairment  
2.2.1  Context 
This section is based on the article ‘Apolipoprotein E allele 4 effects on Single-Subject Gray 
Matter Networks in Mild Cognitive Impairment’, Gretel Sanabria-Diaz, Jean-Francois 
Demonet, Borja Rodriguez-Herreros, Bogdan Draganski, Ferath Kherif, Lester Melie-Garcia, 
for the Alzheimer's Disease Neuroimaging Initiative. (2021). NeuroImage: Clinical (under 
review) (Annex 6.2).  
2.2.2 Summary of findings 
This study demonstrated the ApoE4 role in disrupting specific parameters of the gray matter 
network topology. ApoE4 simultaneously affects morphometric, cognitive variables, and CSF 
variables. Significantly, the rate of change in time of these variables is also affected by the 
allele. In particular, in Carriers, there is a decreased CSF Aβ42 levels, entorhinal cortex atrophy, 
and increased T-tau and P-tau levels. On the other hand, I uncover specific disruption in 
topological network properties, morphometric, cognitive, and CSF-derived markers in those 
MCI patients that will progress to AD. Disease progression conducts more pervasive brain 
alterations than ApoE4. The clustering index at the regional level showed widespread changes 
across the brain cortex, driven mostly for the disease, including critical nodes of the DMN 
related to AD pathology. 
I found that the ApoE4 mainly modulated two network properties, clustering index normalized, 
and sigma. In both cases, MCI Carriers showed higher values than non-Carriers independently 
of the future disease progression status. These increments (i.e., higher similarity between 
neighboring nodes) associated with the E4 allele may reflect synchronous atrophy between 
brain areas, where Carriers will show a more uniform neurodegeneration pattern across the 
whole gray matter volume.  
In particular, the MCI non-Carriers who will progress into AD showed in advance lower 
clustering index normalized values than those who will remain stable. However, only for MCI 
Converters, I detected differences associated with the ApoE4. The MCI Carriers Converters 
showed increased values over those non-Carriers. The rate of change analysis revealed the 
same patterns as a confirmation of this result's robustness. The findings suggest that the 




progression in MCI. In general, a lower cluster index suggests a topological organization more 
like a random network.  
My study revealed regional normalized clustering index differences between groups driven by 
the disease progression. These regional differences were widely distributed across the brain 
with a common denominator: lower values for those MCI converted to AD. It suggests that in 
MCI, the risk of disease progression is characterized by worse local communication between 
'topological neighboring' areas (graph theory concept). These regional changes may be related 
to AD neuropathological processes that are already operating in this phase, affecting the 
intracortical gray matter properties similarity. 
Interestingly, the CSF Aβ42 level was positively associated with the characteristic path length 
in the Carriers group, while I did not find correlations with P-tau and T-tau. This result agrees 
with previous studies showing that the E4 allele regulates Aβ aggregation and deposition (for 
review, see (Liu et al., 2013). Moreover, the positive association between these two measures 
was confirmed only for the ApoE4 and not for the disease progression factor. These finding 
suggests that the characteristic path length informs the detrimental E4 allele effects on the 
amyloid-related pathways in network terms.  
Based on these findings, I considered the single subject gray matter network a valid approach 
that sheds light on the interaction gene-structural covariance. My study provides further 
information in the current understanding of how ApoE4 -thus far the most important genetic 
factor known in late-onset AD- influences the brain network topology in MCI subjects.  
 
Reference: Apolipoprotein E allele 4 effects on Single-Subject Gray Matter Networks in Mild 
Cognitive Impairment. Author: Gretel Sanabria-Diaz, Jean-Francois Demonet, Borja 
Rodriguez-Herreros, Bogdan Draganski, Ferath Kherif, Lester Melie-Garcia, for the 
Alzheimer's Disease Neuroimaging Initiative. (2021). NeuroImage: Clinical (under review) 
Contribution: elaborated study design, analyzed data, wrote the paper. 
Abstract: There is evidence that gray matter networks are disrupted in Mild Cognitive 
Impairment (MCI) and associated with cognitive impairment and faster disease progression. 
However, it remains unknown how these alterations are related to the Apolipoprotein E isoform 
E4 (ApoE4) presence, the most prominent genetic risk factor for late-onset AD. To investigate 
this topic, we explore the impact of ApoE4 and the disease progression on the Single-Subject 
Gray Matter Networks (SSGMNets) using the graph theory approach. Our data sample 
comprised 200 MCI patients selected from the ADNI database classified in non-Converters 




ApoE4+) and 50 ApoE4-negative ('non-Carriers', ApoE4-). The SSGMNets were estimated 
from structural MRI at two-time points: baseline and conversion. We investigated whether 
altered network topological measures at baseline and their rate of change (RoC) between the 
two-time points were associated with ApoE4 and disease progression. We also explored the 
SSGMNets attributes correlation with general cognition score (MMSE), memory (ADNI-
MEM), and CSF-derived biomarkers of AD (Aβ42, T-tau, and P-tau). Our results showed that 
ApoE4 and the disease progression modulated the global network properties independently but 
not in the RoC. MCI Converters showed a lower clustering index in several regions associated 
with neurodegeneration in AD. The global network properties were revealed to predict 
cognitive and memory measures. These findings suggest that SSGMNets might have used in 
identifying MCI ApoE4 Carriers with a high risk for AD progression. 
 
2.3 Additional Research contributions: Cerebrovascular reactivity effects on the 
brain network detected by graph theoretical analysis in MCI 
2.3.1  Context 
This section is based on the article ‘Subtle alterations in cerebrovascular reactivity in mild 
cognitive impairment detected by graph theoretical analysis and not by the standard approach’, 
Sánchez-Catasús, Carlos A, Sanabria-Diaz, Gretel, Willemsen, Antoon, Martinez-Montes, 
Eduardo, Samper-Noa, Juan, Aguila-Ruiz, Angel, Boellaard, Ronald, De Deyn, Peter, Dierckx, 
Rudi A J O, Melie-Garcia, Lester. (2017). NeuroImage: Clinical, Volume 15, 2017, Pages 151-
160. Elsevier BV. ISSN 2213-1582. https://doi.org/10.1016/j.nicl.2017.04.019 (Annex 6.3). 
Previous neuroimaging results using the graph theory approach have shown its potential to 
reveal subtle pathological processes in MCI ((Dai and He, 2014; Tijms et al., 2013b). In 
principle, this methodology can also be applied to brain perfusion SPECT data to investigate 
possible subtle network-related Cerebrovascular reactivity (CVR) abnormalities in MCI. Since 
the regional Cerebral Blood Flux (CBF) is, in most circumstances, tightly coupled to neuronal 
metabolism, it is assumed that the radiotracer distribution reflects levels of neuronal activity in 
different brain areas (Devous, 2013; Warwick, 2004). We previously demonstrated this 
approach's feasibility using brain perfusion SPECT data of healthy control subjects (Melie-






2.3.2  Summary of findings 
The finding revealed different clustering index and mean strength of association changes in 
subjects with normal cognition and MCI, while the standard approach did not detect substantial 
differences. Thus, the results support the concept that multivariate measures (i.e.co-variations) 
combined with a graph theoretical approach are more sensitive to identifying complex 
pathological processes, as found in other brain diseases (Bassett et al., 2012; He et al., 2009b).  
The MCI group showed a decrease in both network measures, suggesting that the 
cardiovascular reactivity is possibly altered to some extent in MCI stage not detected by the 
standard analysis. On the other hand, although speculative, the mean strength of association 
globally increase in the MCI group network in the basal condition might represent an adaptive 
mechanism in response to pathological processes.  
Interestingly, regional clustering index changes overlap to a certain extent with the DMN, 
which is very active at resting state (for a review (Hafkemeijer et al., 2012)). These nodal 
alterations could be related to an altered DMN's vascularity based on the two resting states 
comparisons: without and under the effect of Acetazolamide (ACZ), a vasodilatory challenge. 
It is known that DMN also overlaps to a certain degree the brain network underlying the 
episodic memory (Rugg and Vilberg, 2013) that is affected in MCI due to AD (Albert et al., 
2011). 
 
Reference: Subtle alterations in cerebrovascular reactivity in mild cognitive impairment 
detected by theoretical graph analysis and not by the standard approach. Author: Sánchez-
Catasús, Carlos A, Sanabria-Diaz, Gretel, Willemsen, Antoon, Martinez-Montes, Eduardo, 
Samper-Noa, Juan, Aguila-Ruiz, Angel, Boellaard, Ronald, De Deyn, Peter, Dierckx, Rudi A 
J O, Melie-Garcia, Lester. NeuroImage: Clinical, Volume 15, 2017, Pages 151-160. Elsevier 
BV. ISSN 2213-1582. https://doi.org/10.1016/j.nicl.2017.04.019 
Contribution: contributed to the study design, analyzed the data, provided feedback on data 
analysis and manuscript preparation/writing, contributed to writing the manuscript. 
Abstract: There is growing support that cerebrovascular reactivity (CVR) in response to a 
vasodilatory challenge, also defined as the cerebrovascular reserve, is reduced in Alzheimer's 
disease dementia. However, this is less clear in patients with mild cognitive impairment (MCI). 
The current standard analysis may not reflect subtle abnormalities in CVR. In this study, we 
aimed to investigate vasodilatory-induced changes in the topology of the cerebral blood flow 




For this purpose, four CBFcorr networks were constructed: two using CBF SPECT data at 
baseline and under the vasodilatory challenge of acetazolamide (ACZ), obtained from a group 
of 26 MCI patients; and two equivalent networks from a group of 26 matched cognitively 
normal controls. The mean strength of association (SA) and clustering coefficient (C) were 
used to evaluate ACZ-induced changes on the topology of CBFcorr networks. We found that 
cognitively normal adults and MCI patients show different patterns of C and SA changes. The 
observed differences included the medial prefrontal cortices and inferior parietal lobe, which 
represent areas involved in MCI's cognitive dysfunction. In contrast, no substantial differences 
were detected by standard CVR analysis. These results suggest that graph theoretical analysis 
of ACZ-induced changes in the topology of the CBFcorr networks allows the identification of 







In this thesis, I assessed for the first time the ApoE4-related effects on the structural covariance 
brain networks topology in MCI. The findings provide novel experimental evidence regarding 
the genetic risk impact on the large-scale brain network organization associated with the risk 
of disease progression and AD biomarkers, which are worth investigating to define 
intermediate phenotypes in MCI. Additionally, I tested the graph approach potential application 
to detect cerebrovascular reactivity (CVR) at the network level in MCI patients. This is a 
previous methodological step for a further study that focuses on the ApoE4- Cerebrovascular 
interaction effects on the structural and functional covariance brain networks during AD 
progression. 
Few previous studies have found evidence of the E4 allele modulation on the MCI brain 
networks using graph theory on measures derived from other image modalities (rs-fMRI, FDG-
PET, and DWI). However, I consider my approach pertinent based on the following points:  
- The network analysis is based on sMRI, which is a powerful imaging technique to study 
AD. sMRI derived measures have been the most used as a relatively cheap, non-invasive 
yet powerful biomarker of neuronal loss highly available in current clinical practice and 
research environments. 
- I considered cortical thickness as an appropriate morphometric descriptor that offers unique 
information about AD. Using graph theory formalism, my previous results demonstrated 
that the underlying process of complex relations between other brain regions is captured 
differently by morphometric descriptors like surface area and cortical thickness (Sanabria-
Diaz et al., 2010). In particular, cortical thickness has been proposed as a more stable AD 
diagnosis measure than volume/surface area. The cortical thickness is a direct measure of 
gray matter atrophy due to the cytoarchitecture feature of the cerebral cortex (Lerch and 
Evans, 2005; Regeur, 2000; Singh et al., 2006). 
- The gray matter volume measure extracted from sMRI has been associated with coordinated 
growth patterns, functional coactivation, and axonal connectivity (A. Alexander-Bloch et 
al., 2013; Gong et al., 2012). Previous studies have shown that individual gray matter 
networks are associated with cognitive impairment (Tijms et al., 2013b, 2014) and related 
to faster disease progression (Dicks et al., 2018; Verfaillie et al., 2018). 
- The patterns of morphological covariance between brain regions can capture early AD-




diseases target areas that, in healthy individuals, are particularly highly structurally 
correlated (Seeley et al., 2009). The regional brain atrophy is linked to the deposition of 
the AD-related protein amyloid-β. Similar patterns of gray matter loss in brain regions 
with high structural correlations distinguished cognitively normal young adults genetically 
at risk of developing AD (Alexander et al., 2012). The atrophy within structural covariance 
networks highlights their functional significance in AD research and supports a network 
approach. 
- The patterns of morphometric covariations between brain regions are associated with 
anatomical and functional connectivity. The structural covariance is based on the 
observation that coordinate variations of brain morphometry occur between functionally- 
or anatomically-connected areas (Andrews et al., 1997; Lerch et al., 2006; Mechelli et al., 
2005). These brain areas correlated in size are often part of systems known to subserve 
particular behavioral or cognitive functions. As such, the morphometric covariance 
patterns represent a unique phenomenon. The spatial proximity between brain regions is 
suggestive of white matter tracts between these regions (Honey et al., 2009; Kaiser et al., 
2009; Makris et al., 2006). However, the only whole-brain study comparing white matter 
connections with cortical thickness covariance between regions on a pair-by-pair basis 
suggests a substantial but incomplete overlap (30–40%) (Gong et al., 2012). Also, 
structural covariance between brain regions is indicative of the coupling of their intrinsic 
activity (A. Alexander-Bloch et al., 2013; Honey et al., 2009; Salvador et al., 2005). 
Correlations between brain regions in intrinsic brain activity (using rs-fMRI) show striking 
overlap (but not entirely) with population-based measurements of gray matter covariance 
between those regions (Kelly et al., 2012; Seeley et al., 2009; Segall et al., 2012). Then, 
structural covariance connectivity represents processes that are not reduced to anatomical 
and functional connectivity, making these studies more valuable (for a review, see (A. 
Alexander-Bloch et al., 2013)). 
In the following sections, I summarized the main findings, discuss the results concerning the 
literature, potential methodological considerations, and possible avenues for future research. 
3.1 ApoE4 modifies the structural covariance brain networks topology in MCI 
In this first study, I assessed the ApoE4 impact on the structural covariance (i.e.cortical 
thickness) brain networks topology derived from sMRI using a graph theory approach in MCI. 




topology in MCI. The findings showed a decrease in characteristic path length, clustering index 
normalized, local efficiency, global connectivity, modularity, and increased global efficiency 
for Carriers compared to non-Carriers. These results revealed that multivariate measures (i.e., 
covariations) combined with a graph theoretical approach are sensitive to identifying complex 
pathological processes in MCI, as found in other brain diseases. Univariate measures, cortical 
thickness, in this case, derived from the standard approaches could be insufficient for capturing 
subtle (early) changes associated with ApoE4.   
3.1.1 MCI ApoE4 Carriers present regional network alterations in agreement with previous 
AD neurodegeneration findings 
My results indicated that regional network properties alterations (NBC and hubs) are related to 
AD neurodegenerative patterns described in previous studies using other neuroimaging 
techniques. As an example, I found lower NBC values in crucial structures like the posterior 
cingulate cortex (PCC) in ApoE4 Carriers. The PCC is a key integration node between the 
medial temporal lobe and medial prefrontal subsystems in the DMN (Buckner et al., 2008; 
Raichle et al., 2001). In particular, this region has been consistently noted with significant 
metabolic alterations in AD. It shows very early and comparatively large reductions in cerebral 
metabolic rate for glucose (Minoshima et al., 1995), and it sits at the convergence point of 
multiple metabolic covariance networks (Salmon et al., 2009). Notably, patients at genetic risk 
for AD, such as ApoE4 Carriers, also show similar metabolism differences, implying the 
disturbances occur early during the disease progression (Reiman et al., 1996). 
Another critical structure, the precuneus, was found with lower NBC values in Carriers 
compared to non-Carriers. Together with the anterior cingulate cortex, the precuneus is among 
the earliest brain areas showing pathological changes in AD associated with the aggregation of 
beta amyloid into plaques (Palmqvist et al., 2017; Villain et al., 2012; Villeneuve et al., 2015). 
This finding suggests that network measures change on these nodes may play a key role in the 
AD-related pathological process in MCI and can possibly explain the temporo-spatial 
disconnect between amyloid aggregation and neurodegeneration. Specifically, the precuneus 
may show very subtle atrophy in response to amyloid aggregation in this phase of the disease, 
at which point other brain regions are not yet affected by neurodegeneration. These 
asynchronous atrophy patterns would result in decreased structural covariance between 
neighboring brain regions and path length alterations, which are captured by the NBC measure. 




drive brain atrophy in more distant regions (Salehi et al., 2006; Seeley et al., 2009). However, 
more research is necessary to determine the neurobiological mechanisms with which regional 
networks measure change may facilitate neurodegenerative processes and reflect subtle 
structural alterations in the brain. 
Furthermore, together with other areas, it is a binding site of beta-amyloid deposition (Buckner, 
2005), possibly due to conducive metabolic conditions and the linkages between synaptic 
activity and beta-amyloid metabolism (Bero et al., 2011; Cirrito et al., 2008, 2005). Therefore, 
brain structures such as the PCC and the Precuneus may indicate a particular vulnerability to 
perturbations of energy metabolism in MCI Carriers. This idea is referred to by Buckner and 
colleagues (2005) as the 'metabolism hypothesis' (Buckner, 2005). They state that AD takes a 
foothold earliest in regions of high glycolytic metabolism within the DMN. The implication of 
the ApoE4 may lie in the well-known toxic roles during AD progression, particularly related 
to beta-amyloid pathways. In this direction, ApoE4 is recognized as a disrupted metabolic 
factor (Bero et al., 2011; Liu et al., 2013; Sun et al., 2007), which alters the brain activity 
patterns and directly modulates the molecular cascades that are relevant to the disease.  
Also, in Carriers, lower NBC values were detected in regions that belong to other networks 
like the Salient Network. Lower NBC values in brain regions that belong to this network may 
suggest that ApoE4 Carriers had aberrant communication between networks critical for 
externally oriented cognition compared to non-Carriers. Therefore, a possible hypothesis is that 
MCI Carriers have altered regulation of control processes that subsequently influence their 
memory performance. This network operates on identified salience and, as such, includes 
known sites for sustained attention and working memory (dorsolateral prefrontal cortex, lateral 
parietal cortex), response selection (dorsomedial frontal), and response suppression (prefrontal 
cortex) (Curtis and D’Esposito, 2003; Ridderinkhof et al., 2004).  
Summarizing, Apoe4-related effects on regional brain network properties seem to agree with 
previous structural, functional, and metabolic findings in MCI associated with AD progression.  
The nodal properties might capture additional information related to the E4 allele effects on 
the brain networks at MCI stages.  
3.1.2 ApoE4 affects how the brain networks segregate the information in MCI. 
In general, my results showed that brain network segregation is affected in Carriers compared 
to non-Carriers. Decreasing network segregation is a crucial feature of brain aging (Chan et al., 




that compromises the normal aging process by accelerating it. Multimodal neuroimaging 
findings may lend support to this possible linkage. Several task‐based fMRI studies had 
revealed less deactivation in the DMN in Carriers than non-Carriers during task performance, 
implicating a disrupted balance between the DMN and task‐positive networks (Lind et al., 
2006; Persson et al., 2008). Middle‐aged ApoE4 Carriers also showed activation patterns 
similar to those of the elderly than the non-Carrier during attention and memory tasks (Evans 
et al., 2014). As a result, Carriers might be more vulnerable to network dysfunctions associated 
with AD pathology (Fouquet et al., 2014; Kang et al., 2015; Schultz et al., 2017). 
The finding seems in agreement with this hypothesis. A lower clustering index, local 
efficiency, and modularity suggest more disorganized processing between neighboring 
(topological neighbors, graph theory) brain regions associated with the E4 allele.  However, 
the cortical thickness at the regional level did not show differences between groups. I 
hypothesized that brain network measures derived from the structural covariance analysis may 
have applications as an additional surrogate marker to track AD progression in MCI Carriers 
starting at early stages when atrophy is not yet extensive to show group differences. It holds if 
we assume that the structural covariance phenomenon indeed results from brain connectivity 
of some kind, such as white matter connectivity or the functional connectivity of synchronous 
neuronal activations (for a review, see (A. Alexander-Bloch et al., 2013)). Then I can speculate 
that the network alterations found in MCI Carriers may indicate ultrastructural brain changes 
associated with AD and the ApoE4, such as local cell death, reduction of the dendritic extent, 
and synaptic loss. However, it is challenging to interpret disease-related alterations associated 
with network measures. Nevertheless, my findings seem to indicate a link between the genetic 
risk and brain network topological alterations. They suggested that the brain's structural 
covariance patterns encode different information, which is not captured by other univariate 
structural measures.    
In MCI Carriers, a less segregated brain may facilitate the patterned spreading of AD 
proteinopathies within this network. Because as the complex network theory implies through 
different mechanisms, the dysfunction can spread between linked nodes (structural and/or 
functional connectivity) and trigger a pathological cascade affecting the system when the 
compensatory mechanisms are overwhelmed. Previous studies in AD suggest a link between 
brain network connectivity and the spread of pathological markers like beta-amyloid plaques 
and tau pathology (Liu et al., 2012; Seeley et al., 2009), indicating that this generic network 




"disconnection hypothesis" of AD (Buckner et al., 2009; Delbeuck et al., 2003; Reid and Evans, 
2013), possibly due to the several toxic effects of E4 allele that ultimately affect the neuronal 
synaptic communication. Nevertheless, because this study applied a network reconstruction 
approach that results in one network per group based on cross-sectional results, it remains 
unclear whether these alterations are associated with the clinical progression and other AD 
biomarkers at the individual level. 
3.1.3. ApoE4 increases the brain network global efficiency, decreased the path length, and 
increase NBC in temporal areas: compensatory effects or a pleiotropic case? 
Together with the evidence mentioned above, we found some indicators suggesting 
compensatory processes in MCI Carriers, such as increased global efficiency, shorter 
characteristics path length, and increased NBC in temporal regions.  However, previous studies 
showed that a shorter characteristic path length is associated with more efficient functioning 
(Li et al., 2009; Van Den Heuvel et al., 2009; Wen et al., 2011), which as an inverse measure, 
is expressed on higher global network efficiency. A possible explanation of these results is that 
Carriers have accelerated and more widespread atrophy than non-Carriers; which might lead 
to more synchronous brain-wide atrophy patterns and thus lower path lengths values.   
Why these "better network indicators" were against intuitively found in the ApoE4 Carriers' 
group? An attractive hypothesis is the ApoE4 description as an example of antagonistic 
pleiotropy. The concept comes from the evolutionary biology field, and the idea is that specific 
genes may have a different impact during different life stages. My results suggest that maybe 
in MCI, the allele somehow confers advantages in brain network functions, meaning an 
extension of the model proposed by (for review see (Tuminello and Han, 2011)). But, maybe 
the ApoE4 is not antagonistically pleiotropic but instead interacts with other AD risk factors 
highly prevalent in MCI (cardiovascular factors) to influence the network topology 
differentially.  As a response, the E4 allele may trigger in advance a complex set of adaptative 
responses in Carriers compared to non-Carriers to sustain the same behavior. A neural 
compensation response associated with the ApoE4 has been reported as increase functional 
brain activity. Simultaneously, this persistent hyperactivation may place neurons under 
metabolic stress rendering them susceptible to neurodegeneration later on. This seems to be the 
case of the NBC increases found in MCI ApoE4 Carriers' temporal structures. However, MCI 
Carriers may exhaust this compensatory process faster, as Ye et al. (2017) showed using 




3.1.4 Limitations and future perspectives 
The main limitation of this study is relative to the sample characteristics and selection process. 
First, MCI patients exhibit different progressive trajectories, where some ultimately develop 
AD and others do not. Accordingly, further follow-up longitudinal studies are necessary to 
examine whether the combination of structural covariance network measures with the ApoE 
genotype would improve the prediction of the conversion from MCI to AD. Second, the E4 
allele dosage effect was not investigated due to insufficient numbers of ApoE4 homozygotes. 
Future studies, including homozygotic and E2 Carriers, would be essential to expand upon 
these preliminary findings. Third, the present study applied a cross-sectional design. This 
approach confuses inter-subject and intra-subject variability (Thompson et al., 2011). 
Mostly, MCI represents a heterogeneous entity characterized by differences in cognitive profile 
and clinical progression (Petersen et al., 2001).  Additionally, longitudinal studies are required 
to determine how ApoE4 affects large-scale network organization across the AD spectrum 
(preclinical and clinical phases). Finally, a considerable amount of biological variability existed 
in MCI recruitment based on clinical criteria. This limitation should be overcome by adding 
neuropathological biomarkers such as Aβ and Tau to better characterize the study groups. 
Also, in this research, I did not include the small-world measure in the network analysis. This 
topological property should be explored in a future study because it is thought to 
simultaneously reconcile the opposing demands of functional integration and segregation 
(Tononi et al., 1994)(Tononi et al., 1994). Such a design has been reported affected in various 
degrees in MCI and AD (Tijms et al., 2013b; Xie and He, 2012).  
This network analysis was based on automatic parcellation of human cortical gyri and sulci 
included in the FreeSurfer package (http://surfer.nmr.mgh.harvard.edu/). In terms of cortical 
thickness analysis this atlas offers a precise localization of sulco-gyral structures of the human 
cerebral cortex which is important for the interpretation of structural covariance brain network. 
The atlas is commonly used for this type of analysis in MCI AD patients. However, other 
parcellation schemes should be explore to replicate the present results.  
3.2 ApoE4-related effects on the structural covariance brain networks are associated 
with the risk of AD progression and pathological disease markers in MCI 
In this second study, my goal was to investigate the ApoE4-related effects on the Single-
Subject gray Matter Networks (SSGMNets) in MCI.  I hypothesized that the E4 allele is 




progression affect the network measures related to neuropathological AD biomarkers (i.e., CSF 
amyloid β42 and total Tau levels).   To test this claim, I compared the SSGMNets estimated 
from sMRI at two-time points.  My results indicated that ApoE4 and the disease progression 
modulated the global network properties independently. MCI Converters showed a lower 
clustering index normalized in several regions associated with neurodegeneration in AD. The 
global network properties were revealed to predict cognitive and memory measures. To the 
best of my knowledge, this study is the first to showed that altered network topological 
measures at baseline and their rate of change were associated with ApoE4 and disease 
progression in MCI. 
 In the following sections, I will discuss these findings in light of the existing literature and 
critically expose the advantages and the limitations of the present work. 
3.2.1 ApoE4 and disease progression modulate the clustering index normalized in MCI 
I found differences between groups in the clustering index normalized at baseline. In particular, 
the MCI non-Carriers who will progress into AD showed in advance lower clustering index 
normalized values than those who will not progress at the second time point. However, only 
for MCI Converters, I detected differences associated with the ApoE4. The MCI Carriers 
Converters showed increased values compare to non-Carriers. The rate of change analysis 
revealed the same patterns as a confirmation of this result's robustness. 
The findings have two main implications 1) The clustering index normalized seems to be a 
critical network measure to predict disease progression in MCI in the absence of the genetic 
risk. The change reflects an altered communication between neighboring areas, maybe as a 
direct consequence of a progressive corticocortical dysconnectivity (Dicks et al., 2018; Pereira 
et al., 2016; Tijms et al., 2013b). In general, a lower clustering index suggests a topological 
organization more like a random network. This graph structure has been previously reported in 
AD subjects and associated with MCI conversion into AD (Pereira et al., 2016; Tijms et al., 
2013b, 2018). I suggest future studies concentrate on the clustering index normalized for 
patient classification based on this result. 
2) The ApoE4 effects in MCI Converters seem to be associated with compensatory mechanisms 
reflected on increased clustering index normalized values. It is suggested that the brain 
randomly connects different regions, hypothetically, to retrieve the deafferentation-related 
missing information from wherever it can. In agreement with this idea, previous studies found 




affected by AD (e.g., posterior cingulate) and frontal areas (for a review, see (Tuminello and 
Han, 2011)). Other studies reported in ApoE4 Carriers, regardless of diagnosis, enhanced 
hippocampal activity during encoding in a face-name memory task (Dickerson et al., 2005). A 
notable trend in previous studies is in E4 Carriers, the high regional activity is beyond those 
typically involved in early AD (e.g., prefrontal cortex). As several authors have pointed out, 
Carriers may exhibit decrements in activity in areas initially impacted in AD while continuing 
to compensate for these alterations with increased activity in regions not initially affected by 
the disease (Filbey et al., 2010). However, the 'compensatory network effects' found in MCI 
Carriers seem to be a problem later. As computational studies suggest, too much integration in 
a system that should be segregated represent a shift in its organization. It reflects a network 
breakdown that can facilitate the spread of failures, reduce functional specialization, and result 
in dedifferentiated neural activity (Fornito et al., 2015). 
Summarizing, my findings revealed that some network properties changes in MCI Carriers are 
associated with altered communication between neighboring regions, maybe indicating AD-
related pathological markers (i.e., tau-tangles and amyloid-beta plaques depositions). On the 
other hand, a better global network communication could be considered the expression of 
compensatory/degeneracy mechanisms to sustain the transmission of the information across 
distant brain regions. These changes in topological attributes may be considered sensitive 
markers to detect AD progression. 
3.2.2 Subject-based Network properties alterations in MCI ApoE4 Carriers associated with 
AD-biomarkers. 
My study revealed that ApoE4 affects the association between characteristic path length and 
CSF Aβ42 levels in MCI. Following the graph theory concepts, the characteristic path length is 
related to transferring speed information through the overall network, implying the brain's 
global efficiency. The finding suggests that in MCI, this process is modulated by the beta-
amyloid brain deposition, in turn, affected by the ApoE4. Previous studies have shown that E4 
allele correlates with CSF Aβ42 levels in AD's preclinical phase (Vemuri et al., 2010) and 
cognitively normal subjects (Fleisher et al., 2013). In general, there is an agreement in the 
literature that ApoE4 increases AD's risk by initiating and accelerating Aβ accumulation in the 
brain. 
On the other hand, Carriers exhibited more brain structural disruptions (Brown et al., 2011). 




structural changes (Bu, 2009) that reduce the fidelity of the communication between brain 
regions (Greicius et al., 2004), cause neuronal death and white matter degeneration during AD 
progression (Westlye et al., 2012). I can then speculate that the synergetic interaction of ApoE4 
and Aβ42 eventually affects the anatomical and functional brain connectivity, reflected on the 
characteristic path lengths and global efficiency in MCI. In these patients, where 
epidemiological studies have shown a high risk of conversion and younger age of onset, the 
ApoE4 allele eventually causes significant network topological changes. It may be due to an 
inability to compensate for the inefficient neuronal processes that result from synaptic plasticity 
and neuronal growth (Celone et al., 2006). 
3.2.3 Possible biological meaning of regional covariance alterations associated with the 
ApoE4 
Previous studies suggested that the structural covariance brain network disruptions may reflect 
early neurodegenerative changes that occur in a coordinated way rather than isolation (A. 
Alexander-Bloch et al., 2013). I can only speculate about the mechanisms that underlie 
morphological similarities in the cortex, their relationship to connectivity, and alterations under 
the ApoE4 presence in MCI. It has been consistently demonstrated that ApoE4 is either 
pathogenic or shows reduced efficiency in multiple brain homeostatic pathways. That includes 
lipid transport, synaptic integrity, plasticity, glucose metabolism, and cerebrovascular function 
(Liu et al., 2013; Yamazaki et al., 2019). At a brain macroscale level, all these interactions will 
be reflected by the structural covariance changes in MCI. One possible explanation for this 
phenomenon is that the lack of stimulation and/or neurotrophic factors along these connections 
may drive brain atrophy in more distant regions (Seeley et al., 2009). Specifically, I found a 
widespread set of brain areas where the clustering index normalized was lower for Carriers 
than non-Carriers. These findings suggest that in MCI, the synergetic effect of ApoE4 and 
disease progression induces subtle atrophy in specific regions that may be associated with the 
beta-amyloid aggregation and tau. Still, at this point, some anatomical areas are not yet affected 
by neurodegeneration, at least uncaptured by standard measures. However, the atrophy 
processes at micro and mesoscale would decrease similarity between neighboring brain regions 







3.2.4 Limitations and future perspectives 
There are several potential limitations to this study. First, only two-time points MRI scans were 
analyzed. A future investigation related to the ApoE4 effects on the network properties, 
cognitive decline, and brain atrophy using more time points is necessary. Second, a small group 
of subjects had CSF measures, which might have affected the correlation analysis accuracy. 
Third, a gene-dose analysis and susceptibility and protective loci associated with late-onset AD 
need to be considered in conjunction with ApoE4 for finding possible interaction effects. 
Additionally, the MCI diagnosis based on clinical criteria has limited sensitivity and specificity 
(Nettiksimmons et al., 2014; Wolk et al., 2009). In this study, the ApoE4 effects on gray matter 
network results are limited by the absence of biomarker-based group analysis. It opens up the 
possibility that some subjects were misdiagnosed. Future research based on AT (N) biomarkers 
profiles will show more robust conclusions on the ApoE4 modulation of the network 
properties. 
As a cognitive measure, I used MMSE and ADNI-MEM. They should not be regarded as a 
detailed neuropsychological assessment. Research is needed to examine whether altered graph 
properties are related to dysfunction in specific cognitive domains and are more sensitive to 
detecting decline over time. 
Additionally, here I simulated brain insults using targeted removal of nodes based on their NBC 
values. The negative results obtained could indicate the importance of model attacks based on 
random nodes and edge elimination. My results suggest that MCI ApoE4 Carriers showed a 
shift to more network randomization compared to non-Carriers with may be associated with 
greater resilience to a targeted attack. 
In sum, for the first time, I presented evidence that the topological organization of the single-
subject gray matter networks is affected by ApoE4 and the disease progression. Also, I found 
the topological network properties predictive of Aβ42, P-tau, T-tau, atrophy, and cognitive 
impairment in MCI. 
3.3 The Cerebrovascular reactivity in MCI is detected by the analysis of covariance 
and graph theory 
The third study demonstrates that brain perfusion SPECT can help clarify essential questions 
regarding the MCI neuropathological mechanisms. This project is pertinent given our limited 
understanding of MCI and the low cost of brain perfusion SPECT. We investigated the 




cerebrovascular reserve. It describes cerebrovascular structures' ability to increase cerebral 
blood flow (CBF) above a basal condition in response to a vasodilatory challenge. The results 
indicate that brain perfusion SPECT combined with theoretical graph analysis can reveal 
network CVR alterations.  
3.3.1 Topological measures capture vasodilatory-induced changes in the CBF network in 
MCI 
In MCI, ApoE4 induces progressive cerebrovascular dysfunction through direct signaling and 
indirectly via modulation of peripheral and central pathways. The E4 allele induced other 
changes, including reduced cerebral blood flow (CBF), modified neuron-CBF coupling, 
increased blood-brain barrier leakiness, and cerebral amyloid angiopathy, hemorrhages, and 
disrupted transport of nutrients and toxins. Considering MCI as a transitional phase between 
the cognitive changes associated with aging and dementia (Albert et al., 2011; Petersen, 2016), 
CVR abnormalities will be subtle, partly explaining the ambiguous findings, particularly in 
MCI patients with a low vascular burden. Furthermore, based on the complexity of the cerebral 
microvasculature network, the standard analysis of CVR might not reflect subtle alterations. It 
relies on studying individual regions rather than their interaction.  
The results showed that the control and MCI group networks display different topological 
patterns of CVR changes, especially at the global level. Besides, the observed regional 
differences included the medial prefrontal cortices and inferior parietal lobe, which represent 
areas involved in MCI's cognitive dysfunction. The findings also indicate that graph theory 
analysis identifies network-related CVR alterations in MCI, which could not be detected by the 
standard approach. Since this study is a group-based network analysis, the topological 
measures derived from the CBF covariance network cannot be used to support diagnosis and 
prognosis individually. However, methods to extract the individual patient contribution using 
a graph network approach have been developed, although not yet applied to SPECT data in 
MCI. 
In summary, this study showed that brain perfusion SPECT combined with theoretical graph 
analysis is feasible and useful for investigating problems of complex neurological diseases, 
such as the CVR alterations in MCI. It is a valid approach for future research focus on the 
ApoE4- Cerebrovascular interactions effects on the structural and functional covariance brain 





3.3.2 Limitations and future perspectives 
First, to further clarify some results at the regional level, it may be necessary to increase the 
number of subjects and/or use a more potent vasodilatory challenge in future studies. Second, 
research at the individual level to examine the association between network-related CVR 
alterations and clinical data is essential. Third, longitudinal studies are needed to investigate 
the CBF network's changes along the continuum from normal aging to AD dementia. 
Additionally, several limitations are associated with the CBF network's analysis, such as using 
Pearson's correlation instead of a partial correlation (Melie-Garcia et al., 2013). 
Also, we considered that some of the exclusion criterium applied in this study deserve a careful 
evaluation.  In particular the exclusion of MCI patients based on cerebrovascular disorders, 
carotid stenosis and white matter changes are very challenging criterium as cardiovascular risk 
factors and AD are closely related. On the other hand, white matter alterations for instance, 
clearly impact on CVR. 
3.4 Methodological remarks and Future Perspectives 
3.4.1 Advantages and disadvantages of the graph theory approach to capture ApoE4 related 
effects on the brain networks 
I consider it essential to clarify that the traditional interpretation of networks' properties applied 
in this thesis cannot reflect real physiological mechanisms in the brain. We need to assume that 
the neurophysiological interpretation of the obtained results can present difficulties due to the 
increasing level of conceptual abstraction and steps applied to generate the brain network 
properties. Graph theory analysis and the derived properties depend, in my case, on covariation 
in cortical thickness/gray matter volume/CBF between regions. Still, it is not clear the 
neurobiological basis for the interregional correlations between brain structures. Based on state 
of the art on the topic, researchers usually do not make straightforward assumptions on the 
links' nature but rather emphasize mathematical modeling. The literature on morphological 
connectivity does not always correctly reflect this issue, leading many researchers to believe 
that mathematically derived connections represent real physiological connections. 
My studies assume that any approach investigating genetic risk factors impact on the brain 
network organization needs to consider pairwise relations between brain regions 
simultaneously and that graph theory best achieves this goal. Although graphs do not entirely 
ease deciphering network organization, they can be useful in visualizing the network's 




framework of graph theory allows its application in networks derived from various data. 
Importantly, structural and functional connectivity are mutually interrelated. Morphological 
connectivity is affected by both functional and anatomical connectivity and captures different 
information about brain network properties. The graph theory approach summarizes the brain's 
complex global and regional patterns into biologically meaningful properties.  
As models, the graphs theory approach provides a more highly compact description of the 
network components (Rubinov and Sporns, 2010). The ability to describe multivariate neural 
processes by looking at their network topology makes graph analysis unique compared to 
previous univariate methods that look at the activity in single parts of the brain (e.g., power) or 
bivariate methods looking at pairwise functional connectivity (e.g., cross-correlation). 
The network-based measures, in particular clustering index normalized, modularity and sigma, 
could be considered for potential clinical application in MCI for example to evaluated response 
to neuromodulation therapies. The network properties may help to track modification on 
pathological activity within the nervous system in response to therapeutic effect based on a 
wide spectrum of interventional technologies. Therapies including deep brain stimulation 
(DBS), intracranial cortical stimulation (ICS), transcranial direct current stimulation (tDCS), 
and transcranial magnetic stimulation (TMS) have all shown promising results but still their 
mechanisms of action have not yet been fully elucidated in intermediate stages such as MCI.  
On the other hand, the structural covariance brain connectivity analysis using the graph theory 
approach has some limitations. Here I mentioned those more relevant to this thesis, such as: 
- A critical point of difference between structural covariance and other approach is that fMRI 
and DWI networks can routinely be constructed from measures of inter-regional association or 
connectivity estimated for an individual image. By contrast, most structural covariance network 
studies are built from inter-regional correlations estimated across a group of subjects. The 
group-level analysis limits the opportunity to link structural covariance metrics to inter-
individual differences, such as cognitive functions. 
- The static nature of the structural covariance analysis. The evidence suggests that brain 
networks undergo spontaneous reconfigurations at a temporal scale (Calhoun et al., 2014; 
Chang and Glover, 2010; Park et al., 2012). As such, properties like the modular structure and 
the hub regions may fluctuate over time. These changes could reflect a dynamic balance 
between information segregation and integration (Allen et al., 2014; Betzel et al., 2016; Liao 
et al., 2015). However, the neurophysiological and biochemical mechanisms underlying these 




- Additional methodological problems lie in the sMRI analysis in general and structural 
covariance analysis in particular. Issues like within-scanner subject motion, spatial 
normalization, and MRI tissue contrast make the reliability and accuracy of the extraction of 
morphological properties a challenge. The cellular interpretation of MRI-based morphological 
properties is also non-trivial and challenging to compare across studies. There are 
methodological hurdles inconclusively assessing the relationship between structural covariance 
and anatomical and functional connectivity. I believe technological improvements will allow 
increasingly accurate assessments of these relationships. 
3.4.2 Future perspectives 
My findings suggest that ApoE4-related disruptions on the structural covariance brain 
networks play an essential role in MCI and AD progression. Together with other established 
biomarkers, it may help inform the individual clinical outcome. Still, several questions remain 
that need to be addressed in futures research. I have shown that structural covariance brain 
networks (gray matter/cortical thickness) become affected in response to E4 allele in MCI. 
However, much less is known about the (temporal and/or spatial) relationship between the 
network's properties and other AD-related processes, such as e.g., tau pathology. For example, 
it has been suggested that brain connectivity may represent a pathway along which pathological 
factors may spread (Seeley et al., 2009). It is currently also unclear whether network disruptions 
based on structural covariance brain patterns initiate other downstream pathological events. 
Future studies that include longitudinal assessments of network measures and other AD 
biomarkers should address these questions. 
Additionally, it remains largely unclear what the different network measures precisely indicate. 
In this line, multimodal approaches may also be helpful since ApoE4 effects on brain 
connectivity can also be measured based on other imaging modalities (e.g., fMRI, DTI). It is 
still unclear how network measures derived from these different connectivity types are related 
to each other within individuals, which would help interpret theoretical graph measures. Still, 
out of these imaging modalities, sMRI is the most robust, the easiest to obtain, and already 
included in standard dementia workups. As such, biomarkers based on sMRI have the highest 
potential to be implemented for patient identification in clinical trials. 
I showed that in MCI, a more disorganized network configuration is associated with the ApoE4; 
however, there are currently no cut-off values available. Future studies that combine the ApoE4 




measures and assess their accuracy in predicting disease progression on an individual patient 
level. Also, future studies should specifically investigate the E4 allele effect stratifying the MCI 
groups based on new biomarkers profiles (e.g AT(N) system) in multiple independent datasets 
and exclude the possibility that cohort effects drove these effects. 
Finally, the results indicate that network measures based on the graph theoretical approach can 
help identify the risk of disease progression in ApoE4 Carriers and non-Carriers before other 
measures such as global cortical thickness and grey matter volume. The network's properties 
seem to offer additional information together with regional atrophy, CSF-derived biomarkers, 
and cognitive decline, as such, have use to predict and monitor AD progression. The clustering 
index normalized, sigma, and modularity could be implemented to test treatment effects from 
this perspective. I envision that brain network topological measures could be the target of 
neuromodulation treatments (e.g., TMS) and their variation applied on the prediction 





4 GENERAL CONCLUSIONS 
My results suggest that ApoE4 affects the structural covariance brain network topology in MCI, 
and these changes are related to AD progression and disease biomarkers. I considered that some 
of these network measures, in particular, clustering index normalized might have applications 
to predict and monitor MCI patients in the absence of cortical thickness or gray matter volume 
changes. Here, I demonstrated that ApoE4 and disease progression affect global and regional 
network properties in different ways. Finally, the studies revealed that independently of the 
ApoE4, the network properties changes were associated with AD progression and linked to a 
steeper memory and CSF-derived measures alterations. Together my findings suggest that 
network measures might contain prognostic information about the future clinical outcome. 
In MCI, regional network properties change (betweenness centrality, clustering index 
normalized, and hubs) associated with the ApoE4 seem to express altered communication 
between neighboring regions. It may be an early response to AD-related pathological markers 
(i.e., amyloid-beta plaques depositions). On the other hand, a better global network 
communication (global efficiency) could be considered the expression of 
compensatory/degeneracy mechanisms to sustain the transmission of the information across 
distant brain regions associated with the genetic challenge. These regional changes in 
topological attributes may be considered sensitive markers to detect early brain network 
changes related to the disease progression. 
The baseline and rate of change results suggest that the clustering index normalized offers 
consistent information about the risk of AD progression in MCI Carriers and non-Carriers. It 
could provide additional information to select genetically at-risk individuals for potential 
prevention opportunities at the earliest AD stages. 
Finally, as an additional research contribution, I demonstrated the graph theory approach's 
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Apolipoprotein E4 effects 
on topological brain network 
organization in mild cognitive 
impairment
Gretel Sanabria‑Diaz1*, Lester Melie‑Garcia1, Bogdan Draganski1, 
Jean‑Francois Demonet2 & Ferath Kherif1
The Apolipoprotein E isoform E4 (ApoE4) is consistently associated with an elevated risk of developing 
late‑onset Alzheimer’s Disease (AD); however, less is known about the potential genetic modulation 
of the brain networks organization during prodromal stages like Mild Cognitive Impairment (MCI). 
To investigate this issue during this critical stage, we used a dataset with a cross‑sectional sample 
of 253 MCI patients divided into ApoE4-positive (‛Carriers’) and ApoE4-negative (‘non‑Carriers’). 
We estimated the cortical thickness (CT) from high‑resolution T1‑weighted structural magnetic 
images to calculate the correlation among anatomical regions across subjects and build the CT 
covariance networks (CT-Nets). The topological properties of CT-Nets were described through the 
graph theory approach. Specifically, our results showed a significant decrease in characteristic path 
length, clustering‑index, local efficiency, global connectivity, modularity, and increased global 
efficiency for Carriers compared to non‑Carriers. Overall, we found that ApoE4 in MCI shaped the 
topological organization of CT-Nets. Our results suggest that in the MCI stage, the ApoE4 disrupting 
the CT correlation between regions may be due to adaptive mechanisms to sustain the information 
transmission across distant brain regions to maintain the cognitive and behavioral abilities before the 
occurrence of the most severe symptoms.
Late-onset Alzheimer’s Disease (AD) is a degenerative brain disease and the most common form of dementia in 
late-life, affecting millions of people  worldwide1. Because of the lack of treatment, identifying causal risk factors 
at the early stages is paramount in clinical investigation. Most of the research is focusing its attention on the 
Mild Cognitive Impairment (MCI) stage. MCI is considered an intermediate phase between normal aging and 
AD. It is mainly characterized by a decline in cognitive abilities that do not interfere with daily  functioning2. 
These patients are at increased risk of developing AD or another  dementia1. Epidemiological research suggests 
an estimated 40% to 60% of MCI individuals aged 58 years and older have underlying AD  pathology3,4.
Nevertheless, MCI does not always lead to dementia; some patients remain stable or revert to a normal state 
while other progress to different brain pathologies. This clinical variability is based on the interplay between 
physiological, environmental, and genetic factors as part of the disease multifactorial  etiology5,6. In those MCI 
cases destined to evolve to Alzheimer’s Disease, this “window” is an opportunity to develop biomarkers that help 
to identify etiology and predict progression.
Our study is motivated by the fact that the Apolipoprotein E isoform E4 (ApoE4) is the best-established 
genetic risk factor for  AD7. Among MCI ApoE4 Carriers, previous studies have reported an increased risk of 
developing AD, a younger mean age of onset and more rapid cognitive decline than non-Carriers8. Likewise, in 
MCI, the prevalence of this genotype is substantially higher than in control  individuals9. The ApoE4 mechanisms 
in AD’s pathogenesis are not entirely understood but have been related to amyloid-β-dependent and independent 
 pathways10. Although the amount of evidence linking ApoE4 with cognitive deficits, morphological, structural, 
and functional brain alterations during AD  progression11,12 at this point, it is still unclear how this genetic risk 
factor impairs the brain networks organization.
Our study’s second motivation is based on previous research supporting the idea of AD being a disconnection 
syndrome, which disrupts higher-order neuronal  networks13. In this context, using a network-based approach 
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is critical to understand brain alterations and cognitive deficits during the disease progression. One feasible 
mathematical approach to elucidate the AD impact on brain networks is the graph  formalism14. In graph theory 
terms, our brain is studied as a model to describe some essential elements -nodes- (brain regions) and the rela-
tionship between them (edges). Afterward, the brain complex covariance patterns are translated into global and 
regional graph  metrics15. During the last decade, the graph analysis has been applied to characterize the brain 
structural covariance in AD and  MCI16. It is based on the phenomenon that regions correlated in morphometric 
descriptors (i.e., cortical thickness) are often part of the same brain system that subserve specific behavioral and 
cognitive  functions17. The mechanisms underlying these coordinated patterns seem to be related to mutually 
trophic effects, common pathological vulnerabilities, and genetic  factors16.
Following this modeling approach, studies using different neuroimaging modalities have shown aberrant 
brain network properties in AD, MCI, and preclinical  states18. They revealed disease-related network alterations 
such as a loss of balance between segregation and integration of information (small-world attribute) and redistri-
bution of regions considered central for the information flux over the network (hub regions)19–23. Additionally, 
Alzheimer’s patients show decreased long-distance-interhemispheric correlations- and increased correlations 
between brain regions targeted by the  disease18,19,23. These disruptions could reflect that the whole-brain net-
work is more segregated and less integrated during AD progression than in healthy individuals. Despite such 
findings, the ApoE4 risk factor’s inclusion has been scarce and limited mostly to healthy aging subjects and AD 
 patients24–28.
There is only a handful of investigations on the ApoE4 effects on topological brain networks organizations 
in MCI. Two studies using resting-state Functional Magnetic Imaging (rs-fMRI) and diffusion weight imag-
ing (DWI) compared MCI Carrier and non-Carriers  groups29,30. In both cases, the network analysis showed 
specific aberrant patterns in MCI Carriers. Yao and  colleagues31 reported for the first time differences between 
Carriers and non-Carriers based on metabolic covariance networks using Fluorodeoxyglucose Positron Emis-
sion Tomography (FDG-PET). Carriers were found to have lower clustering index and disruptive long-distance 
interregional correlations.
Nevertheless, ApoE4-related effects on the structural covariance network topology have not yet been fully 
explored in MCI. Such work is necessary to clarify how the genetic risks mediate and constrain the covariance 
patterns and the phenotypic expression in MCI. The identification of these subtle alterations at the network 
level may help detect, at earlier stages, the risk of AD progression in MCI ApoE4 Carriers compared to other 
disease-related markers like atrophy.
Precisely, we focus on the ApoE4-related modulation of the topological organization of cortical thickness 
covariance brain networks in MCI through structural MRI (sMRI) and graph-theory approach. We examine 
different features of the structural brain topology: (1) regional cortical thickness, (2) global network attributes 
(clustering index, characteristic path length, local and global efficiency, global connectivity, and homologous 
region connectivity) (3) nodal properties (normalized betweenness centrality, hubs) (4) network community 
detection (modularity) and resilience to insults (target attack). We hypothesize that ApoE4 is related to both 
local and global network properties changes in MCI.
Materials and methods
Subjects. Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuro-
imaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public–private 
partnership, led by Principal Investigator Michael W. Weiner, MD. ADNI’s primary objective has been to test 
whether serial magnetic resonance imaging, positron emission tomography, other biological markers, and clini-
cal and neuropsychological assessment can be combined to measure the progression of MCI and early Alzhei-
mer’s Disease. For up-to-date information about ADNI, including Police and Procedures, see www.adni-info.
org.
In the present study, 253 MCI participants with baseline T1-weighted structural magnetic resonance images 
were selected and downloaded from the USC’s Laboratory of Neuroimaging ADNI (http://www.loni.ucla.edu/
ADNI/).
The inclusion criteria were as follows: Mini-Mental-State-Examination (MMSE) scores between 24 and 30 
(inclusive), a memory complaint, objective memory loss measured by education adjusted scores on the Wechsler 
Memory Scale Logical Memory II, a Clinical Dementia Rating (CDR) of 0.5, and absence of significant levels of 
impairment in other cognitive domains, essentially preserved activities of daily living and an absence of dementia.
Exclusion criteria included: (1) the presence of a major depressive disorder or significant symptoms of depres-
sion; (2) modified Hachinski ischemia score greater than 5; (3) significant neurological or psychiatric illness; (4) 
use of antidepressant drugs with anticholinergic side effects; (5) high dose of neuroleptics, chronic sedatives, hyp-
notics, antiparkinsonian medication, and use of narcotic analgesics. Detail about inclusion/exclusion criterium 
can be found in http://adni.loni.usc.edu/wp-conte nt/theme s/fresh newa-dev-v2/clini cal/ADNI-1_Proto col.pdf)32.
The MCI group was stratified into those with one ApoE4 allele (Carriers) and those without (non-Carriers). 
ApoE genotyping details can be accessed at http://adni.loni.usc.edu/data-sampl es/clini cal-data/33. Participants 
with one or more E2 allele(s) were excluded from this study due to the allele’s possible protective  effects34.
The subjects also met the following criteria: anatomical study acquired in a 1.5 T MRI-scanner, right-hand-
edness, high sMRI image quality. For biomarker’s measurements (Cerebrospinal fluid) characteristics, see Sup-
plementary Information.
Ethical statements. As per ADNI protocols, all procedures performed in studies involving human par-
ticipants were under the institutional national research committee’s ethical standards and the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards. More details can be found at adni.loni.
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usc.edu. Participants were studied under ADNI protocols approved by the Institutional Review Board (IRB) at 
each recruitment site, and written informed consent was obtained from all subjects prior to enrollment. A listing 
of sites with named Site Investigators can be found online at http://adni.loni.usc.edu/wp-conte nt/theme s/fresh 
news-dev-v2/docum ents/polic y/ADNI_Ackno wledg ement _List%205-29-18.pdf.
Data acquisition and preprocessing. Preprocessed versions of the 253 baselines T1-weighted MRI scans 
were downloaded. Further details are available in the ADNI-MRI technical procedures manual (http://adni.loni.
usc.edu/metho ds/docum ents/MRI protocols). Preprocessing steps can be found  elsewhere35–37.
Computation of mean cortical thickness matrices. Cortical reconstruction and volumetric seg-
mentation were performed using the Freesurfer analysis software suite with default settings (http://adni.loni.
usc.edu/metho ds/docum ents/MRI protocols). The technical details of these procedures have been previously 
 described38. FreeSurfer provides the cerebral cortex’s parcellation based on Destrieux sulci-gyral-based  atlas39 
and the mean cortical thickness for each cortical structure. We used these outputs to construct our data matrices 
for each group. The number of rows corresponds to the number of subjects, while the number of columns cor-
responds to the number of structures (Fig. 1).
Cortical thickness network construction. We defined a connection as statistical associations in cortical 
thickness between each pair of brain regions for a parcellation scheme of N = 148 anatomical structures (sub-
cortical gray nuclei were excluded) (Supplementary Table S1 online). The synchronized covariations in cortical 
thickness between two regions were computed using Pearson’s correlation coefficient across subjects. Thus, the 
interregional correlation matrix (N × N, N is the number of brain regions) of such connections was obtained 
using all pairs of anatomical structures. Self-connections were excluded implying zeros in the diagonal of the 
symmetric matrix. It is essential to point out that a partial correlation analysis could not be used in our case 
because the sample size was not large enough for a robust estimation of this measure.
Before the correlation analysis, a linear regression was performed at every region to remove the effects of age, 
gender, age-gender interaction, and cerebral mean cortical thickness.
In the next step, we obtained for each MCI group Nboot = 2000 bootstrap samples of the connectivity matrix 
by selecting a random subset of subjects with replacement using the classical bootstrapping procedure described 
 in40.
Figure 1.  Flowchart of the cortical thickness matrix construction. (a) Representation of the M individual 
anatomic MRI images. (b) During FreeSurfer processing, the cortical surface of the M subjects was extracted. (c) 
Using the FreeSurfer toolbox, the cortical surfaces were labeled using a reference atlas. (d) The cortical thickness 
for each structure was calculated as the mean thickness of all vertices defined as belongs to that structure. (e) All 
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The connectivity matrices obtained from bootstrapping were thresholded to create sparse binary graphs. We 
explored the Network Properties of the graphs over a range of sparsity degrees varied from 0.5 to 0.9 in steps of 
0.0241. This range of sparsity degree has been indicated in previous studies to be  optimal42,43. Similarly to other 
papers, only the positive correlation values are used to define the connectivity matrices. This choice is based on 
the lack of a clear physiological justification for negative correlations and the possible contamination by spurious 
negative correlation as a side effect of regressing out global effects in the preprocessing step (Fig. 2).
Network properties analysis, graph theory approach. In general, a complex network can be rep-
resented as a graph G = [N, K], the components of this system are called nodes (N), and the relations or con-
nections between them are called edges (K)44. The nodes are the anatomical regions, and the edges are the cor-
relations in cortical thickness across subjects between pairs of these brain regions. It is important to note here 
that this is a mathematically derived network whose connections do not necessarily constitute brain functional 
or physiological mechanisms directly. However, these networks are based on structural data. Therefore, they 
indirectly reflect the underlying mechanism, allowing us at the same time to use them and their properties as 
possible biomarkers of the differences between normal and pathological brain states.
In particular, we analyzed the following global network attributes: clustering  index45, characteristic path 
 length44,45, local and global  efficiency46, global connectivity, and homologous regions  connectivity47. To describe 
the network’s nodal properties, we computed the normalized betweenness centrality (NBC)19,23 measure to 
identify the network hubs. We also performed a modularity analysis representing a network with densely inter-
connected nodes and relatively few connections between nodes in different  modules48. It is a reflection of the 
natural segregation within a  network49–51. Additionally, we carried out a ’Targeted-Attack’ study to evaluate the 
cortical thickness covariance network’s resilience when the most critical regions (hubs) are virtually attacked. 
Definitions for these measures within the traditional interpretation of complex networks  framework52 can be 
found in Supplementary Information and Table S2 online.
Methodology for studying differences in regional cortical thickness. Cortical vertex-wise regres-
sion analyses were performed using the SurfStat MATLAB toolbox (http://www.math.mcgil l.ca/keith /surfs tat). 
Age, gender, and mean cortical thickness (CT) were statistically controlled. The statistical significance of the 
t-statistic maps for cortical thickness differences was corrected for multiple comparisons using Random Field 
Figure 2.  Steps for assessing the networks of cortical thickness covariance. (a) Matrix of the morphometric 
descriptor (cortical thickness) for the Destrieux parcellation. (b) The data matrix was substituted by residuals 
of the linear regression to subtract effects of age, gender, interaction age–gender, and the global effect (global 
mean cortical thickness) represented in (c). (d) Correlation matrix representing the concurrent changes among 
all pairs of anatomical structures. (e) The thresholding process for different sparsity levels to generate binary 
graphs. (f) Assessment of the network properties for all binary graphs obtained in (e).
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Theory (RFT) to avoid false positives when more than 80,000 tests were  performed53. RFT identifies statistically 
significant "clusters" of vertices and vertex "peaks". Cluster p-values show regions of connected vertices with 
p-values below 0.001 in clusters whose extent is significant at p < 0.05, i.e., a collection of connected vertices with 
p < 0.001 that was unlikely to occur by chance.
Statistical methods to study ApoE4 modulation of global network properties. Network prop-
erties (NP) of the cortical thickness correlation matrices were computed for each sparsity degree values and 
different bootstrap samples in each MCI group. Thus, we had a set of Nboot = 2000 NP curves for each network 
property. The area under the curve (AUC) was computed for each network attribute to contrast the global behav-
ior of these  attributes54. The NP curves’ monotonic changes make AUC a suitable descriptor of the networks’ 
global performance.
We followed three main steps to examine differences in global network properties between groups: (1) con-
struction of the empirical bootstrapped distribution of differences by subtracting the corresponding bootstrap 
samples between groups; (2) definition of the statistical significance level: a 95 percent confidence interval (CI) 
(biased corrected percentile bootstrap CI)55 of the distribution of the empirical difference is estimated; (3) 
Hypothesis testing: a significant difference between groups is accepted if CI does not contain zero, no significant 
difference is considered otherwise. A p-value associated with each hypothesis test is also reported.
Methodology to explore nodal betweenness centrality (NBC) differences between groups. For 
each bootstrap sample of the cortical thickness connectivity matrix, the NBC was computed at every single spar-
sity degree. Previously to this process, the largest  component54 of all bootstrap samples of the cortical thickness 
covariation matrices were calculated. The minimum sparsity degree for the largest connected components (equal 
to the number of structures) was used as an upper limit of the sparsity degree range. This step guarantees that 
all nodal NBCs come from fully connected cortical thickness networks. Similarly to global network properties, 
we take the AUC and follow the three main steps to examine differences between groups for each anatomical 
structure. To control for multiple comparisons (across the number of structures), we applied the False Discovery 
Rate (FDR) correction.
Hubs were selected as those with mean NBC superior to 1.5, similar  to41.
Construction of the Cortical Thickness Network and computation of network metrics were performed using 
the MorphoConnect  toolbox56 and subroutines of the Brain Connectivity  Toolbox52 (https ://sites .googl e.com/
site/bctne t/). The figures were created using the BrainNet Viewer  package57 (http://www.nitrc .org/proje cts/bnv) 
and the Gephi  package58 (https ://gephi .org/).
Results
Demographic and neuropsychological variables. There were no significant differences in gender, 
education, MMSE scores, and mean cortical thickness between groups (Table 1). However, the age was signifi-
cantly different between MCI Carriers compared to non-Carriers (U (6542) = − 2.51, p = 0.01). The MCI Carriers 
group was younger than non-Carriers on the diagnosis age (74.17 vs. 76). This result agrees with previous studies 
were ApoE4 had been associated with a younger age of  onset59.
ApoE4‑related changes in regional cortical thickness. Differences in cortical thickness between 
MCI Carriers and non-Carriers were not statistically significant after FDR correction (Supplementary Fig. S1 
online). However, percent difference maps show trends for a reduced thickness bilaterally in the anterior tem-
poral lobe and frontal lobe regions in the Carriers group compared with non-Carriers. The non-Carriers group 
tended to lower cortical thickness values in left posterior parietal areas, the precuneus, posterior cingulate gyrus, 
and frontal pole. For a list of clusters, see Supplementary Table S3 online.
Table 1.  Demographics and neuropsychological variables for MCI groups. Age, Education, MMSE, and Mean 
cortical thickness values are represented by means and standard deviations. Gender (M/F) is represented by 
the number of subjects. Significant set at p < 0.05. The superscripts “&” represents χ2 test; “+” represents the 
Mann–Whitney U test. Key: MCI mild cognitive impairment; Carriers: ApoE4-positive; non-Carriers: ApoE4-
negative; M male; F female; y years; MMSE mini-mental state examination.
MCI
StatisticsCarriers Non-carriers
N 126 127 –
Gender (M/F) 80/46 88/39 p = 0.33&
Age (y) 74.17 (6.91) 76 (7.97) U(6542) = − 2.51, p = 0.01+
Age range 56.8–88.9 54.6–89.8 –
Education (y) 15.63 (3.03) 15.61 (3.38) U(7878) = − 2.21, p = 0.83+
MMSE 26.97 (1.85) 27.17 (1.83) U(7492) = − 0.87, p = 0.38+
Mean cortical thickness (mm) 2.23 (0.12) 2.23 (0.14) U(7902) = − 0.17, p = 0.86+
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ApoE4 modulates the global network properties. Figure 3 shows the cortical thickness matrices for 
negative (Fig. 3a,b) and positive correlation values (Fig. 3c,d) for each group. Only matrices with positive values 
were used for the subsequent analysis.
Figure 4 shows the changes in global network properties for both groups across various densities thresholds 
(0.5 to 0.9). The two networks exhibit differences in clustering index, characteristic path length, local and global 
efficiency, global connectivity, homologous regions connectivity, and modularity. The Target Attack simulation 
was not significantly different between groups (p > 0.05) for the whole range of densities values (Table 2).
The comparison of the global network properties based on the AUC values revealed in MCI Carriers as 
compared with non-Carriers a decrease in clustering index, characteristic path length, local efficiency, homolo-
gous regions connectivity, global connectivity strength, and modularity. In contrast, the MCI Carriers group 
exhibited higher global efficiency (Fig. 5). The results of the statistical analysis, including confidence intervals, 
can be found in Table 2.
Group‑based differences in normalized betweenness centrality (NBC). We also studied the 
effects of ApoE4 on the Normalized Betweenness Centrality (NBC), a regional network property. The AUC 
analysis showed 11 regions with NBC differences between groups after FDR correction (p < 0.05) (Fig. 6). The 
full list of structures and the statistical analysis results (including confidence intervals) can be found in Supple-
mentary Table S4 online. NBC regional differences between groups comprise mainly occipital-temporal brain 
areas followed by limbic and frontal regions. Compared with non-Carriers, Carriers showed lower NBC for all 
brain regions except for the right lingual gyrus, left inferior temporal sulcus, right medial occipitotemporal sul-
cus (collateral sulcus), and lingual sulcus.
ApoE4 modifies the brain network hubs. We also studied the effects on the hubs of the cortical thick-
ness covariance network due to the presence of ApoE4. There were identified 24 hubs in each group (Fig. 7). The 
detailed list of structures and its NBC values were tabulated in Supplementary Table S5 online. We identify 11 
common hubs to both groups (Fig. 7, yellow structures), including limbic (bilateral anterior part of the cingulate 
Figure 3.  Cortical thickness correlation matrices for each group. (a) and (b) display matrices with positive 
and negative correlation values. (c) and (d) represent matrices with positive correlation values. The strength 
of the connection is indicated by the color bar. The ’R-’R’ and ’L-’L’ quadrants represent the intra-hemispheric 
cortical thickness correlations in the right and left hemispheres. The ’R-’L’ and ’L-’R’ quadrants depict the 
inter-hemispheric interactions. The diagonal of the ’L’-’R’ quadrant shows the correlations in cortical thickness 
between homologous structures across hemispheres.
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gyrus and sulcus, left posterior-dorsal part of the cingulate gyrus), insular (bilateral posterior ramus of the lateral 
sulcus, anterior segment of the circular sulcus of the insula), frontal (central operculum and sulci), temporal 
(superior temporal sulcus) and temporal-occipital and parietal-occipital regions (parieto-occipital sulcus, ante-
rior transverse collateral sulcus).
Compared to non-Carriers, where hubs comprised mainly parietal-occipital-temporal areas, in the Carri-
ers group were localized predominantly in frontal and parietal-occipital-temporal regions. Hub regions found 
only in Carriers, including the posterior-dorsal part of the cingulate gyrus, inferior occipital gyrus and sulcus, 
superior temporal and orbital gyrus. Areas identified as hubs in the non-Carriers comprised the lingual aspect 
of the medial occipitotemporal gyrus, supramarginal gyrus, and subcallosal gyrus.
ApoE4‑related change of the cortical thickness network modularity. Modularity estimation was 
performed on the groups averaged connectivity matrix using Newman’s metric. The resulting analysis (Fig. 8) 
divided the 148 cortical nodes into five modules for MCI Carriers and three modules in the non-Carriers group.
The modules are represented on a circular graph layout, where the nodes are placed in circles if they belong 
to the same module. Three communities defined the non-Carriers modularity with similar region numbers 
(community 1: N = 41, community 2: N = 59, and community 3: N = 48). Each module included a distributed set 
of regions. However, the analysis per lobule showed an anterior community based mainly in the frontal areas, 
a central module with similar frontal, parietal and occipital regions, and a posterior module integrated by tem-
poral and temporal-occipital areas. On the other hand, Carriers showed more segregated modularity based on 
5 communities with two large modules (community 2: N = 33 and community 3: N = 39) and three smaller ones 
(community 1: N = 30, community 4: N = 22, and community 5: N = 24). In this group, the community compo-
sition was more diverse as compared with non-Carriers. However, we were able to identify that the modules 
showed a specific pattern of regions summarized as follows: community (1) temporal-occipital, community (2) 
Figure 4.  Global network properties as a function of sparsity degrees.
Table 2.  Network properties differences between groups. Network properties in each group are represented by 
the mean and standard deviations: mean (s.d). In bold, the significance differences, those confidence intervals 
that do not contain zero.
Network property Carriers Non-carriers Confidence interval (95%) p-value
Clustering index 7.92 (0.2) 8.57 (0.3) [− 1.62, − 0.61] 0.04*10–4
Characteristic path length 28.74 (0.06) 29.04 (0.15) [− 0.88, − 0.28] 0.03*10–3
Target attack 16.24 (0.09) 16.25 (0.09) [− 0.12, 0.42] 0.67
Local efficiency 12.39 (0.08) 12.70 (0.13) [− 0.78, − 0.32] 0.09*10–4
Global efficiency 11.24 (0.01) 11.19 (0.03) [0.04, 0.14] 0.06*10–3
Global connectivity 0.06 (0.01) 0.07 (0.01) [− 0.01, − 0.001] 0.04
Homologous regions connectivity 0.36 (0.01) 0.4 (0.01) [− 0.08, − 0.01] 0.02
Modularity 3.83 (0.20) 4.45 (0.28) [− 1.61, − 0.29] 0.02
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Figure 5.  The area under the curves (AUC) of the cortical thickness covariance global properties. The bar 
heights represent the mean of the network properties, and the error bars are their standard deviation.
Figure 6.  Significant differences between groups based on NBC. The bar heights represent the mean NBC 
values for each group, and the error bars the standard deviations. R: right hemisphere, L: left hemisphere. The 
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frontoparietal, community (3) parietal-occipital, community (4) insula, community (5) frontal regions. For a 
complete list of regions per module in each group, see Supplementary Table S6 online.
It is worth noting that modules 2 and 3 in Carriers are assigned to the second module in non-Carriers and 
modules 4 and 5 to module 3, suggesting a low level of segregation for non-Carriers. The sub-modules combine 
to form predominantly anterior–posterior large communities.
Discussion
We investigated for the first time the cortical thickness structural covariance networks in ApoE4 Carriers and 
non-Carriers groups to assess the effect of genetic risk on large-scale network topology in MCI. Few previous 
studies have found evidence of the ApoE4 modulation on the MCI brain network topology using graph theory 
based on physiological variables derived from other image modalities (rs-fMRI, FDG-PET, and DWI). However, 
our approach is timely based on the following points:
(1) As a morphometric descriptor, cortical thickness offers unique information about morphological covari-
ance patterns between brain regions compared to other cortical  measures41.
(2) Structural covariance analysis is attractive because of the wide availability (in clinical and research settings) 
of high-quality sMRI scans compared with other modalities. Additionally, the cortical thickness derived 
from sMRI has proved consistent across scanner systems and field  strengths60.
(3) It has been shown that anatomical covariance patterns are related to functional and anatomical connectiv-
ity. However, comparing these connectivity measures has demonstrated that brain structural covariance 
networks capture complementary information of the same physiological  processes16,61.
(4) Graph theory provides a unique description of the multivariate neural process by looking at their local and 
global connectivity topology.
(5) Unlike the previous  studies29–31, we introduced the modularity and target attack analyses providing further 
information about the topological organization of the structural covariance networks in MCI.
Figure 7.  Hubs regions in MCI Carriers and non-Carriers based on the Normalized Betweenness Centrality 
(NBC). The blue regions represent hubs in the Carriers and the red ones the non-Carriers. In yellow are 
represent hubs common to both groups. The NBC values were mapped onto the cortical surfaces using the 
BrainNet Viewer package (http://www.nitrc .org/proje cts/bnv).
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Summarizing, our research presents novel experimental evidence regarding the ApoE4 effects on the brain 
network topology, which are worth investigating to define intermediate phenotypes in MCI.
In general, our findings revealed a decrease in global and homologous connectivity strength, clustering index, 
characteristic path length, local efficiency, modularity, and an increase of global efficiency in MCI Carriers 
compared to non-Carriers. MCI carriers showed lower values of NBC in several brain regions. Together, these 
findings concur with the evidence that ApoE4 is associated with an aberrant brain network topology in MCI. 
On the other hand, the changes are not detectable with the standard univariate approach based on the cortical 
thickness’s differences. Our results support the concept that multivariate measures (i.e., covariations) combined 
with a graph theoretical approach are more sensitive to identifying complex pathological processes, as found in 
other brain diseases. Univariate measures derived from the standard methods could be insufficient for capturing 
subtle (early) abnormal changes.
Some of these results deserve more attention and will be discussed in the following.
In particular, we observed a decrease in the clustering coefficient index in MCI Carriers relative to non-
Carriers, indicating lower local cortical thickness correlations. This finding suggests a topological organization 
more like a random network in this group of patients, a structure previously reported in AD  subjects18,62,63. 
Moreover, it has been demonstrated an association between longitudinal decreases of the clustering index and 
risk of MCI conversion into  AD63. Previous studies showed no differences between groups or reported similar 
 results29,31. The disagreement between investigations could be related to several factors like group composition, 
sample size, different neuroimaging modalities, and atlas parcellation.
In the current study, we also observed a shorter characteristic path length associated with the presence of 
the ApoE4, indicating that fewer steps are required to carry on the information across remote brain  regions64. A 
similar result was found in previous research in cognitively normal elderly ApoE4  Carriers26 using FDG-PET. A 
compensatory mechanism for early local pathological events seems a plausible hypothesis when the clustering 
index decreases in the presence of shorter characteristic path length. Also, the ApoE4 allele has been proposed 
as an example of antagonistic  pleiotropy65. The concept means that ApoE4 may offer benefits during early and 
Figure 8.  Module distributions for both Carriers and non-Carriers groups estimated using Newman’s spectral 
community detection algorithm at sparsity degree 0.88. The circular representation of the modules was based on 
the Gephi package (https ://gephi .org/). Inferior panels show the cortical surface mapping of the modules in both 
Carriers and non-Carriers groups using the BrainNet Viewer package (http://www.nitrc .org/proje cts/bnv). Each 
color represents those regions that belong to a specific module.
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middle age and promote better compensatory mechanisms during early disease phases like MCI that can be 
captured using a complex network approach.
Like in the clustering index, one previous study reported no differences between groups in characteristic path 
 length31. However, our results seem to be more reliable since Yao et al. (2015) gathered the MCI, AD, and healthy 
controls to form the Carriers and non-Carriers groups, making it challenging to disentangle group  differences31.
Our analysis also showed a decrease in global connectivity strength- an aggregate measure of the correlation 
values between all possible pairwise anatomical structures- in MCI Carriers relative to non-Carriers. Previous 
studies did not report on this network  property29–31. This finding may indicate that mechanisms underlying 
cortical thickness are differentially coordinated across this group of patients. Another possibility is that ApoE4 
increases the interindividual differences between regional cortical thicknesses in Carriers. It may be due to less 
cortical thickness coordinated patterns concerning the homogeneity effects created by putative compensatory 
and shared brain region vulnerability associated with the aging processes and interactions with the MCI stage.
The nodal properties results allowed us to generate hypotheses about the ApoE4 impact on brain network 
integration and segregation in MCI. Similar to previous studies, we found the opposite effects of the ApoE4 
genotype on nodal  centrality30,31. There is probably more than one cause for these alterations, which makes 
disease-related changes in structural covariance challenging to interpret. A regional lower NBC may be sugges-
tive of dysconnectivity due to a localized degeneration. By contrast, an increase may indicate over connectivity 
or synchronized cortical thickness loss in several areas targeted by the same neurodegenerative process. Most 
brain regions reported here are different from previous  studies30,31 based on other neurophysiological variables. 
It is indicative that the networks of cortical thickness covariance capture supplementary information of the 
anatomical brain organization. Other factors could also be playing a role like sample characteristics and differ-
ent statistical approaches.
Our findings showed agreements with previous studies in AD neurodegeneration. The fact that crucial struc-
tures like Posterior Cingulate Cortex (PCC) showed lower NBC values in the Carriers group suggests that 
regional topological properties may capture disease-related effects that can be further explored in association 
with the risk of AD progression. We identified between-group differences in NBC across different lobes, consist-
ent with previous  findings26,30. Several regions in the Limbic and Frontal cortex decreased centrality in Carriers 
as compared with non-Carriers. Notably, for all detected hubs, NBC was lower in Carriers than non-Carriers. 
Some of these structures were: cingulate gyrus, middle occipital gyrus, occipital pole, superior frontal sulci, and 
orbital gyrus. It is important to note that several of these regions are part of the Default Mode Network (DMN). 
As is recognized, the DMN is involved in self-referential functions such as episodic  memory66 affected by AD. 
In this network, the PCC is a key integration node between the medial temporal lobe and medial prefrontal 
 subsystems66,67. Previous studies reported in the DMN (including PCC) high glycolytic metabolism, enhancing 
abnormal amyloid deposition  aggregation68,69. ApoE4, as a disrupted metabolic  factor10, may alter the DMN 
resting-state activity and ultimately bringing atrophy in MCI ApoE4 Carriers, accelerating AD pathology early 
during the disease course.
Lower NBC values were also found in regions that belong to the Saliente Network (i.e.insula). This network 
operates on identified salience and, as such, includes known sites for sustained attention and working memory 
(dorsolateral prefrontal cortex, lateral parietal cortex), response selection (dorsomedial frontal), and response 
suppression (prefrontal cortex)70–72. Our findings may suggest that ApoE4 Carriers have altered regulation of 
control processes that subsequently influence memory performance.
To the best of our knowledge, we reported, for the first time, a modularity analysis of the structural covari-
ance network in MCI. We observed a decreased modularity in Carriers as compared with non-Carriers. A less 
modular network implies fewer connections within modules and more connections to other modules. In graph 
theory terms, Carriers shows better cost-efficiency wiring regarding the physical volume occupied, conduction 
delay, and metabolic cost. On the other hand, the increase of interconnectedness between modules can lead to 
the rapid spreading of disease pathological markers (neurodegenerative process) and loss of  specialization73. In 
many networks, as in our case, modularity and global efficiency are inversely related, as a highly modular topol-
ogy could require long communication paths to integrate information across the network.
In addition to these differences, the module size and composition also change associated with the ApoE4. This 
analysis revealed in Carriers a spatial rearrangement of these communities. They include sets of brain regions that 
are anatomically proximal, and they mainly belong to the same lobule. However, in non-Carriers, the module’s 
compositions are more distributed across the cortex. We identified anterior-medial-posterior network modular-
ity mainly formed by frontal, frontal-parietal, and temporal-occipital modules. This modular topology has been 
described previously in resting-state networks in normal aging. It evidences the brain network evolves from a 
preferentially local connectivity pattern to a more distant and functionally community  structure74. Further lon-
gitudinal studies on modularity patterns differences between Carriers and non-Carriers could offer an exciting 
opportunity to distinguish those MCI patients at high risk of AD progression.
In conclusion, our study applies the graph theory to assess the ApoE4-related changes on global and local 
network topology in MCI based on the concurrent variations of the cortical thickness across anatomical struc-
tures. Our findings showed that some network properties changes in MCI Carriers seem to be associated with 
altered communication between neighboring regions. It may be an early response to AD-related pathological 
markers (i.e., tau-tangles and amyloid-beta plaques depositions). On the other hand, a better global network 
communication could be considered the expression of compensatory/degeneracy mechanisms to sustain the 
transmission of the information across distant brain regions associated with the genetic challenge. These changes 
in topological attributes may be considered sensitive markers to detect early brain network changes related to 
the disease progression.
The methodological approach used in this study has several limitations. The structural covariance analysis 
has a static nature. Evidence suggests that the brain undergoes spontaneous reconfiguration at a temporal  scale75, 
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as such properties like modular structure and hub may fluctuate over time. A quantitative comparison of the 
network topological attributes between studies is difficult. These properties’ values depend on experimental 
parameters like brain parcellation, nodes-edge definitions, and sample  size76. Despite providing useful infor-
mation, structural covariance analysis is a group approach. It does not allow individual analysis and statistical 
associations between topological network attributes and clinical/cognitive measures.
Other aspects need to be addressed in future investigations. (1) MCI patients exhibit different progression 
trajectories that we did not consider here; accordingly, further follow-up longitudinal studies are warranted to 
examine the interaction between network properties, disease progression, and ApoE4 (2) The inclusion of healthy 
elderly sample, as well as AD patients, would help to fully characterize the ApoE4 effect on the brain network 
properties across the disease spectrum (4) This study did not investigate whether the ApoE4-related impact on 
the brain network topology is mediated by pathological disease markers like beta-amyloid and tau deposition. 
Further investigations on this topic will clarify the underlying mechanisms associated with the brain network 
properties changes. Despite these limitations, our study sheds light on the structural connectomics of MCI associ-
ated with the ApoE4. We considered a complex network analysis with the genetic risk factors inclusion, a valu-
able approach to understanding the AD spectrum, which could improve the personalized medicine perspective.
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Supplementary Information 
Supplementary Table S1. List of anatomical structures 




1   G and S frontomargin Fronto-marginal gyrus (of Wernicke) and 
sulcus 
FMarG.S F 
2   G and S occipital inf Inferior occipital gyrus (O3) and sulcus InfOcG.S T -O 
3   G and S paracentral Paracentral lobule and sulcus PaCL.S F-P 
4   G and S subcentral Subcentral gyrus (central operculum) and 
sulci 
SbCG.S F 
5   G and S transv 
frontopo 
Transverse frontopolar gyri and sulci TrFPoG.S F 
6   G and S cingul Ant Anterior part of the cingulate gyrus and 
sulcus (ACC) 
ACgG.S L 
7   G and S cingul Mid 
Ant 
Middle-anterior part of the cingulate gyrus 
and sulcus (aMCC) 
MACgG.S L 
8   G and S cingul Mid 
Post 
Middle-posterior part of the cingulate gyrus 
and sulcus (pMCC) 
MPosCgG.S L 
9   G cingul Post dorsal Posterior-dorsal part of the cingulate gyrus 
(dPCC) 
PosDCgG L 
10   G cingul Post ventral Posterior-ventral part of the cingulate gyrus 
(vPCC, isthmus of the cingulate gyrus) 
PosVCgG L 
11   G cuneus Cuneus (O6) Cun O 
12   G front inf Opercular Opercular part of the inferior frontal gyrus InfFGOpp F 
13   G front inf Orbital Orbital part of the inferior frontal gyrus InfFGOrp F 
14   G front inf Triangul Triangular part of the inferior frontal gyrus InfFGTrip F 
15   G front middle Middle frontal gyrus (F2) MFG F 
16   G front sup Superior frontal gyrus (F1) SupFG F 
17   G Ins lg and S cent 
ins 
Long insular gyrus and central sulcus of the 
insula 
LoInG.CInS I 
18   G insular short Short insular gyri ShoInG I 
19   G occipital middle Middle occipital gyrus (O2, lateral occipital 
gyrus) 
MOcG O 
20   G occipital sup Superior occipital gyrus (O1) SupOcG O 
21   G oc temp lat fusifor Lateral occipito-temporal gyrus (fusiform 
gyrus, O4-T4) 
FuG T-O 
22   G oc temp med 
Lingual 
Lingual gyrus, lingual part of the medial 




23   G oc temp med 
Parahip 
Parahippocampal gyrus, parahippocampal 
part of the medial occipito-temporal gyrus, 
(T5) 
PaHipG O-T 
24   G orbital Orbital gyri OrG F 
25   G pariet inf Angular Angular gyrus AngG P 
26   G pariet inf Supramar Supramarginal gyrus SuMarG P 
27   G parietal sup Superior parietal lobule (lateral part of P1) SupPL P 
28   G postcentral Postcentral gyrus PosCG P 
29   G precentral Precentral gyrus PrCG F 
30   G precuneus Precuneus (medial part of P1) PrCun P 
31   G rectus Straight gyrus, Gyrus rectus RG F 
32   G subcallosal Subcallosal area, subcallosal gyrus SbCaG L 
33   G temp sup G T 
transv 
Anterior transverse temporal gyrus (of 
Heschl) 
HG T 
34   G temp sup Lateral Lateral aspect of the superior temporal gyrus SupTGLp T 
35   G temp sup Plan polar Planum polare of the superior temporal gyrus PoPI T 
36   G temp sup Plan 
tempo 
Planum temporale or temporal plane of the 
superior temporal gyrus 
TPI T 
37   G temporal inf Inferior temporal gyrus (T3) InfTG O-T 
38   G temporal middle Middle temporal gyrus (T2) MTG T 
39   Lat Fis ant Horizont Horizontal ramus of the anterior segment of 
the lateral sulcus (or fissure) 
ALSHorp F 
40   Lat Fis ant Vertical Vertical ramus of the anterior segment of the 
lateral sulcus (or fissure) 
ALSVerp F 
41   Lat Fis post Posterior ramus (or segment) of the lateral 
sulcus (or fissure) 
PosLS I 
42   Pole occipital Occipital pole OcPo T-O 
43   Pole temporal Temporal pole TPo T-O 
44   S calcarine Calcarine sulcus CcS O 
45   S central Central sulcus (Rolando's fissure) CS F 
46   S cingul Marginalis Marginal branch (or part) of the cingulate 
sulcus 
CgSMarp F 
47   S circular insula ant Anterior segment of the circular sulcus of the 
insula 
ACirInS I 
48   S circular insula inf Inferior segment of the circular sulcus of the 
insula 
InfCirInS I 
49   S circular insula sup Superior segment of the circular sulcus of the 
insula 
SupCirInS I 
50   S collat transv ant Anterior transverse collateral sulcus ATrCoS O-T 
51   S collat transv post Posterior transverse collateral sulcus PosTrCoS O-T 
52   S front inf Inferior frontal sulcus InfFS F 
53   S front middle Middle frontal sulcus MFS F 
54   S front sup Superior frontal sulcus SupFS F 
55   S interm prim Jensen Sulcus intermedius primus (of Jensen) JS P 
56   S intrapariet and P tra Intraparietal sulcus (interparietal sulcus) and 
transverse parietal sulci 
IntPS.TrPS P 
57   S oc middle and 
Lunatus 
Middle occipital sulcus and lunatus sulcus MOcS.LuS O 
58   S oc sup and 
transversa 
Superior occipital sulcus and transverse 
occipital sulcus 
SupOcS.TrOcS O 
59   S occipital ant Anterior occipital sulcus and preoccipital 
notch (temporo-occipital incisure) 
AOcS T-O 
60   S oc temp lat Lateral occipito-temporal sulcus LOcTS O-T 
61   S oc temp med and Medial occipito-temporal sulcus (collateral CoS.LinS O-T 
3 
 
Lingu sulcus) and lingual sulcus 
62   S orbital lateral Lateral orbital sulcus LOrS F 
63   S orbital med olfact Medial orbital sulcus (olfactory sulcus) MedOrS F 
64   S orbital H Shaped Orbital sulci (H-shaped sulci) OrS F 
65   S parieto occipital Parieto-occipital sulcus (or fissure) POcS P-O 
66   S pericallosal Pericallosal sulcus (S of corpus callosum) PerCaS L 
67   S postcentral Postcentral sulcus PosCS P 
68   S precentral inf part Inferior part of the precentral sulcus InfPrCS F 
69   S precentral sup part Superior part of the precentral sulcus SupPrCS F 
70   S suborbital Suborbital sulcus (sulcus rostrales, 
supraorbital sulcus) 
SbOrS F 
71   S subparietal Subparietal sulcus SbPS P 
72   S temporal inf Inferior temporal sulcus InfTS T-O 
73   S temporal sup Superior temporal sulcus (parallel sulcus) SupTS T 
74   S temporal transverse Transverse temporal sulcus TrTS T 
 
The regions are listed following the anatomical brain atlas described in Destrieux et al. (2010). The subcortical 
regions were not included. The short names, as well as the full structure names, are specified. The lobe to which the 
structure belongs is also included. L: Limbic; I: Insula; P: Parietal; O: Occipital; F: Frontal; T: Temporal. G: gyri; S: 
sulcus. 
 
Supplementary Table S2. Network properties definition and interpretation. 
Network Property Definition Interpretation 
 
Measures of functional brain segregation  
 






. Nodes are considered neighbors when 
a connection between them exists, 
which is not reduced to a physical 
neighborhood concept. 
 
In anatomical networks, the clusters 
suggest the potential for functional 
segregation, while the presence of 
clusters in functional networks suggests 
an organization of statistical 









Many complex networks, like the brain, 
consisting of several modules. Modules 
are derived from a decomposition of the 
network into subcomponents that are 
internally strongly coupled but 
externally only weakly correlated.  
Each module contains several densely 
interconnected nodes (brain regions).  
Dense connectivity within modules 
allows brain regions within each 
module to interact with one another 
easily. In contrast, sparser connectivity 
between modules allows each set of 
brain regions to be relatively 
independent of one another (specialized 
functions). 
Diminished connectivity between 
communities can result in loss of 
essential interactions or even 
disconnection of an entire community. 
On the other hand, excessive 
connectivity between modules may 
result in loss of compartmentalization 
or specialization of this brain region 
group. 









brain as a system is fault-tolerant, 
showing how efficient the 
communication is among the first 
neighbors of a node (brain region) when 
it is removed.  
 
   
Measures of functional brain integration 
 






Characteristic path length 
The path length is the minimum number 
of edges that must be traversed to go 
from one node (brain region) to 
another. It is a measure of the typical 
separation between two brain regions.  
The average shortest path length 
between all pairs of nodes in the 
the network is known as the 
characteristic path length of the 
network.  
Connection lengths are typically 
dimensionless and do not represent 
spatial or metric distance. 
Lengths of paths consequently 
estimate the potential for functional 
integration between brain 
regions. Shorter paths are implying a 
more substantial potential for 
integration between brain regions.  
Paths in functional/morphological 
networks represent statistical 
associations and may not correspond to 
information flow on anatomical 
connections. In this case,  
paths are less straightforward to 






It is the average inverse of the shortest 
path length.  
 
The global efficiency es primarily 
affected by the shorth path length, 
represents a superior measure of 
integration. 







It summarizes the interregional 
correlations coefficients between all 
possible pairs of nodes (brain regions). 
Describes the degree to which nodes are 
connected in a network. It can be 
quantified based on network metrics 
such as the relative density, the shortest 
path, or the diameter of the network. 
Previous studies have found strong 
correlations between regions with no 
direct structural (white matter tracts) 
connection. The total interregional 
morphometric correlations could 
capture all indirect structural 
correlations between two brain regions 
facilitated by a third party, from which 
diverse factors such as pathologic 
changes to the connectivity patterns 











Normalized betweenness centrality  
The centrality of a node (brain region) 
measures how many of the shortest 
paths between all other brain regions 
pairs in the network pass through it. 
Bridging nodes that connect disparate 
parts of the network have a high 
betweenness centrality.  
 
A node (brain region) with high 
centrality is thus crucial to efficient 
communication. It is based on the idea 
that central nodes participate in many 
short paths within a network, 
and consequently, act as essential 
controls of information flow. 
Their loss is particularly disruptive to 
the brain network. Several regions in 
the frontal and parietal cortex have high 
centrality in the human brain, 
particularly the posterior cingulate and 
precuneus. These are areas of the brain 
defined as transmodal or heteromodal. 
They are involved in integrating 
processing across several cognitive 
modalities.  Some of these regions 
overlap with the DMN, while others 
coincide with the frontoparietal system.  




Sample Biomarkers Characteristics 
Cerebrospinal fluid (CSF) samples at baseline were collected from 192 MCI subjects as part of 
the ADNI-1 protocol. The overlap between this sample and the one selected for the present study 
corresponds to 132 subjects (67 MCI-Carriers and 65 MCI non-Carriers). For details about CSF 
samples and methods see UPENN CSF Biomarkers Elecsys [ADNI1,GO,2].csv and UPENN 









high centrality. Measures of node 
centrality assess the importance of 
individual nodes.  
The hubs of the network are the regions 
with high values of NBC. 
 
areas, facilitate functional integration, 
and play a vital role in the brain 
network resilience to insult. Hubs are a 
cost-efficient solution to increase 
network efficiency to support cognitive 
processes without requiring many 
metabolically expensive connections. 
Hubs are suggested to be essential for 
cognition because they are located 
along the shortest paths in the network, 
and therefore are likely to play a critical 
role in distributed patterns of 
communication. 
This location is evident both by their 
high degree and by their tendency to 
connect, forming a core or "rich-club" 
that boosts inter-hub communication's 
robustness and promotes efficient 
communication across the brain.  
Damage to brain hubs is expected to 
have critical consequences for cognitive 
function in terms of the severity 
and pervasiveness of cognitive deficits. 
Measures of network resilience 










The importance of an individual node to 
network efficiency can be assessed by 
deleting it and estimating the 
the efficiency of the 'lesioned' network. 
It is an indirect measure of resilience  
that reflects network vulnerability to 
insult. Complex networks like the brain 
are highly vulnerable to disruptions of 
the central node (hubs). 
 
Robustness refers either to the 
network's structural integrity following 
the deletion of nodes or edges or to the 
effects of perturbations on local or 
global network states. 
Direct measures of network resilience 
generally test the network before and 
after a presumed insult by 
computationally simulated targeted 
removal of nodes and links. The effects 
of such lesions on the brain network 
may then be quantified by 
characterizing changes in the resulting 




MCI groups characterization based on ADNI1 CSF biomarker measurements (Aβ (1-42), tTau, 




Values are represented by the mean (pg/mL) and the Standard deviations (SD).  N: number of subjects;  MCI: Mild 
Cognitive Impairment; Carriers: ApoE4-positive; non-Carriers: ApoE4-negative; Aβ(1-42): β-Amyloid (1-42); tTau: 




MCI groups characterization as biomarker positive and negative based on Aβ (1-42), tTau and 
pTau  
 Group 






 Aβ(1-42) 56 (83.9) 11(16.4) 30 (46.1) 35 (53.8) 
pTau 45 (67.2) 22 (32.8) 24 (36.9) 41 (63) 
tTau 41 (61.2) 26 (38.8) 22 (33.8) 43 (66.1) 
pTau/ Aβ(1-42) 55 (82) 12 (17.9) 29 (44.6) 36 (55.2) 
tTau/ Aβ(1-42) 56 (83.6) 11 (16.4) 28 (43) 37 (56.9) 
 
Values are represented by the number of subjects (%). The positive (+) and negative (-) status are based on PET-
optimized cut-offs for Aβ(1-42), pTau/Aβ(1-42) and tTau/Aβ(1-42). CSF, cerebrospinal fluid; BM, biomarker; 
Aβ(1-42): β-Amyloid (1-42); tTau: Total-Tau; pTau: Phospho-Tau; MCI, mild cognitive impairment. For 
biomarkers, cut-offs description, see Hansson et al. (2018).  
 
 
CSF Biomarkers groups characterization. The Amyloid plaque burden +/- represented by Aβ (1-






Values are represented by the number of subjects (%). The positive (+) and negative (-) status are based on PET-
optimized cut-offs for Aβ(1-42), pTau/Aβ(1-42) and tTau/Aβ(1-42). CSF, cerebrospinal fluid; Aβ(1-42): β-Amyloid 
Biomarkers  MCI-Carriers (N,67) MCI non-Carriers (N, 65) 
Aβ(1-42)* 710.88 (398.26) 1068.54 (528.09) 
tTau* 335.79 (125.94) 276.52 (109.45) 
pTau* 35.77 (16.90) 26.05 (11.93) 
Biomaker MCI-Carriers MCI non-carriers 
Aβ(1-42)+/ tTau + 37 (55.2%) 5 (7.5%) 
Aβ(1-42)+/ tTau - 19 (28.4%) 25 (37.3%) 
Aβ(1-42)-/ tTau + 4 (5.9%) 17 (25.6%) 
Aβ(1-42)-/ tTau - 7(10.5%) 18 (26.9%) 
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(1-42); tTau: Total-Tau; pTau: Phospho-Tau; MCI, mild cognitive impairment. For biomarkers, cut-offs description, 
see Hansson et al. (2018).  
 
 
Graph Theory Metrics 
The following group theoretical metrics were computed in the present study: 
Clustering index ( C ). The clustering index of a node ‘i’ is defined as the number of existing 
connections between the node’s neighbors divided by all possible connections. It is a measure of 
the inherent tendency to cluster nodes into strictly connected neighborhoods. Nodes are 
considered neighbors when a connection between them exists, which is not reduced to a physical 
neighborhood concept. The clustering index for the whole graph G is defined as the average 
clustering around each node: 






    (1) 
 
Represent the number of nodes. Clearly, 0 < C < 1; and C= 1 if and only if the network is fully 
connected, that is, each node is connected to all other nodes. 
Characteristic path length ( L ). The characteristic path length L of the graph G is the smallest 
number of connections required to connect one node to another, averaged over all pairs of nodes. 
It is a measure of the typical separation between two nodes (structures) i and j  ,i j N  , and it 













   (2) 
 
In the unweighted network context, the geodesic length dij is defined as the number of edges 




globE , locE ). The concept of efficiency has also been expressed in terms of 
information flow. That is, small-world networks are very efficient in terms of global and local 
communication and they are defined to have high global globE  and local locE efficiency. The 
global 













   (3) 
 
This measure reflects how efficiently the information can be exchanged over the network, 
considering a parallel system in which each node sends information concurrently through the 








    (4) 
 
Where iG  is the subgraph of the neighbors of ‘i’. This measure reveals how much the system is 
fault-tolerant, showing how efficient the communication is among the first neighbors of i when it 
is removed. As above, nodes are considered neighbors when a connection between them exists, 
which is not reduced to a physical neighborhood concept. 
Global and Homologous regional connectivity. We assessed the global connectivity and 
homologous region connectivity. First, the absolute correlation coefficient values were converted 
to z using Fisher’s r-to-z transformation, followed by taking the mean and transforming back to 
correlations through the inverse Fisher’s z-to-r transformation. All anatomical regions were used 
to estimate the global connectivity, whereas only the correlation values between homologous 
regions were used in the mean homologous region connectivity. 
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Nodal centrality: normalized betweenness centrality (NBC). The ‘betweenness centrality’ Bi of a 
node i is defined as the number of shortest paths between any two nodes that run through node i. 
We measured the normalized betweenness centrality as bi= Bi /<B>, where <B> was the average 
betweenness of the network. bi is a global centrality measure that captures a node's influence 
over information flow between other nodes in the network. In our case, betweenness centrality bi 
could be used to reflect the effects of ApoE4 on the global roles of regions in the cortical 
thickness covariance networks. Hubs were selected as those with bi superior to 1.5, similar to 
previous investigations. 
Modularity. A complex network module is a subset of nodes that are densely connected within 
the modules but sparsely connected between the modules. Here we have adopted Newman's 
metric as a modularity measure to compare our results with previous studies that used this 
method in other neuroimaging modalities. 
Targeted Attack: Methodology to study the robustness of the cortical thickness covariance 
network 
We calculated a surrogate measure of the resilience of the cortical thickness covariance network 
against a targeted attack. In a simulated targeted attack study, network hubs are removed one by 
one in order of betweenness centrality (NBC). Each time a node was removed from the network, 
the largest connected component's size was recomputed. We defined the robustness parameter as 
the  AUC showing the relative largest connected component's size versus the number of nodes 
removed94. Robust networks retain large connected components even when several nodes have 
been knocked out, represented by a large  AUC. As before, we repeated this procedure for all 
bootstrapped connectivity matrices and sparsity degrees. The same statistical procedure used for 
10 
 
evaluating the ApoE4 effect of global network properties was applied to explore network 
robustness differences between groups. 
 
 
Fig S1. Spatially distributed differences in cortical thickness between MCI Carriers and non-Carriers (p<.01, 
uncorrected). Relative deficits in Carriers compared with non-Carriers are displayed in red/yellow, while excesses 
are shown in blue/cyan. Surfaces are presented in lateral, medial, and frontal views for the left and right pial (outer) 
surface. After Random-field theory-based cluster-corrected (q<.05) there were no clusters of significant differences 
between groups. 
 
Supplementary Table S3. Cortical thickness cluster differences between MCI Carriers vs 
non-Carriers for p<0.01 (uncorrected) 
Structure Name t-Student p-value 
rh G front middle -4.10 3E-05 
rh S front inf -4.00 4E-05 
rh S precentral-inf-part 3.92 6E-05 
rh G pariet inf-Supramar 3.75 1E-04 
lh S oc-temp med and Lingual 3.69 1E-04 
rh G occipital sup 3.61 2E-04 
rh S orbital med-olfact -3.40 4E-04 
lh G and S paracentral -3.39 4E-04 
rh Medial wall -3.37 4E-04 
rh G rectus -3.37 4E-04 
lh G and S subcentral 3.35 5E-04 
lh G pariet inf-Supramar 3.34 5E-04 
lh G parietal sup -3.26 6E-04 
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rh G oc-temp med-Lingual -3.18 8E-04 
rh S oc sup and transversal 3.10 1E-03 
rh Pole occipital -3.09 1E-03 
lh G front sup -3.05 1E-03 
lh S front sup -3.05 1E-03 
lh Lat Fis-post 3.02 1E-03 
rh G temp sup-Lateral 2.98 2E-03 
rh S intrapariet and P trans 2.98 2E-03 
lh G orbital -2.95 2E-03 
rh S postcentral 2.94 2E-03 
rh S interm prim-Jensen 2.92 2E-03 
rh G front sup -2.92 2E-03 
rh G postcentral 2.92 2E-03 
rh G and S cingul-Mid-Post -2.90 2E-03 
rh S central 2.90 2E-03 
lh S central 2.87 2E-03 
lh Lat Fis-ant-Horizont -2.86 2E-03 
rh G and S occipital inf -2.86 2E-03 
rh S circular insula sup 2.86 2E-03 
rh S front middle -2.84 2E-03 
rh G occipital middle -2.84 2E-03 
rh S temporal inf 2.83 3E-03 
rh G precuneus -2.83 3E-03 
lh G temp sup-Lateral 2.83 3E-03 
lh G precentral 2.82 3E-03 
lh S orbital med-olfact -2.79 3E-03 
rh G temporal middle 2.78 3E-03 
rh G subcallosal -2.77 3E-03 
lh Medial wall -2.77 3E-03 
lh G front inf-Orbital -2.76 3E-03 
lh G front middle -2.75 3E-03 
lh G front inf-Triangul -2.73 3E-03 
rh G front inf-Opercular 2.70 4E-03 
lh Pole occipital -2.68 4E-03 
rh Lat Fis-post 2.66 4E-03 
rh Pole temporal 2.66 4E-03 
lh S calcarine -2.64 4E-03 
lh S temporal sup -2.60 5E-03 
rh S temporal sup 2.59 5E-03 
rh S precentral-sup-part 2.56 6E-03 
lh G cuneus -2.54 6E-03 
rh G orbital -2.53 6E-03 
rh G precentral 2.53 6E-03 
lh S orbital lateral -2.52 6E-03 
lh S front middle -2.52 6E-03 
rh G temp sup-Plan tempo 2.47 7E-03 
lh Lat Fis-ant-Vertical -2.44 8E-03 
lh G temporal middle 2.41 8E-03 
lh S parieto occipital -2.40 8E-03 
lh G postcentral -2.37 9E-03 
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lh G occipital sup -2.37 9E-03 
rh S front sup -2.35 1E-02 
lh G temporal inf -2.35 1E-02 
lh G occipital middle -2.35 1E-02 
rh G and S subcentral 2.34 1E-02 
rh G pariet inf-Angular -2.34 1E-02 
lh G precuneus 2.33 1E-02 
lh S circular insula ant -2.32 1E-02 
rh G temp sup-Plan polar 2.30 1E-02 
lh G insular short -2.30 1E-02 
lh S intrapariet and P trans -2.30 1E-02 
lh G rectus -2.30 1E-02 
lh S postcentral 2.29 1E-02 
lh G oc-temp med-Lingual -2.28 1E-02 
rh G parietal sup -2.27 1E-02 
lh S oc middle and Lunatus -2.26 1E-02 
rh G and S cingul-Mid-Ant -2.25 1E-02 
rh S pericallosal 2.25 1E-02 
rh G and S paracentral -2.24 1E-02 
rh S subparietal -2.23 1E-02 
rh S parieto occipital -2.22 1E-02 
rh S cingul-Marginalis -2.21 1E-02 
rh S calcarine -2.21 1E-02 
rh G oc-temp med-Parahip 2.21 1E-02 
lh G pariet inf-Angular -2.20 1E-02 
rh S orbital-H Shaped -2.18 2E-02 
rh S occipital ant 2.17 2E-02 
rh G cingul-Post-dorsal 2.17 2E-02 
lh G oc-temp med-Parahip -2.14 2E-02 
lh G and S cingul-Mid-Post 2.13 2E-02 
rh G front inf-Triangul -2.13 2E-02 
lh S circular insula sup 2.11 2E-02 
rh Lat Fis-ant-Vertical -2.09 2E-02 
lh S suborbital -2.08 2E-02 
rh S circular insula inf 2.08 2E-02 
rh G cingul-Post-ventral 2.08 2E-02 
lh G temp sup-G T transv 2.06 2E-02 
rh G and S transv frontopol -2.05 2E-02 
rh G Ins lg and S cent ins 2.05 2E-02 
lh S circular insula inf 2.03 2E-02 
rh S temporal transverse 2.02 2E-02 
rh G temporal inf -2.02 2E-02 
rh G temp sup-G T transv 2.01 2E-02 
lh S oc-temp lat 2.00 2E-02 
lh S collat transv post -1.99 2E-02 
lh G temp sup-Plan tempo 1.97 2E-02 
lh G Ins lg and S cent ins -1.96 3E-02 
lh S pericallosal -1.93 3E-02 
lh S front inf 1.93 3E-02 
lh S precentral-inf-part -1.92 3E-02 
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lh G and S frontomargin -1.92 3E-02 
lh G and S transv frontopol -1.90 3E-02 
rh S collat transv ant 1.88 3E-02 
lh G and S cingul-Ant -1.88 3E-02 
lh G and S occipital inf -1.88 3E-02 
lh G front inf-Opercular -1.86 3E-02 
lh G and S cingul-Mid-Ant -1.85 3E-02 
lh S oc sup and transversal -1.84 3E-02 
rh S suborbital -1.83 3E-02 
lh S orbital-H Shaped -1.81 4E-02 
rh S oc middle and Lunatus -1.76 4E-02 
rh G cuneus -1.75 4E-02 
lh S temporal inf 1.74 4E-02 
lh S temporal transverse 1.73 4E-02 
rh S oc-temp med and Lingual 1.72 4E-02 
lh S occipital ant 1.71 4E-02 
lh S precentral-sup-part 1.69 5E-02 
rh S oc-temp lat -1.67 5E-02 
lh S interm prim-Jensen 1.65 5E-02 
 
 
Supplementary Table S4. Significant differences in NBC between MCI Carriers and non-
Carriers groups (FDR-corrected). Values represent the NBC mean and standard deviation 
(s.d). NBC: Normalize Betweenness Centrality. 
Structure Carriers NBC (s.d) non-Carriers NBC (s.d) p-value 
Rh G and S cingul-Mid-Post 0.82 (0.17) 1.44 (0.23) 1.2*10-9 
Rh G oc-temp med-Lingual 1.19 (0.20) 0.94 (0.18) 0.02 
Rh Lat Fis-ant-Horizont 0.80 (0.18) 1.36 (0.19) 0.009*10-5 
Rh S oc-temp med and Lingual 1.46 (0.29) 0.99 (0.19) 0.02 
Rh S pericallosal 0.82 (0.18) 1.06 (0.20) 0.008*10-5 
Rh S temporal transverse 0.80 (0.17) 1.09 (0.17) 0.007*10-3 
Lh G subcallosal 0.83 (0.20) 1.10 (0.20) 0.04 
Lh S circular insula ant 1.08 (0.19) 1.28 (0.23) 0.02 
Lh S collat transv post 0.75 (0.15) 1.30 (0.20) 2.3*10-11 
Lh S precentral-sup-part 0.68 (0.17) 1.10 (0.21) 0.05*10-3 





Supplementary Table S5. Hubs regions for Carriers and non-Carriers listing by the 
descending order of the normalized betweenness centrality in each group 
  
Carriers Hubs NBC non-Carriers Hubs NBC 
Rh S temporal sup 2.73 Rh G and S cingul-Ant 2.69 
Rh G and S cingul-Mid-Post 2.40 Rh S parieto occipital 2.59 
Rh G cingul-Post-ventral 2.23 Lh S parieto occipital 2.26 
Rh Lat Fis-ant-Horizont 2.02 Lh S oc-temp lat 2.15 
Lh S collat transv post 1.81 Rh S oc-temp med and Lingual 1.99 
Lh G and S occipital inf 1.70 Lh G oc-temp med-Lingual 1.78 
Lh S circular insula ant 1.65 Rh G pariet inf-Supramar 1.78 
Lh G and S subcentral 1.59 Lh S circular insula sup 1.73 
Rh S collat transv post 1.50 Lh Lat Fis-ant-Horizont 1.69 
Rh G cuneus 1.47 Rh Lat_Fis-post 1.68 
Lh G and S cingul-Ant 1.41 Lh G and S subcentral 1.58 
Rh S front inf 1.35 Rh S circular insula ant 1.57 
Rh G orbital 1.35 Lh G and S cingul-Ant 1.55 
Rh S circular insula inf 1.28 Rh S temporal sup 1.33 
Lh G cingul-Post-dorsal 1.19 Lh S occipital _ant 1.31 
Rh S orbital med-olfact 1.17 Lh Lat Fis-post 1.22 
Lh G temp sup-G T- transv 1.12 Lh S calcarine 1.20 
Rh S circular insula ant 1.11 Rh G cingul-Post-dorsal 1.13 
Rh S parieto occipital 1.08 Rh S interm prim-Jensen 1.10 
Lh S temporal transverse 1.07 Rh G oc-temp med-Lingual 1.07 
Lh S front inf 1.04 Rh S orbital-H Shaped 1.07 
Lh Lat Fis-post 1.04 Lh G cingul-Post-dorsal 1.03 
Rh S front middle 1.03 Rh S collat transv post 1.02 
Rh Lat Fis-post 1.03 Rh S precentral-inf-part 1.00 
 
Values represent the regional NBC means. Regions considered hubs per group if NBC>1. In bold hub regions with 
the higher NBC values (NBC>1.5). NBC: Normalize Betweenness Centrality.  
 
Supplementary Table S6. List of brain regions module composition per group 
Structure Full name Atlas Name Carriers non-Carriers 
Fronto-marginal gyrus (of Wernicke) and 
sulcus 
  G and S frontomargin V I 
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Inferior occipital gyrus (O3) and sulcus   G and S occipital inf III II 
Paracentral lobule and sulcus   G and S paracentral II II 
Subcentral gyrus (central operculum) and sulci   G and S subcentral II (L), IV (R) I 
Transverse frontopolar gyri and sulci   G and S transv frontopo V I 
Anterior part of the cingulate gyrus and sulcus 
(ACC) 
  G and S cingul Ant V I 
Middle-anterior part of the cingulate gyrus and 
sulcus (aMCC) 
  G and S cingul Mid Ant IV I 
Middle-posterior part of the cingulate gyrus 
and sulcus (pMCC) 
G and S cingul Mid Post II (L), IV (Ll) I 
Posterior-dorsal part of the cingulate gyrus 
(dPCC) 
  G cingul Post dorsal IV (R), V (L) III 
Posterior-ventral part of the cingulate gyrus 
(vPCC, isthmus of the cingulate gyrus) 
  G cingul Post ventral IV (R), V (L) III 
Cuneus (O6)   G cuneus III II 
Opercular part of the inferior frontal gyrus   G front inf Opercular II (L), IV (R) I 
Orbital part of the inferior frontal gyrus   G front inf Orbital II (L), IV (R) I 
Triangular part of the inferior frontal gyrus   G front inf Triangul II I 
Middle frontal gyrus (F2)   G front middle II II 
Superior frontal gyrus (F1)   G front sup II II 
Long insular gyrus and central sulcus of the 
insula 
  G Ins lg and S cent ins IV III 
Short insular gyri   G insular short IV III 
Middle occipital gyrus (O2, lateral occipital 
gyrus) 
  G occipital middle III II 
Superior occipital gyrus (O1)   G occipital sup III II 
Lateral occipito-temporal gyrus (fusiform 
gyrus, O4-T4) 
  G oc temp lat fusifor I II (R), III (L) 
Lingual gyrus, lingual part of the medial 
occipito-temporal gyrus, (O5) 
  G oc temp med Lingual I (R ), III (L) II 
Parahippocampal gyrus, parahippocampal part 
of the medial occipito-temporal gyrus, (T5) 
  G oc temp med Parahip I III 
Orbital gyri   G orbital V I 
Angular gyrus   G pariet inf Angular III II 
Supramarginal gyrus   G pariet inf Supramar II II (R), III (L) 
Superior parietal lobule (lateral part of P1)   G parietal sup III II 
Postcentral gyrus   G postcentral II II 
Precentral gyrus   G precentral II II 
Precuneus (medial part of P1)   G precuneus III II 
Straight gyrus, Gyrus rectus   G rectus I (L), V (R) I 
Subcallosal area, subcallosal gyrus   G subcallosal I I (R), III (L) 
Anterior transverse temporal gyrus (of Heschl)   G temp sup G T transv II I 
Lateral aspect of the superior temporal gyrus   G temp sup Lateral I III 
Planum polare of the superior temporal gyrus   G temp sup Plan polar I III 
Planum temporale or temporal plane of the 
superior temporal gyrus 
  G temp sup Plan tempo II III 
Inferior temporal gyrus (T3)   G temporal inf I III 
Middle temporal gyrus (T2)   G temporal middle I III 
Horizontal ramus of the anterior segment of 
the lateral sulcus (or fissure) 
  Lat Fis ant Horizont IV (L), V (R) I 
Vertical ramus of the anterior segment of the 
lateral sulcus (or fissure) 
  Lat Fis ant Vertical II (L), IV (L) I 
Posterior ramus (or segment) of the lateral 
sulcus (or fissure) 
  Lat Fis post II (L), IV (R) I (L), III (R) 
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Occipital pole   Pole occipital III II 
Temporal pole   Pole temporal I III 
Calcarine sulcus   S calcarine III II 
Central sulcus (Rolando's fissure)   S central II II 
Marginal branch (or part) of the cingulate 
sulcus 
  S cingul Marginalis II (R ), III (L) II 
Anterior segment of the circular sulcus of the 
insula 
  S circular insula ant IV I 
Inferior segment of the circular sulcus of the 
insula 
  S circular insula inf IV III 
Superior segment of the circular sulcus of the 
insula 
  S circular insula sup IV III 
Anterior transverse collateral sulcus   S collat transv ant I III 
Posterior transverse collateral sulcus   S collat transv post III II 
Inferior frontal sulcus   S front inf V I 
Middle frontal sulcus   S front middle V I 
Superior frontal sulcus   S front sup II II 
Sulcus intermedius primus (of Jensen)   S interm prim Jensen III II 
Intraparietal sulcus (interparietal sulcus) and 
transverse parietal sulci 
  S intrapariet and P tra III II 
Middle occipital sulcus and lunatus sulcus   S oc middle and Lunatus III II 
Superior occipital sulcus and transverse 
occipital sulcus 
  S oc sup and transversa III II 
Anterior occipital sulcus and preoccipital 
notch (temporo-occipital incisure) 
  S occipital ant III II 
Lateral occipito-temporal sulcus   S oc temp lat I III 
Medial occipito-temporal sulcus (collateral 
sulcus) and lingual sulcus 
  S oc temp med and Lingu I III 
Lateral orbital sulcus   S orbital lateral V I (L), III (R) 
Medial orbital sulcus (olfactory sulcus)   S orbital med olfact I (L), V (R) III 
Orbital sulci (H-shaped sulci)   S orbital H Shaped V III 
Parieto-occipital sulcus (or fissure)   S parieto occipital III II 
Pericallosal sulcus (S of corpus callosum)   S pericallosal I (L), V (R) III 
Postcentral sulcus   S postcentral III II 
Inferior part of the precentral sulcus   S precentral inf part II (L) , III (R ) I (L), II (R) 
Superior part of the precentral sulcus   S precentral sup part II II 
Suborbital sulcus (sulcus rostrales, 
supraorbital sulcus) 
  S suborbital V I (L), III (R) 
Subparietal sulcus   S subparietal III II 
Inferior temporal sulcus   S temporal inf I III 
Superior temporal sulcus (parallel sulcus)   S temporal sup I (R), III (L) III 
Transverse temporal sulcus   S temporal transverse I, IV (L) I 
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There is evidence that gray matter networks are disrupted in Mild Cognitive Impairment (MCI) 
and associated with cognitive impairment and faster disease progression. However, it remains 
unknown how these alterations are related to the presence of Apolipoprotein E isoform E4 
(ApoE4), the most prominent genetic risk factor for late-onset Alzheimer’s disease (AD). To 
investigate this topic at the individual level, we explore the impact of ApoE4 and the disease 
progression on the Single-Subject Gray Matter Networks (SSGMNets) using the graph theory 
approach. Our data sample comprised 200 MCI patients selected from the ADNI database, 
classified as non-Converters and Converters (will progress into AD). Each group included 50 
ApoE4-positive ('Carriers', ApoE4+) and 50 ApoE4-negative ('non-Carriers', ApoE4-). The 
SSGMNets were estimated from structural MRIs at two-time points: baseline and conversion. 
We investigated whether altered network topological measures at baseline and their rate of 
change (RoC) between baseline and conversion time points were associated with ApoE4 and 
disease progression. We also explored the correlation of SSGMNets attributes with general 
cognition score (MMSE), memory (ADNI-MEM), and CSF-derived biomarkers of AD (Aβ42, 
T-tau, and P-tau). Our results showed that ApoE4 and the disease progression modulated the 
global topological network properties independently but not in their RoC. MCI converters 
showed a lower clustering index in several regions associated with neurodegeneration in AD. 
The SSGMNets' topological organization was revealed to be able to predict cognitive and 
memory measures. The findings presented here suggest that SSGMNets could indeed be used 
to identify MCI ApoE4 Carriers with a high risk for AD progression. 
Keywords: Mild Cognitive Impairment; Alzheimer Disease; gray matter networks; single-
subject gray matter networks; graph theory. 
 




1. Introduction  
Late-Onset Alzheimer’s Disease (LOAD) is the most common cause of dementia, accounting 
for 60% to 80% of cases (Hardy, 1997). However, there are no disease-modifying treatments 
and clinical drug trials have a high failure rate (Cummings et al., 2014). The postulate for this 
result is that AD brain pathology begins years before the cognitive decline. Consequently, in 
recent years, research has moved toward the study of the earliest clinical signs of 
neurodegeneration that are likely to evolve to AD. In this effort, a particular interest has been 
dedicated to Mild cognitive impairment (MCI) as a transitional phase between the cognitive 
changes associated with aging and early AD (Petersen, 2004; Petersen et al., 2001). It is a 
window in which it may be possible to intervene and modulate the disease progression (Albert 
et al., 2011; Gauthier et al., 2006; Mueller et al., 2005; Petersen et al., 1999). 
However, MCI is especially challenging because of the considerable variability in terms of 
individual clinical outcomes (Jack et al., 2013; Scheltens, 2013), dependent on multiple genetic 
and environmental risk factors involved in AD pathogenesis (Collie and Maruff, 2000; 
Petersen, 2000). In terms of genetic markers,  the best-established genetic risk factor for AD is 
the Apolipoprotein E (ApoE) ε4 allele (ApoE4) (for reviews, Bekris et al., 2010; Bookheimer 
and Burggren, 2009; Liu et al., 2013). While there are evidence linking ApoE4 to cognitive 
deficits, morphological, structural, and functional brain alterations during AD progression 
(Cherbuin et al., 2007; Chia-Chan Liu et al., 2013), at this point, it is still unclear how this 
genetic risk factor affects the organization of brain networks. 
One viable mathematical approach to elucidate the ApoE4 impact on MCI brain networks is 
graph formalism (Boccaletti et al., 2006). In graph theory, our brain is studied as a model 
composed of some basic elements -nodes- (brain regions) and their relationship (edges); and 
the brain’s complex co-variance patterns are translated into global and regional graph metrics 




(Bullmore and Bassett, 2011). During the o past decade, graph analysis has already been 
applied to study the structural co-variance networks in AD and MCI (Alexander-Bloch et al., 
2013). It is based on the phenomenon that regions that are correlated in morphometric 
descriptors (e.g., cortical thickness) are highly probable to be part of the same brain system 
underlying particular behavioral and cognitive functions (Lerch et al., 2006). 
Using graph theory formalism, previous studies found evidence of the ApoE4-related 
modulation on healthy aging, MCI, and the AD co-variance brain network based on 
physiological variables derived from different image modalities (rsFMRI, FDG-PET, and 
DWI) (Brown et al., 2011; Giau et al., 2015; Goryawala et al., 2015; Li et al., 2019; Sanabria-
Diaz et al., 2021; Seo et al., 2013; Wang et al., 2015; Yao et al., 2015; Zhu et al., 2018). Their 
findings propose a link between the possession of ApoE4 and brain network organization 
abnormalities in AD, suggesting disease-related disconnection mechanisms (Delbeuck et al., 
2003; Filippi and Agosta, 2011; He et al., 2009). Moreover, these studies have provided new 
insights into the understanding of the biological mechanism of AD. They could lead to the use 
of a network-based imaging biomarker for MCI diagnosis and monitoring. 
Nevertheless, it is essential to highlight that the inclusion of MCI is only reported by one 
previous study conducted by Yao et al. (Yao et al., 2015). Yet, in this case, the sample design 
makes the interpretation of the MCI brain network topology challenging as the groups (NC, 
MCI, and AD) were pulled together to conform the Carriers and non-Carriers samples. 
Additionally, only one study used data from structural Magnetic Resonance Imaging (sMRI) 
to construct the brain network structural co-variance, in this case, applied to a healthy aging 
sample (Goryawala et al., 2015). sMRI is an attractive technique because of the wide 
availability in clinical and research settings and its high anatomical resolution compared with 
other neuroimaging modalities (i.e PET).  




Recently our group published the first study about the ApoE4-related effects on the structural 
co-variance brain network topology in MCI (Sanabria-Diaz et al., 2021).  We found that the 
E4 allele shaped the topological organization of cortical thickness networks in this phase.  Our 
results revealed several network measures alterations in MCI Carriers (ApoE4-positive) 
compared to non-Carriers, such as a decrease in global and homologous connectivity strength, 
clustering index, characteristic path length, local efficiency, modularity, and an increase of 
global efficiency. In general, they support an aberrant network topology associated with the 
genetic risk, which was not detectable with a standards univariate approach.   
However, this study has main limitations 1) we applied a group-based graph analysis that 
generated one correlation matrix per group. This method did not allow us to establish 
associations between the network properties changes and other AD biomarkers (i.e., CSF 
Aβ42, tau, hippocampal atrophy) at the individual level. In our opinion, it is a critical aspect to 
gain insight into the biological meaning of the structural co-variance network alterations. 
Second, the study was based on a cross-sectional design where information about the final 
clinical outcome was not included. As MCI is highly heterogenic in terms of prognosis, the 
progression into AD is essential to control confounding effects and relate the ApoE4 to the 
brain network topological alterations. Finally, ApoE4 and AD progression's interaction effects 
were not analyzed, making it challenging to disentangle each factor's implication on the results. 
In the recent past, the group-based graph analysis limitation has been overcome by a 
methodology that constructs single-subject brain networks from the native gray matter 
segmentation space (Dicks et al., 2018, 2020; Tijms et al., 2012, 2013a, 2014, 2018). This 
method accounts for the similarity in gray matter structure between brain areas measured with 
sMRI (Mechelli et al., 2005; Tijms et al., 2012). These co-variance patterns have been 




associated with coordinated growth trajectories of gray matter during development, functional 
co-activation, and axonal connectivity (Alexander-Bloch et al., 2013; Gong et al., 2012). 
Few prior studies applied this approach to explore Single-Subject Gray Matter Networks 
(SSGMNets) in AD and MCI (Dicks et al., 2018, 2020; Tijms et al., 2013a, 2016, 2018). These 
studies showed that the more network topology randomness, the worse cognitive impairment 
level in AD patients (Tijms et al., 2013a, 2014). Additionally, in preclinical phases, the network 
measures changes predicted hippocampal atrophy rate and faster atrophy in other areas 
associated with AD progression (Dicks et al., 2020). In MCI, the network measures showed 
sensitivity to initial structural alterations related to amyloid deposition (Tijms et al., 2018). The 
network properties alteration revealed a relation with cognitive impairment and a faster decline 
in almost all cognitive domains (Dicks et al., 2018). 
Despite these preceding findings, we are unaware of any studies that focused on how ApoE4 
affects SSGMNets in MCI. Moreover, no neuroimaging study has so far explored the interaction 
between ApoE4 and disease progression on these networks' topological properties in MCI. 
Such longitudinal follow-ups are required to reveal changes associated with the genetic risk 
allele per se and to be able to identify possible network properties alterations related to 
subsequent progression into AD. Additionally, the ApoE4 modulation on the association 
between the network topology and other neuropathological AD biomarkers (e.g., CSF amyloid 
β 42 (Aβ42) and total tau levels) in MCI is still unexplored. 
This paper precisely addresses these crucial questions and provides experimental evidence of 
MCI pathological processes, which may help implement future strategies to prevent or delay 
the progression into AD. 




2. Materials and Methods 
2.1 Participants 
Data used in the preparation of this article were obtained from the Alzheimer's Disease 
Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). The ADNI was launched 
in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. 
The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), 
positron emission tomography (PET), other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of mild cognitive 
impairment and early Alzheimer's disease. ADNI was approved by the institutional review 
board of all participating institutions, and written informed consent was obtained from all 
participants at each site. For up-to-date information, see www.adni-info.org. Full details of 
subject recruitment, biomarkers as quantitative phenotypes, MRI scanning protocols, and data 
pre-processing were published elsewhere (C. R. J. Jack et al., 2010; Mueller et al., 2005; Saykin 
et al., 2010) (http://www.loni.ucla.edu/ADNI/), and only a brief account is given here. 
We selected participants with a clinical diagnosis of late amnesic MCI who had completed at 
least two visits and fulfilled ADNI I inclusion/exclusion criteria (http://adni.loni.usc.edu/wp-
content/uploads/ 2010/09/ADNI_GeneralProceduresManual.pdf.). Details of the diagnostic 
protocol have been previously described in (Aisen et al., 2015; Petersen et al., 2010). Briefly, 
the inclusion criteria for MCI were as follows: Mini-Mental-State-Examination (MMSE) 
scores between 24 and 30 (inclusive), a memory complaint, objective memory loss measured 
by education adjusted scores on the Wechsler Memory Scale Logical Memory II (Aisen et al., 
2015; Petersen et al., 2010), a Clinical Dementia Rating (CDR) of 0.5, and absence of 




significant levels of impairment in other cognitive domains, essentially preserved activities of 
daily living and a lack of dementia. 
Exclusion criteria included: 1) the presence of a major depressive disorder or significant 
symptoms of depression; 2) modified Hachinski ischemia score greater than five; 3) significant 
neurological or psychiatric illness; 4) use of antidepressant drugs with anticholinergic side 
effects; 5) high dose of neuroleptics, chronic sedatives, hypnotics, antiparkinsonian 
medication, and use of narcotic analgesics. Details about the criteria can be found in 
http://adni.loni.usc.edu/wp-content/themes/freshnewa-dev-v2/clinical/ADNI-1_Protocol.pdf) 
(Petersen et al., 2010).  
We stratified the MCI group into those with only one ApoE4 allele (ApoE4+, Carriers) and 
those without (ApoE4-, non-Carriers). 
We excluded homozygotic subjects as well as participants with an  E2 allele due to the possible 
protective effects (Serrano-Pozo et al., 2015). ApoE genotyping was performed at the time of 
participant enrollment and included in the ADNI-I database. The samples were sent to the 
ADNI Biomarker Core at the University of Pennsylvania within 24 hours of collection for 
analysis. ApoE genotyping details can be accessed at http://adni.loni.usc.edu/data-
samples/clinical-data/ (Saykin et al., 2010). For genotyping methods see www.ADNI.org.  
Following the aforementioned criterium we selected from the ADNI I database a sample of 200 
late MCI participants subdivided into 100 late MCI non-Converters and 100 Converters to AD 
(Tables 1 and Table S2).  Each subgroup was subdivided into 50 Carriers (ApoE4+) and 50 
non-Carriers' (ApoE4-) patients. The final number of subjects in each subgroup (50) was 
determined by a lower number of patients classified as stable MCI ApoE4 Carriers, the 
similarity between groups in general demographic variables (age, gender, education level), 
genotype and clinical inclusion criterium and MRI technical requirements.  




Table 1. Demographics and Clinical Characteristics of the MCI non-Converters and Converters. MMSE, Gray 
matter Volume, normalized Gray matter volume, CDR were found differences between groups (in bold), 
specifically in MCI that converted to AD in the second diagnosis time. 
 
MCI non-Converters MCI Converters 
Diagnosis Time 1 
(MCI) 
Diagnosis Time 2 
(MCI) 
Diagnosis Time 1 
(MCI) 
















50 50 50 50 50 50 50 50 
males/ 
females 






















































CDR 0.5 50 50 50 50 50 50 15 20 
CDR 1 na na na na na na 28 23 












































































Data are presented as number or mean and standard deviations (SD). MMSE is Mini-mental state examination, mm3: cubic millimeter, MCI 
is Mild Cognitive Impairment, CDR is Clinical Dementia Rate, TIV is total intracranial volume, na is not applicable. 
 
2.2 Cognitive and biomarker measures 
We used a composite score for memory (ADNI-MEM) using data from the ADNI 
neuropsychological battery. The ADNI‐MEM description can be found in (Crane et al., 2012). 
The authors described the composite score as an empirically derived memory measure that 
includes items from four memory tests available within the ADNI test battery, including the 
ADAS‐Cog, the Rey Auditory Verbal Learning Test (RAVLT) (Rey, 1958), Logical Memory 




from the Wechsler Memory Scale (Wechsler, 1945), and the word list from the Mini‐Mental 
State Examination (Folstein et al., 1975). ADNI-MEM has been validated in published papers 
(Folstein et al., 1975; C. R. Jack et al., 2010; Jack and Holtzman, 2013). The ADNI-MEM 
scores for each ADNI participant at each study visit are reported in the UWNPSYCHSUM file. 
More details about the cognitive tests can be found at ADNI website 
(http://adni.loni.usc.edu/methods/documents/) under clinical protocols. The individual 
cognitive measurements downloaded from the ADNI website 
(https://ida.loni.usc.edu/pages/access/studyData.jsp?categoryId=12&subCategoryId=36) and 
the composite ADNI-MEM method information can be found at (UW - Neuropsych Summary 
Scores Methods.pdf). 
2.3 Biomarker measurements in CSF: Aβ42, P-tau, T-tau. 
In the present study, we used the CSF core biomarkers measurements for AD performed with 
the Elecsys® total-tau CSF, the Elecsys® Phospho-Tau (181P) CSF, and the Elecsys® β-
amyloid (1–42) CSF immunoassays on a Cobas E 601 instruments (Hansson O et al., 2018; 
Bittner et al., 2016). The data is available in the 'UPENNBIOMK9.csv' file at the ADNI 
database (downloaded on May 11th, 2019). The analyzed measuring ranges of these assays are 
the following: 80 to 1300 pg/ml for total-Tau CSF, 8 to 120 pg/ml for Phospho-Tau (181P) 
CSF, and 200 to 1700 pg/ml for Elecsys® β-Amyloid (1-42) CSF immunoassays. The CSF 
biomarkers have been shown to predict cognitive decline and progression to dementia in 
patients with MCI (Hansson et al., 2018; Shaw et al., 2009). 
Details about CSF biomarker group classification based on the A/T/N scheme (Jack CR et al., 
2016) are described in Supplementary Table S3. 




2.4 MRI acquisition and pre-processing 
Pre-processed versions of the 400 T1-weighted MRI scans were downloaded from LONI Image 
Data Archive. Further details are available in the ADNI-MRI technical procedures manual 
(ADNI-MRICore, 2005). Further details are available in the ADNI-MRI technical procedures 
manual (http://adni.loni.usc.edu/methods/documents/MRI protocols). Pre-processing steps can 
be found elsewhere (Fornito et al., 2008; Jovicich et al., 2006; Sled et al., 1998). Images were 
pre-processed using Statistical Parametric Mapping software version 12 (SPM12) 
(https://www.fil.ion.ucl.ac.uk/spm/software/spm12/). First, the structural T1 weighted images 
are segmented into gray matter, white matter, and cerebrospinal fluid tissue classes using 
default settings. Next, 114 gray matter regions were parcellated based on Neuromorphometrics 
atlas using the Neuromorphometrics toolbox (Full list of structures listed in Supplementary 
Materials Table S1) (unpublished, Prof. John Ashburner personal communication) 
(http://www.Neuromorphometrics.com/) to obtain individual anatomical atlases. This atlas has 
proved to show high sensitivity detecting age modulation on the networks of myelin co-
variance topological features (Melie‐Garcia et al., 2018).  The scans from subjects ranging in 
age from 5 to 96 have been painstakingly labeled and double-checked by experts using two 
protocols that precisely define neuroanatomical region boundaries. Unlike an atlas of a single 
subject, this data provides an indication of the variation of the living human brain. 
The Total intracranial volume (TIV) was computed as the sum of gray and white matter and 
cerebrospinal fluid volumes in cm3. Normalized gray matter volume is defined as the ratio 
between gray matter volume and TIV. 
The native T1-weighted images were re-oriented to the canonical MNI space of the SPM12 
'avg305T1' template using a rigid-body transformation and resliced to a voxel size 2×2×2 mm. 
Both transformations were applied to the native space gray matter segmented images and 




individual atlases using trilinear and nearest-neighbor interpolations, respectively. These pre-
preprocessing steps help to standardize voxel sizes and reduce dimensionality. 
2.5 Single Subject Gray Matter Networks and it's Topological Properties 
2.5.1 Extraction of Single Subject Gray Matter Networks. 
Single Subject Gray Matter Networks (SSGMNets) were extracted from transformed gray 
matter segmentation using a method developed and published by Tijms et al. 2012 
(https://github.com/bettytijms/Single_Subject_Gray_Matter_Networks; (Tijms et al., 2012)). 
This toolbox was implemented in MATLAB programming language 
(http://www.mathworks.com). 
Briefly, to extract SSGMNets, each individual's gray matter segmentation is parcellated into 
multiple small cubes of 3 x 3 x 3 = 27 voxels each. These non-overlapping cubes serve as the 
'nodes' in the network, thereby using geometrical information and gray matter density values 
(i.e., from the tissue segmentation) in the voxels. Their 'connection' refers to 'edges' indicating 
statistically similar gray matter morphology of two cubes as determined by calculating the 
Pearson's correlation. Notably, the term 'connection' in this methodology should not be 
confused with anatomical connections (axonal connections). The cortex is a curved object, and 
hence two similar cubes could be at an angle to each other, incorrectly decreasing similarity 
values (Tijms et al., 2012). Therefore, each seed node was rotated by an angle θ with multiples 
of 45 degrees and reflected over all axes to identify the target node's maximal similarity value. 
Nodes with zero variance in their gray matter density values were excluded (average across all 
subjects <0.01%) since, in this case, the correlation coefficient is undefined (Tijms et al., 2012). 
All pairwise correlations are entries in a matrix denominated 'connectivity' or 'adjacency 
matrix' in graph theory terms. The presence or absence of connections between nodes is 




determined according to an individualized threshold with a random permutation method that 
ensures a maximum of 5% spurious connections for each SSGMNets (Tijms et al., 2012). 
A correction for multiple comparisons was applied using the False Discovery Rate (FDR) to 
determine a corrected-threshold (FDR-threshold) (Benjamini and Hochberg, 1995; Benjamini 
and Yekutieli, 2001). The FDR-threshold was applied to binarize the SSGMNet. An edge 
(element of the connectivity matrix) indicated by '1' occurs when a correlation is higher than 
the FDR-threshold. On the contrary, the absence of an edge is represented by 0 while the 
correlation is lower than FDR-threshold. 
2.5.2 Network properties computation: graph theory approach 
Formally, a complex network can be represented as a graph G=[N, K], the components of this 
system are called nodes (N), and K refers to the relations or connections between them are 
called edges (Boccaletti et al., 2006). In our case, the nodes are the cubes defined over the 
individual's gray matter segmentation, and the edges are derived from the statistical similarity 
in gray matter morphology between pairs of cubes (i.e., nodes). 
Technically, we used the following global network attributes to characterize the SSGMNet 
topological organization. The attributes include the clustering coefficient (Clux) (i.e., the level 
of interconnectedness between the neighbors of a node), the characteristic path length 
(CharPath) (i.e., the minimum number of edges between any pair of nodes), the normalized 
clustering index (Clux-Normalized), the normalized characteristic path length (CharPath-
Normalized), and global efficiency (Eglobal) (i.e., how efficiently the information can be 
exchanged over the network). The global connectivity (GConnect) is defined as the mean 
correlation of all the connectivity matrix elements. 




To estimate Clux-Normalized (gamma) and CharPath-Normalized (lambda), we first 
constructed 20 randomized reference networks matching the original ones in size and degree 
distribution. The Clux and CharPath mean over the 20 random networks are calculated and 
denoted as Clux_rand and CharPath_rand. So, Clux-Normalized and CharPath-Normalized are 
defined as the ratios: Clux-Normalized = Clux/Clux_rand and CharPath-Normalized = 
CharPath/CharPath_rand (Humphries and Gurney, 2008; Maslov and Sneppen, 2002; Watts 
and Strogatz, 1998). The small world (sigma) attribute is computed as the ratio between Clux-
Normalized and CharPath-Normalized. 
We estimated the normalized clustering index attribute for each node to describe the network's 
nodal properties and summarized it at each of 114 anatomical structures defined in the 
Neuromorphometric atlas. 
We define the sparsity of the networks as the density of the connection within the connectivity 
matrix. This measure was calculated as the percentage number of existing edges respect the 
maximum number of possible edges (N x (N – 1), where N is the number of nodes). 
All network measures were computed with functions from the Brain Connectivity Toolbox 
(www.brain-connectivity-toolbox.net). More information about the graph network topological 
properties definition and meaning can be found elsewhere (Rubinov and Sporns, 2010). 
2.6  Rate of change analysis 
We also were interested in evaluating the impact of ApoE4 and progression factors on the Rate 
of Change (RoC) of the SSGMNets topological properties, morphometric, psychological, and 
CSF variables. RoC provides information about how fast the variables change linearly with 
time. If a variable Y is defined in two-time points t1, t2 as Y(t1) and Y(t2), RoC is estimated 
as follows: RoC=ΔY/Δt where Δt = t2 - t1 and ΔY= Y(t2)-Y(t1). Also, RoC normalizes the 




variable's change between two-time points by the elapsed time. This time normalization step is 
necessary when subjects have different Δt between baseline and second visit time. 
2.7  Statistical analysis 
We checked the normal distributions of all variables using Kolmogorov–Smirnov tests and 
visual inspection of the histograms. To test a significant separation from the normality of the 
variables' distributions, the Lilliefors tests were applied. The Log-transformation successfully 
rendered the data normal in some variables. For other variables that remain not normal, a rank 
transformation was applied instead to conform to the use of parametric statistical models 
(Conover and Iman, 1981). Comparisons of clinical and demographic variables between groups 
were performed with Analysis of Variance (ANOVA), Kruskal-Wallis, or Chi-square tests 
where appropriate. 
Baseline network topological measures were compared between groups with Analysis of 
Covariance statistical models (ANCOVA) to estimate the two main effects ApoE4 status 
(Carriers vs. non-Carriers) and disease progression (Converters vs. non-Converters) and the 
interaction term ApoE4*progression. The additional covariates were age, gender, educational 
level, MRI magnetic field strength, handedness, and gray matter volume. We checked whether 
the dependent variable's variance is equal between the groups by performing Levene's test of 
equal variances. If significant differences were found (all p>0.05), either a 'rank' or a 'log10' 
transformation was applied to the dependent variable. Additionally, we used a Games-Howell 
method when equal group/level variances are not assumed and posthoc comparisons with 
Tukey's or Bonferroni corrections to adjust for multiple comparisons. These statistical 
verifications are essential to ensure the dependent variable transformations' reliability and 
results’ validity using parametric models. 




As reported previously, the size, degree, and connectivity density might influence other 
network properties (van Wijk et al., 2010; Zalesky et al., 2010). Therefore, we first tested group 
effects for these network properties defining size, connectivity density, and average degree. 
For those significant, these properties were added as additional covariates (Dicks et al., 2018; 
Tijms et al., 2013a) 
ANCOVA analysis was performed for the normalized clustering index at each brain region 
defined in the Neuromorphometric atlas. We also included the regional gray matter volume 
and nodal degree as additional covariates. False discovery rate (FDR) correction was used to 
adjust for multiple comparisons by the number of structures. 
The association of network properties with psychological (ADNI-MEM, MMSE) and CSF 
variables (Aβ42, T-tau, and P-tau) were assessed using a partial correlation model. The method 
allows calculating the linear partial correlation between our variables of interest adjusting for 
different covariates. Our covariates were: age, gender, educational level, and TIV. Where 
appropriate, we adjust for multiple comparisons using FDR correction. 
To find statistical differences between partial correlation coefficients, we first applied the 
Fisher's Z transform z=ln((1+r)/(1-r))/2 for each correlation coefficient. After, we used the Z-
test correcting for degrees of freedom as follows: Z = (z1-z2)/sqrt (1/(n1-q-3) + 1/(n2-q-3)) 
(Afifi et al., 2003) (assuming standard normal distribution under the null hypothesis of no 
difference in 'mean' partial correlations); where 'z1' and 'z2' are the two transformed partial 
correlations, 'n1' and 'n2' are sample sizes, and 'q' is the number of covariates involved in the 
partial correlation computation. 
The statistical analysis was performed using the JASP software (https://jasp-stats.org/). For the 
partial correlation analysis, we used MATLAB software ('partialcorri.m' function) 
(https://www.mathworks.com/). 





3.1 Sample Description statistics 
The groups did not significantly differ in age, gender, education, or network size (number of 
nodes) at time points 1 and 2 (see Table 1). All SSGMNets followed a small-world topology 
and did not exhibit disconnected nodes. 
3.2 Baseline effects of ApoE4 and disease progression on the network properties 
All groups showed a small-world architecture (i.e., σ > 1). We found significant group 
differences in disease progression and ApoE4 factors in the ANCOVA analysis after correcting 
for multiple hypotheses.  
 
Figure 1. ANCOVA results for Network topological attributes. It is represented the bar plots of Clustering index 
normalized (Clux-Normalized), Characteristic path length normalized (CharPath-Normalized), and sigma. The 
first column of graphs  (panels a), d) and g)) shows the groups subdivided into non-Converters (non-Conv), 
Converters (Conv), and Carriers (ApoE4+), non-Carriers (ApoE4-). The second column (panels b), e) and h)) 
shows the results of the ApoE4 main effect comparing ApoE4+ versus ApoE4-. The third column (panels c), f) 
and i)) shows the disease progression's results as comparing non-Converters (non-Conv) versus Converters 
(Conv). Asterisks indicate statistically significant differences. The bars' height represents the mean, and the error 
bars the 95% confidence interval (CI). 




MCI Converters showed lower values in all network properties than non-Converters (Figure 1, 
panels c), f), i)). We did not find ApoE4*disease progression interaction effects. More details 
about these results can be found in Table S4, Supplementary Material. 
 
Figure 2. ANCOVA results for the Rate of Change (RoC) of the Network topological attributes. It is represented 
the bar plots of Clustering index normalized (Clux Normalized), Characteristic path length (CharPath), Clustering 
index (Clux), global efficiency (Eglobal), and Global connectivity (Gconnect). Panels a), c), e), g) and i) show the 
groups subdivided into non-Converters (non-Conv), Converters (Conv), and Carriers (ApoE4+), non-Carriers 
(ApoE4-). Panels b), d), f), h) and j) represent the disease progression's main effect results as comparing non-
Converters (non-Conv) versus Converters (Conv). 'Clux Normalized' and 'CharPath' showed an interaction effect 
ApoE4*disease progression. All topological network attributes depicted a significant disease progression effect. 
A log10 transformation was applied to all variables to meet the equal group variances condition in the parametric 
ANCOVA statistical design. Asterisks indicate statistically significant differences (p-corrected<0.05). The bars' 
height represents the mean, and the error bars the 95% confidence interval (CI). 
 
3.3 ApoE4 and disease progression effects on the network properties rate of change 
We found differences (Figure 2) in the rate of change (RoC) related to progression factor in 
Clux (F(1,190)= 5.273, p=0.023, ω2 =0.021), CharPath (F(1,190)= 10.378, p=0.002, ω2 
=0.044 ), GConnect (F(1,190)= 10.153, p=0.002, ω2 =0.043) and Eglobal (F(1,190)= 10.712, 
p=0.001, ω2 =0.046). The ApoE4*disease progression interaction effect was found in Clux-
Normalized (F(1,190)= 7.414, p=0.007, ω2 =0.031) and CharPath (F(1,190)= 5.566, p=0.019, 




ω2 =0.222) Figure 2, panels a) and c). The highest interaction size effect was found in the 
CharPath (size-effect ω2 =0.222). Interestingly, the post hoc analysis shows that only in the 
non-Carriers group,  non-Converters showed higher Clux-Normalized and CharPath RoC than 
Converters. On the other hand, in the Converters group, the Carriers depicted significantly 
more  Clux-Normalized as compared with non-Carriers. The ApoE4 effects, as a global factor, 
were not present in this analysis. Details about this analysis can be found in Supplementary 
Material Table S6.  
 
Figure 3. ANCOVA results for Cerebrospinal Fluid (CSF) variables. Bar plots for Aβ42, T-tau, and P-tau 
variables. The first column of graphs (panels a), d) and g)) shows the groups subdivided into non-Converters (non-
Conv), Converters (Conv), and ApoE4+, ApoE4-. The second column (panels b), e) and h)) represents the ApoE4 
main effect results comparing ApoE4+ versus ApoE4-. The third column (panels c), f) and i)) shows the disease 
progression's results as comparing non-Converters (non-Conv) versus Converters (Conv). The CSF measures were 
log10 transformed to meet the equal group variances condition in the parametric ANCOVA statistical design. 
Asterisks indicate statistically significant differences (p-corrected<0.05). The bars' height represents the mean, 
and the error bars the 95% confidence interval (CI). 




3.4 Effects of ApoE4 and disease progression on cognitive, morphometric, and CSF-derived 
measures in baseline 
Figures 3 and 4 show the ANCOVA results for the baseline groups' differences in cognitive, 
regional gray matter volume, and CSF biomarkers. 
The CSF-derived measures (Aβ42, T-tau and P-tau) showed significantly group differences in 
the ANCOVA analysis for ApoE4, disease progression and the ApoE4*disease progression 
interaction.  
 
Figure 4. ANCOVA results for the volumetric and cognitive variables. The volumetric variables were: normalized 
volume of the left Entorhinal cortex (L.Ent.Cortex Vol Norm.) (panels a) and b)), and right Entorhinal cortex 
(R.Ent.Cortex Vol Norm.) (panels c) and d)); the normalized volume of the left Hippocampus (L.Hipp Volume 
Norm.) (panels e) and f)), and right Hippocampus (R.Hipp Volume Norm.) (panels g) and h)). The cognitive 
variables are ADNI-MEM (panels i) and j)) and Mini-Mental score (MMSE) (panels k) and l). For all variables, 
a bar plot with the groups subdivided in non-Converters (non-Conv), Converters (Conv), and ApoE4+, ApoE4- 
are shown. All variables showed a significant disease progression main effect as comparing non-Converters (non-
Conv) versus Converters (Conv) (see Materials and Methods section). Asterisks indicate statistically significant 








The results revealed an ApoE4 effect on Aβ42 (F(1,118)= 7.365, p=0.008; ω
2 =0.047); T-tau 
(F(1,118)= 17.734, p=0.001, ω2 =0.110) and P-tau (F(1,118)= 21.739, p=0.001, ω2 =0.133). 
The MCI Carriers’ group exhibited lower CSF Aβ42 levels and higher T-tau and P-tau 
compared to non-Carriers at baseline. 
For the disease progression factor all measures were significantly different between Converters 
and non-Converters (Aβ42: F(1,118)= 9.905, p=0.002, ω
2 =0.065; T-tau: F(1,118)= 9.473, 
p=0.003, ω2 =0.056); P-tau: (F(1,118)= 9.924, p=0.002, ω2 =0.057). 
The ApoE4*disease progression interaction was found only in Tau measures (T-tau: F(1,118)= 
4.899, p=0.029, ω2 =0.026; P-tau: F(1,118)= 4.522, p=0.036, ω2 =0.023). The post hoc 
analysis showed significant differences between Converters and non-Converters in the non-
Carriers group and between Carriers and non-Carriers in the non-Converters group. 
Interestingly we did not find significant differences for MCI Carriers associated with disease 
progression (see Supplementary Material Table S4). 
We found significant effects associated with disease progression in MMSE (F(1,194)= 14.133, 
p=0.001, ω2 =0.058) and ADNI-MEM (F(1,194)= 43.209, p=0.001, ω2 =0.166 ). The test 
scores showed significant differences between Converters and non-Converters in the non-
Carriers group (see Supplementary Material Table S4). ADNI-MEM also captured this 
difference for the Carrier’s group. Finally, the left and right hippocampus and entorhinal gray 
matter volume normalized revealed differences between non-Converters and Converters 
(R.Hipp: (F(1,191)= 25.482, p=0.001, ω2 =0.091; L.Hipp: (F(1,191)= 28.141, p=0.001, ω2 
=0.099; R.EC: (F(1,191)= 17.803, p=0.001, ω2 =0.069; L.EC: F(1,191)= 17.537, p=0.001, 
ω2 =0.070) (Supplementary Material Table S4). However, both right hemisphere regions, 
showed differences associated with disease progression for non-Carrier’s group. In the left 
hemisphere significant differences were also found for Carriers. 




The highest size effects associated with ApoE4 was found for P-tau (ω2 =0.13) and T-tau (ω2 
=0.11). The ADNI-MEM showed the maximum size effect associated with the disease 
progression (ω2 =0.166). 
The post hoc testing results (p-value corrected by Bonferroni) for all variables with statistically 
significant differences can be found in Supplementary Material Table S4. 
 
Figure 5. ANCOVA results for the Rate of Change (RoC) of the volumetric measures. It is represented the bar 
plots of the normalized volume of the left Hippocampus (L.Hipp Volume Norm.) (panels a), b) and c)), right 
Hippocampus (R.Hipp Volume Norm.) (panels d), e) and f)) and the normalized volume of the left Entorhinal 
cortex (L.Ent.Cortex Vol Norm.) (panels g), h) and i)), and right Entorhinal cortex (R.Ent.Cortex Vol Norm.) 
(panels j), k) and l)). The first column of graphs shows the groups subdivided into non-Converters (non-Conv), 
Converters (Conv), and APOE4+, APOE4-. The second column shows the results of the APOE4 main effect 
comparing APOE4+ versus APOE4-. The third column shows the disease progression's main effect as comparing 
non-Converters (non-Conv) versus Converters (Conv). 'L.Ent.Cortex Vol Norm.' and 'R.Ent.Cortex Vol Norm.' 
showed a significant APOE4 effect. A 'rank' transformation was applied to meet the equal group variances 
condition in the parametric ANCOVA statistical design. Asterisks indicate statistically significant differences (p-
corrected<0.05). The bars' height represents the mean, and the error bars the 95% confidence interval (CI). 




3.5 ApoE4 and disease progression effects on the rate of change of cognitive and morphometric 
variables 
The normalized volume in left and right entorhinal cortex showed groups significant 
differences associated with the disease progression (F(1,191)= 10.869, p<0.00, ω2 =0.046; 
F(1,191)= 14.823, p<0.001, ω2 =0.064) as well as in the right and left hippocampus 
(F(1,191)= 9.573, p=0.002, ω2 =0.041; F(1,191)= 9.271, p=0.003, ω2 =0.039) (see Figure 5). 
 
Figure 6. ANCOVA results for the Rate of Change (RoC) of cognitive variables. It is represented the bar plots of 
the cognitive variables are ADNI-MEM (panels a), b) and c)) and Mini-Mental score (MMSE) (panels c), d) and 
e)). The first column of graphs shows the groups subdivided into non-Converters (non-Conv), Converters (Conv), 
and APOE4+, APOE4-. The second column shows the results of the APOE4 main effect comparing APOE4+ 
versus APOE4-. The third column represents the disease progression's main effect, comparing non-Converters 
(non-Conv) versus Converters (Conv). Both variables showed a significant disease progression effect. MMSE 
also showed a significant APOE4 effect (panel e)). A 'rank' transformation was applied to meet the equal group 
variances condition in the parametric ANCOVA statistical design. Asterisks indicate statistically significant 
differences (p-corrected<0.05). The bars' height represents the mean, and the error bars the 95% confidence 
interval (CI). 
 
We found an ApoE4-related effect on the rate of change of MMSE (F(1,194)= 62.744, 
p<0.001, ω2 =0.015), the left and right entorhinal cortex normalized volume (F(1,191)= 8.236, 
p=0.007, ω2 =0.034; F(1,191)= 8.616, p=0.004, ω2 =0.064). The MMSE and ADNI-MEM 
rate of change were also affected by the disease progression (F(1,194)= 62.744, p<.001, ω2 
=0.231; F(1,194)= 77.778, p<.001, ω2 =0.278) (see Figure 6). 




The ApoE4 highest size effect was found for the right entorhinal cortex (ω2 =0.06). The MMSE 
(ω2 =0.231), ADNI-MEM (ω2 =0.278), and right entorhinal cortex (ω2 =0.06) showed the 
maximum size effects associated with the disease progression. The results of the posthoc 
comparison can be found in Supplementary Material Table S6. 
 
Figure 7. ANCOVA results for the nodal normalized clustering index (nodal Clux Normalized) topological 
measure. All structures represented as spheres in panel c) were those with significant p-values (FDR corrected 
multiple comparisons) for the disease progression main effect (Converters versus non-Converters). The larger the 
sphere diameter, the larger the difference between groups. The panels a) and b) represent the results for the right 
Posterior Cingulate gyrus (PCgG.R) and the right Precuneus (PCu.R), respectively. Panel d) and e) show the left 
Anterior Cingulate gyrus (ACgG.L) and right Supramarginal gyrus (SMG.R), respectively. These structures 
showed differences in ApoE4 main effect (p uncorrected). The ACgG.L also shows an interaction effect of APOE-
disease progression. Asterisks indicate statistically significant differences for p-corrected<0.05 (FDR) except for 
panel d) and e) p-uncorrected<0.01. The bars' height represents the mean, and the error bars the 95% confidence 
interval (CI). 
 




3.6 ApoE4 and disease progression-related changes on regional normalized clustering index 
As the network Clux-Normalized showed significant group differences associated with the 
ApoE4 and disease progression factors and its RoC, we studied the origin of these differences 
at the regional level. 
The normalized clustering index is commonly used as an indicator of functional segregation 
and, as such, suggests the role of a particular region on specialized processing that occurs 
within densely interconnected groups of brain regions. 
We found 13 regions with differences between Carriers and non-Carriers (p-uncorrected<0.01) 
(Supplementary Material Table S8). However, only the right supramarginal gyrus - PCgG.R - 
(pFDR=0.043) and the left anterior cingulate gyrus - ACgG.L - (pFDR=0.015) survived multiple 
comparison correction. Both showed higher Clux-Normalized values for Carriers compared to 
non-Carriers. 
For the disease progression effect, 75 regional ANCOVAs were significantly different between 
groups, after FDR correction for multiple comparisons (Supplementary Material Table S9). 
Figure 7 shows the spatial distribution of regional normalized clustering index group 
differences. The MCI that will progress into AD showed lower Clux-Normalized for all regions 
than those that will not. Some of these regions were: right fusiform gyrus (pFDR =0.006), right 
and left middle frontal gyrus (pFDR =0.002; pFDR =0.0001), right and left posterior cingulate 
cortex (pFDR =0.002; pFDR =0.005), right precuneus (pFDR =0.006), right and left superior frontal 
gyrus (pFDR =0.0001; pFDR =0.001) and left supramarginal gyrus (pFDR =0.005). For details of 
regional groups' mean and confident intervals, see Supplementary Material Table S9. 
The left anterior cingulate gyrus (ACgG.L) showed significant interaction effects 
ApoE4*disease progression but for p-uncorrected<0.01. 




3.7 ApoE4 and disease progression effects on the association between network properties and 
cognitive and CSF variables 
We further scrutinized the relationships between network measures, memory deficit measured 
with ADNI-MEM, cognitive decline evaluated with MMSE (available for all subjects), as well 
as CSF Aβ42, T-tau, and P-tau levels. 
 
Figure 8. Differences in the correlation between Network topological attributes and cognitive and CSF variables: 
APOE4 and disease progression effects. Significant differences between APOE4+ versus APOE4- in the 
correlation of the variables Characteristic path length (CharPath) (panel b) and Global Efficiency (Eglobal) (panel 
e)) with Aβ42. Global connectivity (GConnect) correlation with MMSE is different between Converters (Conv) 
and non-Converters (non-Cov) (panel i)). Gray dotted lines in Aβ42 plots denote this parameter's normality limit 
(980 pg/ml). Asterisks indicate statistically significant differences (p<0.05). 
 
The analysis pulling together all groups and at individual groups showed several associations 
between the network properties and other measures (Supplementary Material Tables from S10, 
S11, S12, S13, and S14).The Clux-Normalized was related to ADNI-MEM using all subjects 
(r=0.206, p=0.003) and with Carriers (r=0.225, p=0.03) and non-Carriers (r=0.234, p=0.021) 




groups separated. The clustering index correlated with ADNI-MEM in general (r=0.259, 
p=0.0002, N=200 subjects), non-Converters (r=0.249, p=0.014, N=100), as well as with 
MMSE in the non-Carriers (r=0.217, p=0.033, N=100). Also, clustering index showed a 
correlation with ADNI-MEM in non-Carriers group (r=0.388, p=8.97*10-5, N=100) and not in 
Carriers. 
We found the normalized characteristic path length (CharPath-Normalized) to correlate in 
general with ADNI-MEM (r=0.246, p=0.0005, N=200). In Carriers, CharPath-Normalized was 
associated with ADNI-MEM (r=0.297, p=0.003) and in non-Carriers (r=0.232, p=0.023) as 
well. Finally, CharPath-Normalized show significant correlations with MMSE in non-Carriers 
(r=0.148, p=0.038) and with Aβ42 in Carriers (r=0.283, p=0.039). 
The global connectivity showed association with ADNI-MEM in general (r=0.162, p=0.024), 
non-Converters (r=0.24, p=0.016) and non-Carriers (r=0.287, p=0.004) groups. Finally, in non-
Converters, we found an association between global efficiency and ADNI-MEM (r=0.209, 
p=0.04). The CSF Tau measures did not reveal associations with the network properties. 
For ApoE4, we found significant differences in the correlations between the characteristic path 
length and Aβ42 levels (Carriers r=0.229, non-Carriers r=-0.171, z-stats=2.158, p=0.03). Also 
in global efficiency we obtained the same effect (Carriers r=-0.16, non-Carriers r=0.20, z-
stats=-2.00, p=0.044). 
The correlation between global connectivity and MMSE was different between Converters and 
non-Converters (Converters r=0.2, non-Converters r=-0.08, z-stats=2.01, p=0.04). The 
correlation between network properties with ADNI-MEM and CSF tau measures did not reveal 
significant differences between Converters versus non-Converters and Carriers versus non-
Carriers. 
 





The present study shows that SSGMNet is affected independently by ApoE4 and disease 
progression in late-MCI. The topological network alterations indicate a shift towards a random 
organization, more in Carriers than non-Carriers. Our findings reveal the intricate relationship 
between the SSGMNet attributes and ApoE4 genotype, suggesting modulated effects by 
independent processes associated with disease progression. 
The main results of this research can be summarized as follows: 1) At baseline (all subjects 
classified as MCI) the ApoE4 and the future progression to AD status modulate topological 
network properties differently; 2) the Rate of Change (RoC) of characteristic path length and 
Clux-Normalized were affected by ApoE4 and disease progression status interaction; 3) The 
Clux-Normalized values were lower in MCI who will progress into AD compared to those who 
will not; 4) Clux-Normalized decreased in several regions belonging to the Default Mode 
Network (DMN) in MCI Converters respect to non-Converters; 5) ApoE4 and disease 
progression affect the association between specific topological network features and CSF 
Aβ42; and MMSE variables. 
The present results are in line with the idea that disruptions in gray matter networks start years 
before dementia unfolds and, as such, may be sensitive to the concurrent changes in structural 
integrity across the brain in MCI. The baseline and RoC analysis findings underline the 
importance of considering cross-sectional and longitudinal approaches, as they could provide 
complementary information. Some of these findings deserve more attention and will be 
discussed in the following subsections. 




ApoE4 and progression to AD status impairs the SSGMNet topology in MCI 
Our results revealed that the ApoE4 mainly modulated two network properties, Normalized 
clustering index, and sigma. In both attributes, higher values in MCI Carriers were found than 
non-Carriers independently of the disease progression status. These increments (e.g., higher 
similarity between neighboring nodes) associated with the E4 allele may reflect synchronous 
atrophy between brain areas, whereas Carriers show a more uniform neurodegeneration pattern 
across the brain. This finding seems to contradict previous studies reporting lower clustering 
index in MCI Carriers (Li et al., 2019; Sanabria-Diaz et al., 2021). The source of this variability 
may be primarily related to a different network methodology, morphometric descriptors, group 
selection, and sample size, among other factors. 
Additionally, the higher values of small-worldness in Carriers as indicative of a more random 
network organization, which has often been reported in AD and MCI (Dicks et al., 2018; Tijms 
et al., 2013a; Yao et al., 2010). The disease progression also modulated the sigma property, 
with lower values in Converters compared to non-Converters. This association has been 
demonstrated in previous longitudinal and cross-sectional studies in MCI (Friedman et al., 
2014). 
Independent of the ApoE4 factor, we found that those MCI who will progress into AD have 
lower normalized characteristic path length. It suggests a more random network, consequently 
reducing the potential for functional integration between brain regions. This effect potentially 
reflects the interplay between synchronous atrophy over time (Tijms et al., 2018) and regional 
adaptative/maladaptive mechanisms (Fornito et al., 2015). 
Additionally, only the CSF measures were modified by the E4 allele at baseline. Our results in 
Carriers confirm previous findings where ApoE4 status was associated with brain amyloid 
accumulation and lower CSF Aβ42 as well as higher tau levels in MCI (Hashimoto et al., 2012; 




Chia-Chen Liu et al., 2013; Risacher et al., 2013). Yet, the impact of the disease progression 
status at baseline was captured by the hippocampus, entorhinal volumes and ADNI-MEM 
composite score. The MCI Converter groups showed higher volume loss in both structures and 
lower scores on the memory test than the non-Converters. Both measures have been previously 
associated with MCI progression into AD (Crane et al., 2012; Farlow et al., 2004; Giorgio et 
al., 2020; C. R. Jack et al., 2010; Jack et al., 2013, 2004). 
Compared to our previous paper (Sanabria-Diaz et al., 2021), there are several differences.  
Contrary to the mentioned study, we also classified MCI patients at baseline based on the 
clinical progression (non-Converters versus Converter into AD). Second, the evaluation of the 
network measures is different between studies. We found the Clux-Normalized more sensitive 
to detect ApoE4 effects, a network attribute that was not explored in the previous work.  Each 
research used a different morphometric descriptor (cortical thickness versus grey matter 
density). Based on a prior study from our group, it is known that morphometric descriptors 
capture distinct properties of the interaction between brain structures (Sanabria-Diaz et al., 
2010). Importantly, we explore the modulation on the time Rate of Change (RoC) of network 
attributes, CSF biomarkers, and cognitive measures in the same MCI cohort. This relevant 
contribution is missing in our previous paper. 
ApoE4 genotype differentially modulates the rate of change of SSGMNet properties and other 
AD-related biomarkers 
Our study revealed that the RoC of characteristic path length and Normalized clustering index 
were affected by the interaction between ApoE4 and disease progression status. The effect was 
driven by the non-Carrier's group, were patients who will later on progress into AD showed the 
steepest decline compared to those that will not convert to AD. This result may help to establish 




which network properties changes are associated with AD progression in MCI non-Carriers. It 
supports the hypothesis that a higher rate of decreasing over time in both metrics in MCI is 
associated with an AD progression. In particular, a previous study in non-demented subjects 
(amyloid positive) showed an association between clinical progression over time and lowered 
normalized clustering index values (Tijms et al., 2016). Also, RoC results indicated that the 
gray matter networks seem to move towards a random network organization, which has been 
previously reported for AD subjects by other studies (Pereira et al., 2016; Phillips et al., 2015; 
Tijms et al., 2013a, 2014). 
Interestingly, none of the network measures’s RoC is affected by ApoE4 as a global ANOVA 
effect, although several were sensitive to the disease progression. Longitudinally, the main 
differences associated with the clinical progression were found to have a steeper decrease in 
cluster index normalized, characteristic path length, global connectivity, and global efficiency 
in Converters. Altogether these findings suggest brain connectivity alterations (for a review, 
see (Tijms et al., 2013b)). They may reflect a reduced ability to integrate information across 
distributed brain regions and altered communication between neighboring areas (Dicks et al., 
2018; Pereira et al., 2016). 
Additionally, we found an independent effect of the E4 allele on the entorhinal cortex rate of 
atrophy. The Carriers showed a higher RoC in this structure volume compared to non-Carriers. 
Specifically, a previous study using ADNI database confirms an association between E4 allele 
and a more significant increase in atrophy rate in the hippocampus and entorhinal cortex in 
MCI Carriers' Converters (Hostage et al., 2014; Risacher et al., 2010). In our study, the steeper 
atrophy in these regions in MCI Converters confirms the most extensive effects described in 
areas previously demonstrated to display significant atrophy in AD. Nevertheless, this analysis 




revealed the importance of monitoring the entorhinal cortex volume in MCI since it is affected 
independently by ApoE4 and disease progression. 
A faster cognitive decline associated with ApoE4 was also captured by MMSE. Our result 
suggests that this test score, used in clinical and research settings to measure cognitive 
impairment, is modulated by the ApoE4. Based on this finding, we considered incorporating 
the subject E4 allele information for MCI cognitive characterization a valuable research 
strategy, especially in clinical trials. On the other hand, independently of ApoE4, the RoC for 
ADNI-MEM total score revealed faster memory decline for those who progressed into AD. 
ADNI-MEM has been considered in a previous study using the ADNI database, as the most 
discriminative cognitive feature for classifying stable versus progressive MCI (Giorgio et al., 
2020). 
ApoE4 and disease progression modulate the regional Normalized Clustering index in MCI 
Our study found regional normalized clustering index differences between groups mostly 
driven by the disease progression. These regional differences were widely distributed across 
the brain with a common denominator: lower Clux-Normalized values for those MCI that will 
convert to AD. It suggests that in MCI, the risk of disease progression is characterized by worse 
local communication between 'topological neighboring' areas (graph theory concept). The fact 
that all identified regions showed a lower clustering index normalized in MCI Converters may 
be related to AD neuropathological processes that are already operating in this phase, which in 
turn affect the intracortical gray matter properties similarity. 
It has been previously described that intracortical morphometric similarity is related to 
coordinated changes of cortical structures (for a review, see (Alexander-Bloch et al., 2013)). 
This hypothesis may explain why several regions with lower values in MCI Converters belong 




to the default-mode network (DMN), including the posterior cingulate cortex, precuneus, 
temporal and prefrontal areas (Greicius et al. 2004). This finding agrees with our previous 
study, where several regions belonging to the DMN showed nodal alteration associated with 
the ApoE4 (Sanabria-Diaz et al., 2021). However, many of them diverge between studies 
probably related to several methodological differences (i.e., parcellation schemes and sample 
size).  
Our findings support the idea that a continuous DMN activity increases the metabolism-
dependent cascade conducive to AD (Buckner et al., 2009, 2005; Raichle, 2006). In this regard, 
as part of the DMN, memory systems may be preferentially affected because it plays a central 
role in the resting state activity (Buckner et al., 2005). 
In addition to this hyper functional-activation hypothesis, the regional clustering alterations 
may arise due to axonal connectivity. For example, we found lower values in the posterior 
cingulate cortex and the precuneus for those MCI who will progress into AD. Both structures 
have been reported in previous network studies in MCI and AD at a group and individual-based 
level (Dicks et al., 2018; He et al., 2008; Pereira et al., 2016; Tijms et al., 2014, 2013a; Yao et 
al., 2010). Moreover, the posterior cingulate cortex constitutes a central node in the DMN. This 
structure has reciprocal connections to the medial temporal lobe structures (i.e., entorhinal 
cortex, parahippocampal gyrus, precuneus, orbitofrontal cortex) affected during AD 
progression. Along with the precuneus, the posterior cingulate cortex has a role in episodic 
memory retrieval (Maddock et al., 2001; Nielsen et al., 2005), working memory (Kozlovskiy 
et al., 2012), and it has been implicated in several intrinsic control networks (Leech et al., 
2012). 
These results support the hypothesis that in MCI, regional network alterations are associated 
with network degeneration. There are several mechanisms suggested by which it occurs: 1) 




Selective neuronal vulnerability that may affect functional circuits (Hyman et al., 1984), 
inducing compensatory strategies at the network level (Palop et al., 2007, 2006); 2) Retrograde 
axonal transport deficits that result in axonal degeneration (Salehi et al., 2006); 3) Prion disease 
mechanism where misfolded disease proteins may propagate throughout brain circuits (Scott 
et al., 2013). 
ApoE4 and disease progression effects on the association between network properties, 
cognitive and CSF-derived measures 
Additionally, the present study investigated the associations between the network topological 
properties, memory, general cognition, and CSF-derived measures. We studied the general 
correlation between these variables and, separately, the influence of ApoE4 and disease 
progression factors. We found that in MCI, several network properties showed a positive 
correlation with memory functions evaluated using ADNI-MEM. Our findings agree with a 
recent MCI study in which the gray matter network properties showed the strongest 
associations with a decline in global cognition and memory (Dicks et al., 2018). The correlation 
with ADNI-MEM is consistent with the memory domain being among the first cognitive 
functions affected in the amnesic MCI subtype (Jack et al., 2013). A practical implication of 
this finding is the possible use of the network measures to monitor new therapies' efficiency in 
clinical trials in MCI patients. 
Interestingly, the CSF Aβ42 level was positively associated with the characteristic path length 
in the Carriers group, while we did not find correlations with P-tau and T-tau. This result agrees 
with previous studies showing that the E4 allele modulates the brain Aβ aggregation and 
deposition (for review, see (Chia-Chen Liu et al., 2013)). Moreover, the positive association 
between these two measures was confirmed only for ApoE4 and not for the disease progression 




factor. Our finding suggests that the characteristic path length informs the detrimental E4 allele 
effects on the amyloid-related pathways in network terms. We hypothesized that synaptic 
dysfunction due to increased AD-related brain pathology (amyloid aggregation, tau) renders 
gray matter morphology more dissimilar at a regional level, resulting in differences between 
Carriers and non-Carriers. 
Finally, the CSF P-tau and T-tau levels were not associated with the network topology either 
for ApoE4 or disease progression factors. This finding may suggest that the network attributes 
are not sensitive to Tau levels changes and/or may reflect a different neurodegenerative 
mechanism. Consistent with this explanation, a previous study found gray matter network 
measures contained predictive information in addition to total CSF Tau levels (Tijms et al., 
2018). 
Limitations and Future Considerations 
There are several potential limitations to this study that should be considered. First, two-time 
points MRI scans were analyzed in the current study. Future investigation on the ApoE4-related 
effects on the network properties, longitudinal cognitive decline, and brain atrophy is 
necessary. Second, a small sample of subjects had CSF measures, which might have affected 
the accuracy of the association analysis. Third, this study was specifically limited to those 
subjects who were already clinically diagnosed with amnesic MCI. Thus, our study may not be 
generalizable to other clinical studies or populations. Further studies are needed to support the 
present findings with larger sample sizes. 
A gene-dose analysis as well as susceptibility and protective loci associated with late-onset AD 
need to be considered in conjunction to ApoE4 for studying possible interaction effects. 
Another potential limitation is that our study included an average period of 3 years between 




the two visits (time points). Hence, some patients in the non-Converter MCI group could 
progress to dementia later on. Yet, we demonstrated the impact of the E4 allele on the RoC of 
structural gray matter networks alongside the cross-sectional results. To the best of our 
knowledge, this has not been studied before and warrants further investigation of how gray 
matter network integrity changes over time in MCI. 
Future research is needed to examine whether altered graph properties are related to a particular 
cognitive domain and are more sensitive to predict cognitive decline. The graphs' diagnostic 
potential should be further investigated using classification algorithms and state of the art 
machine learning algorithms. 
It remains an open question how the brain structural co-variance connectivity is related to 
anatomical and functional connectivity and how this relationship changes during AD 
progression. Future multimodal neuroimaging studies are required to answer this question. A 
strength of the current approach is that we illustrated the network properties affected by ApoE4 
and disease progression and their relation to inter-individual differences in other biomarkers in 
MCI, suggesting that they encode additional relevant information. 
5 Conclusions 
This paper demonstrated the role of ApoE4 in disrupting specific parameters of the gray matter 
network topology. ApoE4 simultaneously affects morphometric, cognitive variables, as well 
as CSF variables. Significantly, the time RoC of these variables is also affected by the allele. 
In particular, in Carriers, there are a decreased CSF Aβ42 levels, increased entorhinal cortex 
atrophy and increased T-tau and P-tau levels. We also discovered specific disruption in 
topological network properties, morphometric, cognitive, and CSF-derived markers in those 
MCI patients that will progress to AD. Disease progression conducts more pervasive brain 




alterations than ApoE4. The clustering index normalized at the regional level showed 
widespread changes across the brain cortex, driven mostly by the disease progression, 
overlapping with the critical nodes of the DMN related to AD pathology. 
Based on these findings, we considered the SSGMNets as a valid approach to sheds light on the 
cognition-gene-structural co-variance interaction. This is a potentially significant development 
because it could find use in MCI biomarkers research and may even offer clinical value. The 
study further provides information to advance the current understanding of how ApoE4 -which 
is far the most important genetic factor known in late-onset AD- influences brain network 
topology in MCI subjects. Examining ApoE4 with factors such as the risk of AD progression, 
as we have demonstrated, may be crucial in building classification models in an attempt to 
measure subtle network changes in MCI. 
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Table S1. List of gray matter structures defined in the Neuromorphometrics atlas. 
 
Structure Name Abbreviated Name Left Abbreviated Name Right 
 Accumbens Area                                          Accum.R Accum.L 
 Amygdala                                                Amyg.R Amyg.L 
 Caudate                                                 Cau.R Cau.L 
 Hippocampus                                             Hip.R Hip.L.L 
 Pallidum                                                Pal.R Pal.L 
 Putamen                                                 Put.R Put.L 
 Thalamus Proper                                         Thal.R Thal.L 
 Ventral DC                                              VentDC.R VentDC.L 
 Anterior cingulate gyrus                           ACgG.R ACgG.L 
 Anterior insula                                    AIns.R AIns.L 
 Anterior orbital gyrus                             AOrG.R AOrG.L 
 Angular gyrus                                       AnG.R AnG.L 
 Calcarine cortex                                   Calc.R Calc.L 
 Central operculum                                    CO.R CO.L 
 Cuneus                                              Cun.R Cun.L 
 Entorhinal area                                     Ent.R Ent.L 
 Frontal operculum                                    FO.R FO.L 
 Frontal pole                                        FRP.R FRP.L 
 Fusiform gyrus                                      FuG.R FuG.L 
 Gyrus rectus                                        GRe.R GRe.L 
 Inferior occipital gyrus                            IOG.R IOG.L 
 Inferior temporal gyrus                             ITG.R ITG.L 
 Lingual gyrus                                       LiG.R LiG.L 
 Lateral orbital gyrus                              LOrG.R LOrG.L 
 Middle cingulate gyrus                             MCgG.R MCgG.L 
 Medial frontal cortex                               MFC.R MFC.L 
 Middle frontal gyrus                                MFG.R MFG.L 
 Middle occipital gyrus                              MOG.R MOG.L 
 Medial orbital gyrus                               MOrG.R MOrG.L 
 Postcentral gyrus medial segment                   MPoG.R MPoG.L 
 Precentral gyrus medial segment                    MPrG.R MPrG.L 
 Superior frontal gyrus medial segment              MSFG.R MSFG.L 
 Middle temporal gyrus                               MTG.R MTG.L 
 Occipital pole                                      OCP.R OCP.L 
 Occipital fusiform gyrus                           OFuG.R OFuG.L 
 Opercular part of the inferior frontal gyrus      OpIFG.R OpIFG.L 
 Orbital part of the inferior frontal gyrus        OrIFG.R OrIFG.L 
 Posterior cingulate gyrus                          PCgG.R PCgG.L 
 Precuneus                                           PCu.R PCu.L 
 Parahippocampal gyrus                               PHG.R PHG.L 
 Posterior insula                                   PIns.R PIns.L 
 Parietal operculum                                   PO.R PO.L 
 Postcentral gyrus                                   PoG.R PoG.L 
 Posterior orbital gyrus                            POrG.R POrG.L 
 Planum polare                                        PP.R PP.L 
 Precentral gyrus                                    PrG.R PrG.L 
 Planum temporale                                     PT.R PT.L 
 Subcallosal area                                    SCA.R SCA.L 
 Superior frontal gyrus                              SFG.R SFG.L 
 Supplementary motor cortex                          SMC.R SMC.L 
 Supramarginal gyrus                                 SMG.R SMG.L 
 Superior occipital gyrus                            SOG.R SOG.L 
 Superior parietal lobule                            SPL.R SPL.L 
 Superior temporal gyrus                             STG.R STG.L 
 Temporal pole                                       TMP.R TMP.L 
 Triangular part of the inferior frontal gyrus     TrIFG.R TrIFG.L 
 Transverse temporal gyrus                           TTG.R TTG.L 
 
  
Table S2. Cognitive, CSF, and morphometric measures characteristics of the MCI groups. 
MCI-Non-Converters MCI Converters 
Diagnosis Time 1 
(MCI) 
Diagnosis Time 2 
(stable MCI) 
Diagnosis Time 1 
(MCI) 
Diagnosis Time 2 
(AD) 






















































































































CSF test participant 





















































Legend: Aβ42: Amyloid-beta 42, P-tau: phosphorylated tau, T-tau: total tau, Hipp:  hippocampus, E.C: entorhinal cortex, L: left, R: right, mm3: 
millimeter, pg/ml : picogram/milliliter, CSF : cefaloraquidic liquid, BM+ : biomarker positive.  
Note. For ANOVA, p-value and confidence intervals adjusted using the Tukey method. For Kruskal-Wallis test, we applied the Games-Howell 
method, where equal group/level variances are not assumed. The p-values are corrected with the Tukey method. *p < .05; ** p < .01, ***p<0.001. 
Post hoc contrasts : 1Converter carriers - Converter non-carriers ; 2Converter carriers - non-Converter carriers ; 3Converter carriers - non-Converter 















na na na na na 
Table S3. MCI classification based on the ATN system. 
We assigned “A+” to those individuals that had a CSF Aβ1-42< 980 pg/ml, “T+” to those 
individuals with P-tau > 24 pg/ml and “N+” to those individuals with T-tau > 266 pg/ml. Because 
a number of ATN profiles contained very few participants, we also clustered the 8 biomarker 
profiles into three categories. The A–T–N– profile was labeled as the “normal AD biomarker” 
category (green shadow). We clustered the remaining A– (A–T–N+, A–T+N–, and A–T+N+) as 
“non-AD related pathology” (grey shadow), and we clustered all A+ (A+T–N–, A+T–N+, 













A-T-N- 3 1 4 13 21 
A-T-N+ 1 0 0 1 2 
A-T+N- 1 0 0 0 1 
A-T+N+ 4 0 5 3 12 
A+T-N- 7 3 4 11 25 
A+T-N+ 1 2 2 2 7 
A+T+N- 0 0 0 0 0 
A+T+N+ 17 20 16 4 57 
Total 34 26 31 33 
Legend: ATN: AD-related biomarkers system. It is divided into three binary categories based on the nature of the underlying pathophysiology. 
Biomarkers of fibrillary Aβ deposition (A+) are retention on amyloid (PET or CSF Aβ). Biomarkers of tau pathology (neurofibrillary tangles) (CSF 
phosphorylated tau (p-tau) and tau PET). Biomarkers of AD-like neurodegeneration or neuronal injury (CSF total tau (t-tau), [18F]-
fluorodeoxyglucose (FDG)-PET, sMRI) in regions characteristic of AD. 
  




















Aβ42 (log10) -0.144 -0.023 0.031 118 -2.714 0.008 -0.480 
T-tau (log10) 0.070 0.194 0.031 118 4.211 <.001 0.731 
P-tau (log10) 0.096 0.239 0.036 118 4.662 <.001 0.809 
Clux-
Normalized 
8.2*10-4 0.028 0.007 190 2.091 0.038 0.233 





Aβ42 (log10) 0.036 0.157 0.031 118 3.147 0.002 0.561 
T-tau (log10) -0.158 -0.034 0.031 118 -3.078 0.003 -0.516 
P-tau (log10) -0.184 -0.042 0.036 118 -3.150 0.002 -0.521 
Clux-
Normalized 
0.002 0.030 0.007 190 2.248 0.026 2.248 
CharPath-
Normalized 
3.2*10-4 0.004 9.02*10-4 190 2.330 0.021 0.289 
Sigma 0.001 0.025 0.006 190 2.149 0.033 0.244 
MMSE 0.415 1.331 0.232 194 3.759 <.001 0.520 
ADNI-MEM 0.309 0.573 0.067 194 6.573 <.001 0.914 
L.Hipp 1.37*10
-4 2.9*10-4 4.01*10-4 191 5.305 <.001 0.687 
R.Hipp 1.3*10-4 3.03*10-4 4.32*10-4 191 5.048 <.001 0.655 
L.E.C 4.5*10-5 1.27*10-4 2.06*10-4 191 4.188 <.001 0.577 
R.E.C 4.3*10-5 1.18*10-4 1.9*10-5 191 4.219 <.001 0.565 
Legend: Aβ42: Amyloid-beta 42, P-tau: phosphorylated Tau, T-tau: total Tau, Hipp: hippocampus, E.C: entorhinal cortex, MMSE: Mini-mental 
state examination, ADNI-MEM:  Alzheimer Disease Neuroimaging Initiative composite score for memory, L: left, R: right; log10: logarithmic 
transformation. SE: the standard error of the estimated mean; df: the degrees of freedom of the model; t: the value of the t-statistic; p: probability 
values are corrected by Bonferroni. Cohen’s d: size effect, it is not corrected for multiple comparisons. 
 



















T-tau Converter non-Carrier vs. 
 non-Converter non-Carriers 
-0.273 -0.532 -0.015 0.100 -2.738 0.041 
Converter non-Carriers vs.  
Converter Carriers 
-0.286 -0.535 -0.038 0.096 -2.986 0.019 
 
P-tau 
Converter non-Carriers vs.  
non-Converter non-Carriers 
0.189 0.062 0.315 0.049 3.891 < .001 
non-Converter Carriers vs.  
Converter Carriers 
-0.280 -0.416 -0.145 0.052 -5.383 < .001 
non-Converter non-Carriers vs.  
non-converter Carriers 
-0.244 -0.373 -0.114 0.050 -4.905 < .001 
Legend: P-tau: phosphorylated tau, T-tau: total Tau. SE: the standard error of the estimated mean; t: value of the t-statistics. 
Note.  p-values and confidence intervals adjusted for comparing a family of 4 estimates (confidence intervals corrected using the Tukey 
method). p-values corrected by Bonferroni. 
 
 






















MMSE (rank) -28.990 -1.951 7.108 194 -2.247 0.026 -0.278 
R.EC Norm (rank) -39.043 -7.659 7.955 191 -2.935 0.004 -0.483 






MMSE (rank) 42.612 70.867 7.163 194 7.921 <.001 1.119 
ADNI-MEM (rank) 48.063 75.752 7.020 194 8.819 <.001 1.267 
R.Hipp Norm (rank) 9.134 41.260 8.144 191 3.094 0.002 0.446 
L.Hipp Norm (rank) 8.706 40.733 8.118 191 3.045 0.003 0.437 
R.EC Norm (rank) 15.031 46.611 8.005 191 3.650 <.001 0.524 
L.EC Norm (rank) 10.631 42.298 8.027 191 3.297 0.001 0.473 
Clux (log10) 0.023 0.307 0.072 190 2.296 0.023 0.337 
CharPath (log10) 0.107 0.446 0.086 190 3.221 0.002 0.473 
GConnect (log10) 0.094 0.399 0.077 190 3.186 0.002 0.468 
Eglobal (log10) 0.112 0.450 0.086 190 3.273 0.001 0.484 
Legend: Hipp: hippocampus, E.C: entorhinal cortex, MMSE: Mini-mental state examination, ADNI-MEM:  Alzheimer Disease Neuroimaging 
Initiative composite score for memory, L: left, R: right, log10: logarithm transformation, rank: rank transformation. SE: the standard error of the 
estimated mean; df: the degrees of freedom of the model; t: the value of the t-statistic; p: probability values are corrected by Bonferroni. Cohen’s 
d: size effect, it is not corrected for multiple comparisons. 
 



















Clux (log10) Converter non-Carriers vs.  
non-Converter non-Carriers  




Converter Carriers vs. 
 non-Converter non-Carriers 
-0.273 -0.532 -0.015 0.100 -2.738 0.041 
Converter non-Carriers vs. 
 Converter Carriers 
-0.286 -0.535 -0.038 0.096 -2.986 0.019 
Legend: CharPath-Normalized: Normalized Characteristic path length, Clux: clustering index, log10: logarithm transformation, SE: the standard 
error of the estimated mean; t: value of the t-statistics. 
Note.  p-values and confidence intervals adjusted for comparing a family of 4 estimates (confidence intervals corrected using the Tukey method). 
p-values corrected by Bonferroni. 
  
Table S8. ANCOVA significant results for ApoE4 main effect for nodal Normalized Clustering 
index (Nodal Clux-Normalized). Highlighted in red are the Right supramarginal gyrus (SMG.R) 
(p-corrected = 0.042, p-uncorrected=0.0005) and Left ACgG anterior cingulate gyrus (ACgG.L) 
(p-corrected = 0.015, p-uncorrected=0.00061) that show significant differences after FDR 
correction for multiple comparisons. The rest of the reported p-values are uncorrected p<0.01. 
















Right LiG lingual gyrus LiG.R 0.78 0.055 0.80 0.062 0.009 
Right OFuG occipital fusiform gyrus OFuG.R 0.79 0.063 0.81 0.067 0.007 
Right PoG postcentral gyrus PoG.R 0.80 0.052 0.82 0.052 0.008 
Right PT planum temporale PT.R 0.78 0.065 0.80 0.078 0.005 
Right SMG supramarginal gyrus SMG.R 0.82 0.059 0.85 0.058 0.0005 
Right SOG superior occipital gyrus SOG.R 0.82 0.066 0.84 0.073 0.0037 
Right SPL superior parietal lobule SPL.R 0.80 0.061 0.82 0.059 0.0086 
Right TTG transverse temporal gyrus TTG.R 0.81 0.082 0.85 0.083 0.0030 
Left ACgG anterior cingulate gyrus ACgG.L 0.83 0.065 0.86 0.069 0.00061 
Left AnG angular gyrus AnG.L 0.80 0.058 0.82 0.065 0.0030 
Left LiG lingual gyrus LiG.L 0.78 0.059 0.80 0.063 0.0071 
Left MSFG superior frontal gyrus medial segment MSFG.L 0.84 0.059 0.86 0.066 0.0091 
Left SPL superior parietal lobule SPL.L 0.81 0.059 0.83 0.056 0.0027 
 
 
Table S9. ANCOVA significant results for disease progression main effects for nodal Normalized 
Clustering index (Nodal Clux-Normalized). The reported p-values are FDR corrected for multiple 
comparisons. 
 















 p value 
(FDR) 
Right Caudate Cau.R 0.91 0.066 0.88 0.061 0.015 
Right Pallidum Pal.R 0.99 0.076 0.96 0.076 0.029 
Right Putamen Put.R 0.89 0.054 0.87 0.059 0.012 
Right Thalamus Proper Thal.R 0.93 0.047 0.91 0.050 0.005 
Right Ventral DC VentDC.R 0.95 0.070 0.92 0.062 0.012 
Right AIns anterior insula AIns.R 0.87 0.059 0.85 0.054 0.023 
Right AnG angular gyrus AnG.R 0.83 0.054 0.81 0.061 0.037 
Right Calc calcarine cortex Calc.R 0.77 0.073 0.75 0.073 0.031 
Right CO central operculum CO.R 0.84 0.069 0.82 0.057 0.023 
Right Cun cuneus Cun.R 0.80 0.062 0.77 0.062 0.012 
Right FRP frontal pole FRP.R 0.90 0.066 0.87 0.070 0.024 
Right FuG fusiform gyrus FuG.R 0.82 0.056 0.80 0.058 0.019 
Right GRe gyrus rectus GRe.R 0.85 0.080 0.82 0.068 0.015 
Right IOG inferior occipital gyrus IOG.R 0.87 0.067 0.84 0.061 0.024 
Right ITG inferior temporal gyrus ITG.R 0.87 0.056 0.85 0.058 0.019 
Right LiG lingual gyrus LiG.R 0.80 0.063 0.78 0.055 0.025 
Right LOrG lateral orbital gyrus LOrG.R 0.87 0.070 0.84 0.067 0.031 
Right MCgG middle cingulate gyrus MCgG.R 0.89 0.066 0.86 0.062 0.012 
Right MFG middle frontal gyrus MFG.R 0.84 0.049 0.82 0.054 0.012 
Right MOrG medial orbital gyrus MOrG.R 0.87 0.061 0.84 0.067 0.012 
Right MPrG precentral gyrus medial segment MPrG.R 0.85 0.076 0.82 0.073 0.023 
Right MTG middle temporal gyrus MTG.R 0.84 0.050 0.82 0.056 0.037 
Right OpIFG opercular part of the inferior frontal 
gyrus 
OpIFG.R 0.84 0.068 0.81 0.058 0.004 
Right OrIFG orbital part of the inferior frontal gyrus OrIFG.R 0.86 0.072 0.82 0.081 0.015 
Right PCgG posterior cingulate gyrus PCgG.R 0.89 0.069 0.86 0.062 0.012 
Right PCu precuneus PCu.R 0.83 0.059 0.80 0.062 0.019 
Right PO parietal operculum PO.R 0.85 0.080 0.82 0.073 0.022 
Right PoG postcentral gyrus PoG.R 0.83 0.049 0.80 0.052 0.004 
Right POrG posterior orbital gyrus POrG.R 0.86 0.068 0.84 0.065 0.022 
Right PP planum polare PP.R 0.84 0.076 0.81 0.072 0.015 
Right PrG precentral gyrus PrG.R 0.87 0.059 0.85 0.058 0.031 
Right SCA subcallosal area SCA.R 0.86 0.079 0.83 0.082 0.031 
Right SFG superior frontal gyrus SFG.R 0.88 0.049 0.85 0.054 0.005 
Right SMC supplementary motor cortex SMC.R 0.87 0.071 0.84 0.061 0.015 
Right SMG supramarginal gyrus SMG.R 0.84 0.060 0.82 0.058 0.042 
Right SOG superior occipital gyrus SOG.R 0.85 0.070 0.82 0.068 0.012 
Right SPL superior parietal lobule SPL.R 0.83 0.059 0.80 0.060 0.012 
Right TMP temporal pole TMP.R 0.88 0.051 0.86 0.058 0.023 
Right TrIFG triangular part of the inferior frontal 
gyrus 
TrIFG.R 0.86 0.062 0.83 0.067 0.012 
Left Caudate Cau.L 0.90 0.067 0.88 0.066 0.040 
Left Putamen Put.L 0.88 0.054 0.86 0.055 0.031 
Left Thalamus Proper Thal.L 0.94 0.053 0.92 0.050 0.012 
Left Ventral DC VentDC.L 0.93 0.066 0.90 0.067 0.012 
Left ACgG anterior cingulate gyrus ACgG.L 0.86 0.067 0.83 0.068 0.015 
Left AIns anterior insula AIns.L 0.88 0.060 0.86 0.058 0.026 
Left AOrG anterior orbital gyrus AOrG.L 0.85 0.073 0.82 0.068 0.039 
Left AnG angular gyrus AnG.L 0.82 0.063 0.80 0.062 0.046 
Left Calc calcarine cortex Calc.L 0.77 0.070 0.75 0.069 0.025 
Left CO central operculum CO.L 0.85 0.069 0.82 0.063 0.012 
Left FRP frontal pole FRP.L 0.90 0.071 0.87 0.066 0.012 
Left FuG fusiform gyrus FuG.L 0.81 0.054 0.79 0.059 0.025 
Left GRe gyrus rectus GRe.L 0.83 0.082 0.80 0.064 0.012 
Left ITG inferior temporal gyrus ITG.L 0.87 0.053 0.85 0.054 0.022 
Left LOrG lateral orbital gyrus LOrG.L 0.87 0.076 0.85 0.067 0.022 
Left MCgG middle cingulate gyrus MCgG.L 0.86 0.062 0.83 0.069 0.013 
Left MFG middle frontal gyrus MFG.L 0.85 0.053 0.82 0.053 0.005 
Left MOrG medial orbital gyrus MOrG.L 0.88 0.069 0.85 0.066 0.015 
Left MSFG superior frontal gyrus medial segment MSFG.L 0.86 0.062 0.84 0.064 0.025 
Left MTG middle temporal gyrus MTG.L 0.84 0.055 0.82 0.055 0.023 
Left OCP occipital pole OCP.L 0.85 0.069 0.82 0.072 0.023 
Left OpIFG opercular part of the inferior frontal 
gyrus 
OpIFG.L 0.83 0.064 0.81 0.072 0.041 
Left PCgG posterior cingulate gyrus PCgG.L 0.87 0.065 0.84 0.061 0.018 
Left PCu precuneus PCu.L 0.81 0.056 0.80 0.059 0.031 
Left PO parietal operculum PO.L 0.84 0.072 0.81 0.070 0.025 
Left PoG postcentral gyrus PoG.L 0.83 0.052 0.81 0.056 0.019 
Left POrG posterior orbital gyrus POrG.L 0.85 0.066 0.82 0.063 0.021 
Left PP planum polare PP.L 0.82 0.069 0.80 0.068 0.031 
Left PrG precentral gyrus PrG.L 0.87 0.061 0.84 0.052 0.012 
Left SFG superior frontal gyrus SFG.L 0.88 0.049 0.85 0.056 0.012 
Left SMG supramarginal gyrus SMG.L 0.85 0.060 0.83 0.058 0.019 
Left SOG superior occipital gyrus SOG.L 0.83 0.075 0.80 0.073 0.019 
Left SPL superior parietal lobule SPL.L 0.83 0.056 0.81 0.059 0.029 
Left STG superior temporal gyrus STG.L 0.83 0.058 0.80 0.066 0.015 
Left TMP temporal pole TMP.L 0.88 0.054 0.85 0.055 0.016 
Left TrIFG triangular part of the inferior frontal gyrus TrIFG.L 0.87 0.069 0.85 0.068 0.034 
 
  
Table S10. Correlation between network topological attributes and MMSE taking all data 
sample and dividing groups into Converts and non-Converters and APOE4+, APOE4-. The 
































0.12 0.094 0.007 0.94 0.095 0.35 0.09 0.36 0.15 0.12 
Clux 0.12 0.070 -0.05 0.62 0.18 0.064 0.04 0.69 0.21 0.03 
CharPathL 
Normalized 
0.14 0.038 0.105 0.30 0.068 0.50 0.15 0.12 0.14 0.16 
CharPathL 0.014 0.84 0.095 0.35 -0.11 0.25 0.05 0.57 -0.02 0.82 
Global 
Connectivity 
0.081 0.25 -0.086 0.40 0.203 0.046 0.005 0.96 0.15 0.13 
Eglobal 0.042 0.55 -0.092 0.37 0.17 0.09 -0.02 0.83 0.10 0.32 
 
 
Table S11. Correlation between network topological attributes and ADNI-MEM taking all data 
sample and dividing groups into Converts and non-Converters and APOE4+, APOE4-. The 
































0.206 0.003 0.09 0.37 0.071 0.48 0.22 0.030 0.234 0.021 
Clux 0.26 2*10-4 0.12 0.22 0.25 0.014 0.13 0.176 0.388 8.97*10-5 
CharPathL 
Normalized 
0.246 5*10-4 0.17 0.08 0.072 0.48 0.29 0.003 0.232 0.022 
CharPathL 0.019 0.785 0.07 0.49 -0.145 0.15 0.12 0.243 -0.061 0.55 
Global 
Connectivity 
0.162 0.023 0.040 0.69 0.24 0.016 0.03 0.705 0.287 0.004 
Eglobal 0.087 0.22 -0.007 0.93 0.20 0.040 -0.02 0.785 0.198 0.051 
 
  
Table S12. Correlation between network topological attributes and CSF measure Aβ42 taking all 
data sample and dividing groups into Converts and non-Converters and APOE4+, APOE4-. The 
































0.08 0.36 0.035 0.78 -0.053 0.69 0.25 0.06 0.006 0.95 
Clux 0.07 0.41 0.053 0.68 -0.031 0.81 -0.03 0.81 0.15 0.21 
CharPathL 
Normalized 
0.10 0.27 0.033 0.80 -0.009 0.94 0.28 0.039 -0.03 0.75 
CharPathL 0.006 0.94 -0.02 0.84 -0.014 0.91 0.22 0.09 -0.17 0.18 
Global 
Connectivity 
0.069 0.45 0.065 0.61 0.012 0.92 -0.11 0.41 0.21 0.08 
Eglobal 0.038 0.67 0.049 0.70 0.013 0.91 -0.16 0.22 0.20 0.10 
 
 
Table S13. Correlation between network topological attributes and CSF measure Tau taking all 
data sample and dividing groups into Converts and non-Converters and APOE4+, APOE4-. The 

































-0.06 0.51 -0.08 0.52 0.12 0.37 -0.11 0.39 -0.14 0.25 
Clux -0.005 0.95 0.05 0.66 0.02 0.87 -0.02 0.88 -0.037 0.76 
CharPathL 
Normalized 
-0.05 0.56 -0.06 0.63 0.15 0.26 -0.05 0.72 -0.10 0.40 
CharPathL -0.03 0.72 -0.08 0.54 0.10 0.42 -0.005 0.96 -0.06 0.60 
Global 
Connectivity 
0.005 0.95 0.07 0.57 -0.04 0.76 -0.029 0.83 0.01 0.93 
Eglobal 0.017 0.84 0.07 0.54 -0.07 0.60 -0.015 0.91 0.03 0.78 
 
  
Table S14. Correlation between network topological attributes and CSF measure pTau taking all 
data sample and dividing groups into Converts and non-Converters and APOE4+, APOE4-. The 
































-0.04 0.63 -0.08 0.50 0.16 0.22 -0.13 0.34 -0.11 0.361 
Clux -0.01 0.89 0.03 0.81 0.027 0.83 -0.02 0.88 -0.045 0.72 
CharPathL 
Normalized 
-0.04 0.61 -0.06 0.60 0.17 0.20 -0.07 0.58 -0.077 0.54 
CharPathL -0.02 0.82 -0.06 0.61 0.12 0.37 -0.026 0.85 -0.034 0.78 
Global 
Connectivity 
-0.007 0.93 0.04 0.71 -0.04 0.73 -0.02 0.88 -0.012 0.92 
Eglobal 0.004 0.96 0.05 0.65 -0.07 0.56 -0.0009 0.99 0.0076 0.95 
 
 
Table S15. Statistical differences APOE4+ vs. APOE4- and Converters (Conv) vs. non-Converters 
(non-Conv) in the linear correlation between topological network attributes and MMSE. The 
topological network attributes are: Clustering index normalized (Clux Normalized), Clustering 
index (Clux), Characteristic path length Normalized (CharPathL Normalized), Global 



























0.095 0.007 0.607 0.54 0.094 0.15 -0.457 0.64 
Clux 0.189 -0.05 1.67 0.09 0.040 0.21 -1.243 0.21 
CharPathL 
Normalized 
0.068 0.105 -0.25 0.79 0.15 0.14 0.101 0.91 
CharPathL -0.11 0.095 -1.46 0.14 0.05 -0.02 0.559 0.57 
Global 
Connectivity 
0.20 -0.08 2.01 0.04 0.005 0.15 -1.033 0.30 
Eglobal 0.17 -0.09 1.84 0.065 -0.022 0.10 -0.856 0.39 
Legend: Conv. Corr : Converters group partial correlation coefficient;  non-Conv. Corr: non-Converters group partial correlation 
coefficient; Z-Stats (Conv. vs. non-Conv.): Z-stats Converters vs. non-Converters correlation coefficients; p (Conv. vs. non-
Conv.): p-value of the Z-stats Converters vs. non-Converters; APOE4+ Corr. : APOE4+ group partial correlation coefficient; 
APOE4- Corr. : APOE4- group partial correlation coefficient; Z-Stats (APOE4+ vs. APOE4-) Z-stats APOE4+ vs. APOE4- 
correlation coefficients; p (APOE4+ vs. APOE4-) p-value of the Z-Stats (APOE4+ vs. APOE4-). 
  
Table S16. Statistical differences APOE4+ vs. APOE4- and Converters (Conv) vs. non-Converters 
(non-Conv) in the linear correlation between topological network attributes and ADNI-MEM. The 
topological network attributes are: Clustering index normalized (Clux Normalized), Clustering 
index (Clux), Characteristic path length Normalized (CharPathL Normalized), Global 




























0.071 0.09 -0.143 0.88 0.22 0.23 -0.08 0.93 
Clux 0.25 0.12 0.88 0.37 0.14 0.39 -1.85 0.063 
CharPathL 
Normalized 
0.072 0.17 -0.71 0.47 0.29 0.23 0.48 0.63 
CharPathL -0.14 0.07 -1.49 0.13 0.12 -0.06 1.25 0.20 
Global 
Connectivity 
0.24 0.04 1.43 0.15 0.039 0.29 -1.76 0.078 
Eglobal 0.20 -0.007 1.51 0.12 -0.028 0.199 -1.58 0.11 
Legend: Conv. Corr : Converters group partial correlation coefficient;  non-Conv. Corr: non-Converters group partial correlation 
coefficient; Z-Stats (Conv. vs. non-Conv.): Z-stats Converters vs. non-Converters correlation coefficients; p (Conv. vs. non-
Conv.): p-value of the Z-stats Converters vs. non-Converters; APOE4+ Corr. : APOE4+ group partial correlation coefficient; 
APOE4- Corr. : APOE4- group partial correlation coefficient; Z-Stats (APOE4+ vs. APOE4-) Z-stats APOE4+ vs. APOE4- 
correlation coefficients; p (APOE4+ vs. APOE4-) p-value of the Z-Stats (APOE4+ vs. APOE4-). 
 
Table S17. Statistical differences APOE4+ vs. APOE4- and Converters (Conv) vs. non-Converters 
(non-Conv) in the linear correlation between topological network attributes and CSF measure 
Aβ42. The topological network attributes are: Clustering index normalized (Clux Normalized), 
Clustering index (Clux), Characteristic path length Normalized (CharPathL Normalized), Global 



























-0.05 0.035 -0.47 0.63 0.25 0.006 1.34 0.17 
Clux -0.03 0.053 -0.45 0.65 -0.03 0.158 -1.02 0.30 
CharPathL 
Normalized 
-0.009 0.033 -0.22 0.81 0.28 -0.039 1.76 0.078 
CharPathL -0.014 -0.02 0.057 0.95 0.229 -0.171 2.15 0.03 
Global 
Connectivity 
0.012 0.06 -0.28 0.77 -0.11 0.216 -1.77 0.07 
Eglobal 0.013 0.04 -0.18 0.85 -0.16 0.20 -2.00 0.044 
Legend: Conv. Corr : Converters group partial correlation coefficient;  non-Conv. Corr: non-Converters group partial correlation 
coefficient; Z-Stats (Conv. vs. non-Conv.): Z-stats Converters vs. non-Converters correlation coefficients; p (Conv. vs. non-
Conv.): p-value of the Z-stats Converters vs. non-Converters; APOE4+ Corr. : APOE4+ group partial correlation coefficient; 
APOE4- Corr. : APOE4- group partial correlation coefficient; Z-Stats (APOE4+ vs. APOE4-) Z-stats APOE4+ vs. APOE4- 
correlation coefficients; p (APOE4+ vs. APOE4-) p-value of the Z-Stats (APOE4+ vs. APOE4-). 
 
Table S18. Statistical differences APOE4+ vs. APOE4- and Converters (Conv) vs. non-Converters 
(non-Conv) in the linear correlation between topological network attributes and CSF measure T-
tau. The topological network attributes are: Clustering index normalized (Clux Normalized), 
Clustering index (Clux), Characteristic path length Normalized (CharPathL Normalized), Global 



























0.12 -0.08 1.09 0.27 -0.11 -0.14 0.14 0.88 
Clux 0.02 0.05 -0.18 0.85 -0.02 -0.037 0.09 0.92 
CharPathL 
Normalized 
0.15 -0.06 1.15 0.24 -0.05 -0.10 0.30 0.75 
CharPathL 0.10 -0.08 1.006 0.31 -0.005 -0.066 0.32 0.74 
Global 
Connectivity 
-0.041 0.07 -0.61 0.53 -0.029 0.010 -0.21 0.83 
Eglobal -0.07 0.07 -0.79 0.42 -0.015 0.035 -0.27 0.78 
Legend: Conv. Corr : Converters group partial correlation coefficient;  non-Conv. Corr: non-Converters group partial correlation 
coefficient; Z-Stats (Conv. vs. non-Conv.): Z-stats Converters vs. non-Converters correlation coefficients; p (Conv. vs. non-
Conv.): p-value of the Z-stats Converters vs. non-Converters; APOE4+ Corr. : APOE4+ group partial correlation coefficient; 
APOE4- Corr. : APOE4- group partial correlation coefficient; Z-Stats (APOE4+ vs. APOE4-) Z-stats APOE4+ vs. APOE4- 
correlation coefficients; p (APOE4+ vs. APOE4-) p-value of the Z-Stats (APOE4+ vs. APOE4-). 
 
Table S19. Statistical differences APOE4+ vs. APOE4- and Converters (Conv) vs. non-Converters 
(non-Conv) in the linear correlation between topological network attributes and CSF measure P-
tau. The topological network attributes are: Clustering index normalized (Clux Normalized), 
Clustering index (Clux), Characteristic path length Normalized (CharPathL Normalized), Global 





























0.16 -0.087 1.34 0.178 -0.13 -0.11 -0.07 0.93 
Clux 0.027 0.030 -0.01 0.99 -0.02 -0.04 0.13 0.89 
CharPathL 
Normalized 
0.17 -0.067 1.29 0.19 -0.07 -0.07 0.004 0.99 
CharPathL 0.12 -0.066 1.003 0.31 -0.02 -0.03 0.04 0.96 
Global 
Connectivity 
-0.04 0.048 -0.50 0.61 -0.02 -0.01 -0.04 0.96 
Eglobal -0.07 0.058 -0.73 0.46 -0.00091 0.007 -0.04 0.96 
Legend: Conv. Corr : Converters group partial correlation coefficient;  non-Conv. Corr: non-Converters group partial correlation 
coefficient; Z-Stats (Conv. vs. non-Conv.): Z-stats Converters vs. non-Converters correlation coefficients; p (Conv. vs. non-
Conv.): p-value of the Z-stats Converters vs. non-Converters; APOE4+ Corr. : APOE4+ group partial correlation coefficient; 
APOE4- Corr. : APOE4- group partial correlation coefficient; Z-Stats (APOE4+ vs. APOE4-) Z-stats APOE4+ vs. APOE4- 
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A B S T R A C T
There is growing support that cerebrovascular reactivity (CVR) in response to a vasodilatory challenge, also
defined as the cerebrovascular reserve, is reduced in Alzheimer's disease dementia. However, this is less clear in
patients with mild cognitive impairment (MCI). The current standard analysis may not reflect subtle
abnormalities in CVR. In this study, we aimed to investigate vasodilatory-induced changes in the topology of
the cerebral blood flow correlation (CBFcorr) network to study possible network-related CVR abnormalities in
MCI. For this purpose, four CBFcorr networks were constructed: two using CBF SPECT data at baseline and under
the vasodilatory challenge of acetazolamide (ACZ), obtained from a group of 26 MCI patients; and two
equivalent networks from a group of 26 matched cognitively normal controls. The mean strength of association
(SA) and clustering coefficient (C) were used to evaluate ACZ-induced changes on the topology of CBFcorr
networks. We found that cognitively normal adults and MCI patients show different patterns of C and SA
changes. The observed differences included the medial prefrontal cortices and inferior parietal lobe, which
represent areas involved in MCI's cognitive dysfunction. In contrast, no substantial differences were detected by
standard CVR analysis. These results suggest that graph theoretical analysis of ACZ-induced changes in the
topology of the CBFcorr networks allows the identification of subtle network-related CVR alterations in MCI,
which couldn't be detected by the standard approach.
1. Introduction
There is increasing evidence that patients with Alzheimer's disease
(AD) dementia have decreased cerebrovascular reactivity (CVR) in
response to a vasodilatory challenge, also defined as the cerebrovas-
cular reserve (Glodzik et al., 2013, for a review). However, this is less
clear in patients during the prodromal mild cognitive impairment (MCI)
stage of AD. Some studies show a decrease (Richiardi et al., 2014;
Glodzik et al., 2011; Cantin et al., 2011; Zavoreo et al., 2010), while
others do not (Shim et al., 2015; Fromm et al., 2013; Anzola et al.,
2011). This issue is becoming important in AD research because it could
have implications for early diagnosis and treatment of AD. Early CVR
abnormalities, especially at the microvascular level, affect the neuro-
vascular coupling and consequently the neural activation (Pillai and
Mikulis, 2015), which in turn alters the brain's functional integrity
(Iadecola, 2004).
MCI due to AD is the transition from normal cognition to dementia
(Albert et al., 2011). Accordingly, CVR abnormalities would be subtle
or borderline which may partly explain ambiguous findings, particu-
larly in MCI patients with a low vascular burden. Furthermore,
considering the complexity of the cerebral microvasculature network
the standard analysis of CVR might not reflect subtle network-related
alterations since it relies on the analysis of individual regions (or the
whole brain) rather than on the interaction between them.
Recently, graph theoretical analysis of large-scale structural MRI
(sMRI) correlation networks has shown its potential to reveal subtle
network-related pathological processes in MCI (Tijms et al., 2013; He
et al., 2009a, for reviews). We previously demonstrated that the
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cerebral blood flow correlation (CBFcorr) network, based on CBF SPECT
data, shows a non-random topological organization (Melie-García et al.,
2013). The same topological organization had been previously observed
in sMRI correlation (Alexander-Bloch et al., 2013, for a review) and
fiber tractography networks (Iturria-Medina et al., 2008). Therefore, we
speculate that graph theoretical analysis can also be applied to CBF
SPECT data to detect possible subtle network-related CVR abnormal-
ities in MCI.
Here, we constructed four CBFcorr networks: two using CBF SPECT
data at baseline and under the vasodilatory challenge of acetazolamide
(ACZ), obtained from a group of relatively young MCI patients with
limited vascular risk factors; and two equivalent networks using a group
of matched cognitive normal controls. ACZ is a reproducible, simple,
and a safe vasodilatory stimulus (Vagal et al., 2009, for a review).
Graph metrics based on the concepts of the mean strength of
association (SA) (Bullmore and Bassett, 2011) and clustering coefficient
(C) (Watts and Strogatz, 1998) were used to evaluate ACZ-induced
changes on the topology of the CBFcorr networks. The SA for a particular
brain region (node) measures the correlation's mean (co-variation's
mean) with the rest of the network; while Cmeasures local connectivity
(i.e. how well neighbors of a node are connected).
Hence, using graph theoretical analysis, our aim was to investigate
ACZ-induced changes in the topology of the CBFcorr network to study
possible network-related CVR abnormalities in MCI. We also investi-
gated CVR by the standard approach in the same groups of subjects for
comparing with graph theoretical analysis findings.
2. Methods
2.1. Subjects
Twenty-six MCI patients and twenty-six clinically healthy control
volunteers were studied, selected from one hundred subjects recruited
over a two-year period and a one-year follow-up and based on the
inclusion and exclusion criteria detailed below. The Ethics Committee
of the Center for Neurological Restoration of Havana, Cuba, approved
the study. All participating subjects gave written informed consent
according to the Helsinki Declaration. Table 1 summarizes sociodemo-
graphic and clinical characteristics of the MCI and control groups.
All subjects were screened for a complete medical history, routine
blood tests, cranial MRI, neuropsychological testing and neurological/
psychiatric examinations. Subjects were clinically diagnosed as MCI
using the criteria based on the Clinical Dementia Rating Scale (CDR)
(Morris, 1993). According to these criteria, subjects were classified as
MCI with CDR = 0.5; while normal cognitive subjects with CDR = 0.
All of MCI subjects maintained independence in their daily living. In
addition to the Mini-Mental State Examination (MMSE), specific
mnemonic and non-mnemonic cognitive tests were also performed for
all subjects to further characterize cognitive function (Supplementary
Table S1).
The inclusion criteria were: 1) MCI patients with memory com-
plaints as the main cognitive symptom, which worsened over a period
of one year; 2) subjects (patients and controls) with limited (and
treated) vascular risk factors, based upon clinical examination, blood
tests and magnetic resonance angiography (MRA) findings; 3) subjects
without significant depression, according to the Hamilton Depression
Scale (score < 8) (Hamilton, 1960); 4) no prior or current treatment
with anti-acetylcholinesterase agents; and 5) right-handedness.
The exclusion criteria were: 1) significant medical problems (i.e.
serious cardiac disease, poorly controlled diabetes or hypertension;
severe inflammatory, thyroid, renal, hepatic or other chronic diseases);
2) cerebrovascular disorders (i.e. transient ischemic attack or cerebral
infarction), moderate and severe carotid stenosis by MRA findings,
large white matter changes on MRI (based on T2 and FLAIR sequences),
hydrocephalus or intracranial mass; 3) history of traumatic brain
injury, migraine or another neurological disease; and 4) psychiatric
disorder, substance abuse or dependence.
2.2. CBF SPECT imaging under the acetazolamide challenge
CBF SPECT imaging was carried out by a double-head rectangular
gamma camera (Sopha Medical Vision, France) equipped with ultra-
high-resolution fan beam collimators. More about the acquisition and
reconstruction parameters, including corrections for attenuation and
partial volume effect (PVE) due to atrophy, are described in our
preceding article (Melie-García et al., 2013). A two-day protocol was
used for CBF SPECT imaging at baseline (basal SPECT) and under the
ACZ challenge (ACZ SPECT).
Absolute measurement is necessary to quantify (optimally) the CBF
response to the vasodilatory stimulus (Boles Ponto et al., 2004).
Therefore, global CBF at basal condition (gCBFBasal) and under ACZ
(gCBFACZ) was determined in absolute units (mL/min/100 g) by
spectral analysis of non-invasive radionuclide angiographies
(Takasawa et al., 2002). The radionuclide angiography was performed
before SPECT acquisition, for both basal and ACZ conditions. Briefly, a
radionuclide angiography of the head and chest was performed after
injection of 555 MBq of technetium-99-ethyl cysteinate dimer (ECD)
into the antecubital vein of the right arm under resting condition
(supine, eyes open, dimly lit quiet room) to estimate gCBFBasal. The
same procedure was repeated to estimate gCBFACZ but 20 min after
slow intravenous injection of 1 g of ACZ. Heart rate and arterial
pressure were measured at the time of the two injections of the tracer
(basal and ACZ).
Basal and ACZ SPECT images were then converted to basal and ACZ
quantitative CBF images using gCBFBasal and gCBFACZ, respectively, by
application of Lassen's linearization algorithm (Lassen et al., 1988). For
subsequent voxelwise statistical analysis, basal and ACZ quantitative
CBF images were normalized to the Montreal Neurological Institute
(MNI) space. The image normalization was performed by applying
DARTEL parameters (based on a fast diffeomorphic algorithm) obtained
from MRI preprocessing (see the next subsection). Normalized images
were then smoothed using a 14 mm-kernel to optimize sensitivity (Van
Laere et al., 2002).
2.3. Volumetric MRI
Volumetric high-resolution MRI was also performed to characterize
the MCI group regarding regional brain atrophy. Regional atrophy,
particularly hippocampal, is a biomarker of neuronal injury of MCI due
to AD (Albert et al., 2011; Sánchez-Catasús et al., 2017). Volumetric
MRI also had two other functions: to correct for PVE in CBF SPECT
images and to estimate spatial transformations that were used to
normalize images to MNI space, as described above.
MRI acquisition was performed using a 1.5 Tesla Symphony scanner
(Siemens, Erlangen, Germany). The acquisition protocol for volumetric
MRI is described in details in our previous study (Melie-García et al.,
Table 1
Sociodemographic and clinical features of control and MCI groups.
Control (N = 26) MCI (N = 26) p-value
Age (years) 60.9 ± 7.3 64.7 ± 6.9 0.06a
Gender (female/male) 13/13 14/12 0.78b
Education (years) 13.6 ± 3.9 11.8 ± 4.6 0.13a
MMSE 29.3 ± 1.1 26.9 ± 1.24 10−6a
Hypertension 27% 35% 0.55b
Hyperlipidemia 19% 23% 0.73b
Diabetes 15% 15% 1b
Smoking 27% 19% 0.51b
Data shown as mean ± SD or percent of subjects.
a Student t-tests for independent samples.
b Chi-square test.
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2013). The preprocessing steps were as follows: images were segmented
into GM and WM; imported into the DARTEL toolbox and normalized to
MNI space to generate warped and smoothed (12 mm-kernel) Jacobian
modulated GM and WM images. GM/WM modulated images represent
GM/WM volume images (GMV/WMV images). Global tissue volumes
were estimated in the native space using the Voxel-Based Morphometry
toolbox (VBM8: http://dbm.neuro.uni-jena.de/vbm8/).
For every subject, neurological/psychiatric/neuropsychological ex-
aminations, as well as SPECT and MRI, were carried out within a
maximum interval of one month.
2.4. Construction of the CBF correlation (CBFcorr) network
For each group of subjects (MCI and control) in each condition
(baseline and ACZ challenge), a CBFcorr network was constructed as a
CBF correlation matrix (Melie-García et al., 2013). In short, 90 ROIs
were defined using the AAL atlas (Tzourio-Mazoyer et al., 2002) and
Pearson's correlation coefficients were calculated (across subjects)
between all possible pairs of ROIs. Hence, the interregional correlation
matrix (90 × 90 ROIs) was obtained gathering together all correlation
coefficients. Self-correlations were excluded, implying a diagonal of
zeros in the symmetric matrix. Prior to the correlation analysis, a linear
regression was performed at every ROI to remove the effects of age,
gender, age–gender interaction, and global CBF values. For computing
the CBF correlation matrix, the correlation was carried out between the
residuals of this regression instead of the raw regional CBF values.
Fig. 1 shows CBF correlation matrices for each group in each condition.
For within-conditions and within-groups network metrics compar-
isons (see Sub-section 2.6.2), we obtained 1000 bootstrap samples (with
replacement) of each CBF correlation matrix. Paired bootstrap samples
were used for baseline and the ACZ challenge in each group.
2.5. Network metrics
In the following, we define SA (the mean strength of association)
(Bullmore and Bassett, 2011) and C (the clustering coefficient) (Watts
and Strogatz, 1998) to study ACZ-induced changes in the CBF correla-
tion networks.
The SA for a particular brain region or node i, SAnodal (i), is defined
as the mean of the absolute value of Pearson's correlation coefficients
(Corrij) of node i with the rest N-1 nodes in the network. Formally,
SAnodal (i) is calculated as:
∑SA i
N







where N is the number of nodes (ROIs).
In simple terms, SAnodal measures the correlation's mean (co-
variation's mean) of a node with the rest of the network. SA is also
defined at the network level (SAglobal) as the average of SAnodal:
Fig. 1. CBF correlation matrices (CBF correlation networks) constructed using CBF SPECT data at basal and under the acetazolamide (ACZ) challenge for MCI and cognitively normal
controls. The color bar indicates the value of the correlation coefficient coming from the CBF co-variations among 90 anatomical brain regions (AAL atlas). For the sake of clarity brain
regions of the right (R) and left (L) hemispheres were separated.









On the other hand, C is a measure of the tendency to cluster nodes
into strictly connected neighborhoods (a measure of network segrega-
tion; i.e. local connectivity). Nodes are considered neighbors when a
connection between them exists, which is not limited to a physical
neighborhood concept. Cnodal (i), for a binary and undirected graph G, is
the number of existing connections between the neighbors of node i
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where ti is the number of triangles around node i (see below); and ki is
the degree of node i (number of links connected to node i); (for ki < 2,
Cnodal (i) = 0).
∑t a a a= 1
2i j h G
ij ih jh
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where aij is the connection status between i and j: aij = 1 when link (i, j)
exists (when i and j are neighbors); aij = 0 otherwise (aii = 0 for all i).
In simple terms, Cnodal measures how well neighbors of a node are









For each CBF correlation matrix, SAnodal and SAglobal were calculated
over the bootstrap samples. Since we used C defined for a binary
(undirected) graph, Cnodal and Cglobal were calculated over bootstrap
samples of thresholded binary adjacency matrices. Rather than restrict-
ing the analysis to a binary graph obtained by applying a single
threshold value, Cnodal and Cglobal were calculated over a range of
thresholds or ‘sparsity degree’ values. A sparsity degree of 0.9 means
that 90% of the correlation matrix is discarded; consequently, only the
highest 10% of the values is taken into account. Sparsity degrees
ranging from 0.5 to 0.9 (in steps of 0.02) were used, yielding a set of 21
values. This procedure normalizes the networks to have the same
number of nodes and edges, enabling the examination of Cnodal and
Cglobal. The range of sparsity degree was chosen to allow for these
network properties to be estimated and the number of spurious edges in
each network minimized as indicated in previous studies (Achard and
Bullmore, 2007; He et al., 2007; Sanabria-Diaz et al., 2013).
Before calculating Cnodal (as described above), the largest connected
component (see Achard et al., 2006) of all bootstrap samples of CBF
correlation matrices was computed. The minimum sparsity degree for
the largest connected component (equal to the number of AAL nodes)
was used as the upper limit of the sparsity degree range. This step
guarantees that all Cnodal values come from fully connected CBFcorr
networks. Then, the Cnodal mean curve (across the range of sparsity
degree) was assessed over the bootstrap samples for every node and
used as the Cnodal descriptor.
On the other hand, the descriptor used for Cglobal was the area under
the curve (AUC) extracted from thresholding across the range of
sparsity degree over bootstrap samples for each group and condition.
Since the topology of the Cglobal curve is monotonic with the sparsity
degree, the AUC is a suitable descriptor for characterizing its global
performance. This descriptor was also adopted in previous studies
(Sanabria-Diaz et al., 2013; Wu et al., 2012; He et al., 2009b).
Construction of CBFcorr networks and computation of network
metrics was performed using the MorphoConnect toolbox (Melie-
García et al., 2010) and subroutines of the Brain Connectivity toolbox
(https://sites.google.com/site/bctnet/).
2.6. Statistical analysis
2.6.1. Changes in standard metrics
The data at the voxel level was analyzed by a 2 (group: Control and
MCI) × 2 (condition: basal and ACZ) full factorial design as implemen-
ted in the SPM8 toolbox. Age and gender were modeled as nuisance
covariates. The global effect was also controlled using proportional
scaling.
We examined simple main effects of condition (positive and
negative) in each group by t-contrasts for dependent samples; and
simple main effects of group (positive and negative) in each condition
by t-contrasts for independent samples. We also studied the interaction
of group and condition (positive and negative).
A similar treatment (2 × 2 design) was also performed for global
CBF values, controlling for age and gender.
As a supplementary morphometric analysis, differences at the voxel
level between groups for GMV and WMV images were tested to evaluate
regional brain atrophy in the MCI group. Comparisons were performed
using the Student t-tests for independent samples through the SPM8
toolbox. The GMV and WMV images were masked using an absolute
threshold of 0.25 to avoid as much as possible contamination by
misclassified voxels. Age, gender, and total intracranial volume were
controlled.
In all SPM analyses, the statistical threshold of p = 0.01 (peak level)
was used. The extent threshold used was determined by the cluster of
voxels significant at p = 0.05 (cluster level), corrected for multiple
comparisons (family-wise error method - FWE) and after correction of
non-isotropic smoothness. Anatomical regions were determined by
comparing voxel and cluster location with the AAL atlas (Tzourio-
Mazoyer et al., 2002). The most significant voxels were reported in MNI
coordinates.
2.6.2. Changes in network metrics
Similar to the standard analysis, C and SA (global and nodal) were
analyzed by a 2 × 2 design. To examine simple main effects of the
condition in each group for each network metric (or simple main effects
of the group in each condition), we computed the difference between
the two conditions (or between the two groups) for the corresponding
bootstrap samples. Then, we constructed the bootstrap distribution of
the difference and computed the 95% BC (bias-corrected) bootstrap
confidence interval (CI). A significant difference between conditions (or
between groups) was considered when the CI did not contain the zero.
For Cnodal and SAnodal, we also corrected for multiple comparisons by
Bonferroni adjustment.
Likewise, we studied the interaction of group and condition (global
and nodal) by comparing simple main effects of condition between
groups following the same procedure as described in the previous
paragraph. For instance, the differences between conditions in control
and MCI groups were subtracted and the 95% BC bootstrap CI was
calculated for the subtraction. As before, if CI did not contain the zero,
the interaction effect was considered statistically significant. Due to the
exploratory nature of this study, we also examined the interaction for
uncorrected values at the nodal level.
The network statistical analyses were performed using the
MorphoConnect toolbox (Melie-García et al., 2010), while global CBF
data was analyzed using STATISTICA software (Stat Soft, Inc., version
8.0). The significance level was set at p < 0.05.
3. Results
The administration of ACZ was well tolerated in all individuals.
There were no significant differences between conditions (basal vs.
ACZ) in both groups in heart rate (Control: 68.2 ± 9.9 vs.
67.2 ± 9.4 bpm, respectively, p = 0.6, paired t-test; MCI:
70.4 ± 9.4 vs. 67.4 ± 7.1 bpm, respectively, p = 0.09) and mean
arterial pressure (Control: 106.9 ± 10.8 vs. 106.5 ± 9.9 mm Hg,
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respectively, p = 0.8; MCI: 102. 8 ± 10.9 vs. 105.9 ± 10.8 mm Hg,
respectively, p = 0.1).
3.1. Changes in standard metrics
At the global level, there was a significant increase in gCBFACZ as
compared with gCBFBasal in both groups (Control: 42.0 ± 5.5 vs.
54.9 ± 6.3 mL/min/100 g; p < 10−6; MCI: 38.9 ± 6.7 vs.
51.1 ± 7.3 mL/min/100 g; p < 10−6) (Supplementary Fig. S1). The
percent of the increase in the control group (+31.4 ± 9.2) was
comparable to that found in the MCI group (+32.7 ± 12.9). There
were no significant differences between groups in the basal (p = 0.21)
and ACZ conditions (p = 0.07). No significant interaction of group and
condition was found (p = 0.75).
At the voxel level, the analysis of differences between condition
within-group showed a similar pattern in the control and MCI groups.
Both groups showed significant regional CBF increases mainly in frontal
regions bilaterally, after removal of the effect of global CBF increase
due to ACZ (Fig. 2.A and B, Supplementary Table S2). In the control
group, the voxel with the lowest p-value was found in the right superior
frontal gyrus (medial part) (MNI: x, y, z = 15, 56, 31; PFWE = 10−3,
T = 6.21). In the MCI group, the right superior frontal gyrus (dorso-
lateral part) was the voxel with the lowest p-value (MNI: x, y, z = 15,
35, 55; PFWE = 10−3, T = 6.18). Neither group showed a significant
regional decrease.
On the other hand, the group difference within-condition showed a
regional CBF decrease in the MCI group as compared to the control
group in the basal condition, mostly in temporoparietal regions
bilaterally (Fig. 2.C, Supplementary Table S3). In the right angular
gyrus was the voxel with the lowest p-value (MNI: x, y, z = 45, −70,
34; PFWE = 0.05, T = 4.52). At the ACZ condition, the results were
relatively similar to those observed in basal condition, although less
extensive and the right temporoparietal region showed no difference as
compared to the control group (Fig. 2.D, Supplementary Table S3). In
Fig. 2. CBF changes at the voxel level analyzed by a 2 (group: Control and MCI) × 2 (condition: basal and ACZ) full factorial design using statistical parametric mapping (SPM). Figures A
and B show that the control and MCI groups had a similar regional pattern of CBF increase in frontal lobe bilaterally. Figures C and D show that the regional differences between groups
were relatively similar in the two conditions, although less extensive in the ACZ condition. No interaction of the group by the condition was found.
SPM t-maps are visualized onto the cortical surfaces using the BrainNet Viewer package (http://www.nitrc.org/projects/bnv).
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the left angular gyrus was the voxel with the lowest p-value (MNI: x, y,
z = −45, 61, 37; PFWE = 0.004, T = 5.17). In the basal and ACZ
conditions in the MCI group, as compared to the control group, also no
significant regional CBF increases were found. No significant interac-
tion of group and condition were observed neither positive nor
negative.
3.2. Changes in network metrics
At the global level, the control group showed no significant changes
of Cglobal and SAglobal (no changes of CBF co-variation) in response to the
ACZ challenge. In contrast to the control, the MCI group showed a
decrease in Cgloblal and SAglobal (Fig. 3 and Table 2; see also Supplemen-
tary Fig. S2).
Moreover, SAglobal was higher in the MCI group as compared to the
control in the basal condition (Fig. 3 and Table 2). Although not
significant, a similar difference for Cgloblal in the MCI group was found
(Fig. 3 and Supplementary Fig. S2). At the ACZ condition, no significant
differences were observed for Cglobal and SAglobal between the MCI and
control groups (Fig. 3 and Table 2; see also Supplementary Fig. S2).
However, unlike the standard analysis, we found a significant crossover
interaction effect of group and condition for SAglobal (Table 2). Thus,
compared to the control group, the MCI group showed a specific
decrease in SAglobal induced by the ACZ challenge. For Cglobal, a similar
interaction was observed although did not reach significance (Supple-
mentary Fig. S2).
At the nodal level, the control group showed no significant change
in Cnodal in response to ACZ after multiple comparisons correction (4.A
and 4.B); while SAnodal showed an increase in the right inferior temporal
gyrus (Fig. 4.C) and decreases in the frontal superior and middle
temporal pole on the left side (Fig. 4.D). In contrast to the control, the
MCI group showed decreases in Cnodal in the hippocampus and the
fusiform gyrus on the right side and in the dorsal medial prefrontal
cortex on the left side (Fig. 4.E and F). In this group, SAnodal increased in
the postcentral gyrus (Fig. 4.G) and decreased in the superior frontal,
middle frontal, lingual and fusiform gyri on the right side, and in the
left middle occipital gyrus (Fig. 4.H).
On the other hand, the group difference within-conditions showed
that in the MCI group, in the basal condition, Cnodal was increased in the
inferior parietal lobe bilaterally and in lingual and fusiform gyri on the
right side (Fig. 5.A and B); whereas SAnodal was increased in the lingual
gyrus bilaterally and in the right inferior temporal and left middle
occipital gyri (Fig. 5.C and D). At the ACZ condition, both groups
showed no significant changes in both Cnodal and SAnodal (Fig. 5.E–H).
However, similar to global network metrics, there was a significant
crossover interaction effect of group and condition for both Cnodal and
SAnodal (Fig. 6). Compared to the control group, the MCI group showed
a specific decrease in Cnodal induced by the ACZ in the lingual, fusiform
and superior temporal gyri on the right side after multiple comparisons
correction (Fig. 6.A); and a specific decrease in SAnodal in the middle
frontal region and in the lingual, fusiform and inferior temporal gyri on
the right side and in the left thalamus (Fig. 6.C).
When the interaction effects described above were examined less
conservatively (uncorrected statistic), we found that the MCI group
showed a specific decrease in Cnodal mainly in regions comprising the
inferior parietal lobe and medial prefrontal cortex bilaterally, the
parahippocampal gyrus and the lateral temporal cortex on the right
side (Fig. 6.E and F). Both thalamus also showed a decrease in Cnodal.
Moreover, a specific increase in Cnodal was found mainly in frontal and
occipital regions on the right side, and in the anterior and posterior
cingulate on the left side. Likewise, SAnodal showed concurrent changes
in Cnodal (increase or decrease) in several regions as shown in the
Fig. 6.E–H. An opposite change in Cnodal and SAnodal was also observed
in the right middle frontal region (Fig. 6.E and G).
3.3. Supplementary morphometric analysis
Regional GMV was decreased significantly in the lateral and medial
temporal regions (including hippocampi) in the MCI group compared
with the control group (Supplementary Fig. S3 and Supplementary
Table S4). In contrast to GMV, no significant differences were observed
between groups in WMV.
4. Discussion
This study investigated ACZ-induced changes in the topology of the
CBFcorr networks in normal cognition and MCI subjects. We found that
normal cognition and MCI show different patterns of C and SA changes,
Fig. 3. Global clustering coefficient (Cgloblal) and mean strength of association (SAglobal) in the control and MCI groups in the two condition: basal and under the ACZ challenge. The data
were generated by bootstrapping the CBF correlation matrices (1000 samples per group and condition). Comparisons were performed by estimating 95% bootstrap confident intervals
(see main text for details). *Significant effect.
Table 2
Simple main effects and interactions of group and condition at the global level.
Effect Mean (95% CI) - Cglobal Mean (95% CI) - SAglobal
ACZ vs. basal
(Control)
0.12 (−0.90 –+0.63) 0.00004 (−0.02 – +0.009)
ACZ vs. basal (MCI) −0.68 (−1.44 – −0.97)a −0.026 (−0.04 – −0.01)a
Control vs. MCI
(basal)
−0.56 (−1.28 – +0.16) −0.019 (−0.03 – −0.003)a
Control vs. MCI
(ACZ)
0.24 (−0.61 –+0.84) 0.007 (−0.02 –+0.02)
Interaction 0.79 (−0.14 –+1.75) 0.03 (+0.0006 –+0.04)a
ACZ, acetazolamide; CI, confident interval.
a Significant effect.
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while the standard approach did not detect substantial differences.
Thus, our findings support the concept that multivariate measures (i.e.
co-variations) combined with a graph theoretical approach are more
sensitive to identify complex pathological processes, as has found in
other brain diseases (Bassett et al., 2012; He et al., 2009b). Univariate
measures derived from the standard approach could be insufficient for
capturing subtle (early) abnormal changes.
4.1. CBF imaging under the ACZ challenge
The global CBF increase in both groups verifies the reliability of the
methodology used for CBF imaging under the ACZ challenge. The
percent of the increase in the two groups was comparable to previous
studies in healthy subjects using a similar methodology (Boles Ponto
et al., 2004, for a review).
An interesting observation is the highest regional CBF increase in
response to ACZ in frontal cortices in both groups (Fig. 2.A and B). As
far as we know, this has not been previously reported. The highest
frontal CBF is possibly caused by greater oxygen metabolism in these
regions before ACZ administration. This explanation is substantiated by
the fact that the neuronal activity is high in frontal regions during the
resting state (Ingvar, 1979) and there is a direct relationship between
the CBF response to the ACZ and pre-existing oxygen metabolic activity
(Yamauchi et al., 2002).
Moreover, the basal temporoparietal CBF reduction observed in the
MCI group as compared to the control group (Fig. 2.C) is the typical AD-
like hypoperfusion pattern previously described (Herholz et al., 2002).
The group difference in the ACZ condition was also relatively similar to
those observed in the basal condition. Thus, the basal regional CBF
reduction in the MCI group was not misery perfusion since microvessels
responded to the ACZ. The basal hypoperfusion is likely mainly related
to a reduced level of regional metabolic activity (Herholz et al., 2002).
4.2. Patterns of ACZ-induced changes in CBF correlation networks
The control (cognitively normal) group network showed only a little
or almost no topological changes in response to the ACZ challenge
(Figs. 3 and 4.A–D). That is, the control group network seems to have
the capability to adapt to the challenge. Possibly, this reflects the
process to maintain the brain microenvironment homeostasis (Iadecola,
2004), vital for brain function, in response to the vascular challenge
induced by the ACZ (Vagal et al., 2009). In contrast, the MCI group
network showed a decrease in C and SA, especially at the global level
(Fig. 3), suggesting that the above process is possibly altered to some
extent in the MCI stage not detected by the standard analysis. On the
other hand, although speculative, the SAglobal increase in the MCI group
network in the basal condition might represent an adaptive mechanism
in response to the effects of the pathological process.
Perhaps, the most revealing finding is the crossover interaction
effect between group and condition, in particular, when analyzed in a
less conservative way (Fig. 6.E–H). For example, the patterns of Cnodal
and SAnodal decreases (mainly Cnodal, the bottom of Fig. 6.E and F)
partially correspond with the regional CBF reduction in the MCI group
in the basal condition (Fig. 2.C). The overlap increases if the atrophy
found in the MCI group is included (Supplementary Fig. S3), which
suggests that these functional and structural abnormalities could be
related to the ACZ-induced changes observed in the MCI group network
since they are both biomarkers of neuronal injury of MCI due to AD
Fig. 4. Significant differences between condition within-group at the nodal level for the clustering coefficient (Cnodal) and mean strength of association (SAnodal) in the control (A–D) and
MCI groups (E–H).
Regional changes are mapped onto the cortical surfaces using the BrainNet Viewer package (http://www.nitrc.org/projects/bnv).
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(Sánchez-Catasús et al., 2017, for a review).
Interestingly, the patterns of Cnodal decrease (the bottom of Fig. 6.E
and F) also overlap to a certain extent with the default mode network
(DMN), which is very active in the resting state (Hafkemeijer et al.,
2012, for a review). Thus, it is plausible that these patterns could be
related to altered changes in the topology of the DMN's vascular
component, considering that the CBFcorr network was studied in two
resting states: pre-ACZ and under the effect of the ACZ. It is known that
DMN also overlaps the brain network underlying the episodic memory
(Rugg and Vilberg, 2013) that is specifically affected in MCI due to AD
(Albert et al., 2011).
Furthermore, the DMN regions are also targets of the AD process
(Ingelsson et al., 2004; Villain et al., 2012), which may disrupt CBF co-
variation in response to the vasodilatory challenge. The available
evidence suggests that various pathological mechanisms of AD may
contribute to alterations of CVR as a result of damage to the
cerebrovascular system (Glodzik et al., 2013, for a review). Never-
theless, such mechanisms could have less expression in the MCI stage,
especially in patients with a low vascular load. Consequently, subtle
CVR alterations would be difficult to detect by the standard approach,
in agreement with previous studies with negative findings (Shim et al.,
2015; Fromm et al., 2013; Anzola et al., 2011).
Moreover, the Cnodal increase in the MCI group network in the basal
condition (the top of Fig. 5.A and B) also showed a partial correspon-
dence with the Cnodal decrease induced by the ACZ (the bottom of
Fig. 6.E and F). This overlap implies that in these regions Cnodal is
changing from a high basal to a low ACZ value, thus being the regions
with the greatest negative changes. Notably, these regions include the
inferior parietal lobe bilaterally which also overlap with the regional
CBF reduction in the MCI group in the basal condition (Fig. 3.C).
Of interest is also the opposite change of Cnodal (increase) and SAnodal
(decrease) in the right middle frontal region (the top of the Fig. 6.E and
the bottom of the Fig. 6.G, respectively), which partially corresponds
with the regional CBF increase in the MCI group (Fig. 2.B).
As a final point, let us consider some issues regarding our study
population of MCI patients. The criteria for patient selection and the
episodic memory reduction in the MCI group (Supplementary Table S1)
indicate that our patients presented amnestic MCI. Furthermore,
hippocampal atrophy in the MCI group (Supplementary Fig. S3 and
Supplementary Table S4) suggests that most of our patients could
evolve to AD dementia, with an intermediate level of certainty
according to the latest diagnostic criteria for MCI due to AD (Albert
et al., 2011). Still, we cannot exclude the possibility that some of our
MCI patients evolve to another type of degenerative dementia as MCI is
a complex heterogeneous condition.
4.3. Study limitations
First, some results at the nodal level and their interpretations should
be taken with caution since they are based on an uncorrected statistic.
Yet, these findings are meaningful given the partial correspondence
found with the other results in this study using a corrected statistic. In
order to increase the effect size at the nodal level, it may be necessary to
increase the number of subjects and/or to use a more potent vasodilator
stimulus in future studies. Second, our results are only valid at the
group level. However, the present study is a necessary first step for a
further study based on individual level. A recent study demonstrated
that it is possible to estimate the individual contribution of a single
subject to group-based correlation networks and to examine its
association with clinical data (Saggar et al., 2015). A third limitation
Fig. 5. Significant differences between group within-condition at the nodal level for the clustering coefficient (Cnodal) and mean strength of association (SAnodal) in the basal (A–D) and
ACZ conditions (E–H).
Regional changes are mapped onto the cortical surfaces using the BrainNet Viewer package (http://www.nitrc.org/projects/bnv).
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is that this is a cross-sectional study, whereas longitudinal studies are
needed to clarify the temporal evolution of the CBFcorr network along
the continuum from normal aging to AD dementia. Four, graph
theoretical analysis of the CBFcorr network has limitations that were
discussed in our previous article (e.g. the use of Pearson's correlation
instead of partial correlation; choice of parcellation scheme; possible
variability of results with different sample sizes) (Melie-García et al.,
2013). In addition, a recent study showed that the inclusion of global
CBF as a confounding variable introduces artificial negative correla-
tions in networks using resting state fMRI data (Carbonell et al., 2014),
which might also be present in correlation networks using CBF SPECT.
Nevertheless, all of these limitations are attenuated to some extent by
studying the CBFcorr network in two different conditions, i.e. by
analyzing the vasodilatory effect of ACZ after subtracting the effect of
baseline. The vasodilatory effect of ACZ could be considered compara-
tively greater than the effects of the above methodological short-
comings.
4.4. Conclusions
This study suggests that graph theoretical analysis of ACZ-induced
changes in the topology of the CBFcorr networks can detect subtle
network-related CVR alterations in MCI not reflected by the standard
approach. These alterations involve brain regions directly related to
cognitive dysfunction in MCI. Our results also warrant further research
on the individual level to develop a ‘network’-based CVR biomarker of
MCI due to AD.
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The Supplementary Material includes:  
Assessment of cognitive function in MCI and control groups.  
Supplementary Tables S1-S4.   
Supplementary Figures S1-S3.    
  
 
Assessment of cognitive function in MCI and controls groups   
The cognitive function was assessed for each participant by a neuropsychological battery 
comprising mnemonic and nonmnemonic specific tests. Mnemonic tests included Rey Complex 
Figure test (delayed recall) for episodic memory assessment, logical memories A and B 
(immediate recall) and paired associate learning (easy and hard-word pairs, immediate recall) of 
the Wechsler memory scale (WMS). Nonmnemonic tests comprised the copy of the Rey 
Complex Figure test, attentive matrices [1], token test [2], verbal fluency [3], digit span of WMS 
(forward and backward items), and Trail Making A and B tests.  
All mnemonic test scores, except easy-word pair learning, showed significant reduction in the 
MCI group as compared with control group (Supplementary Table I). In contrast, all 









Supplementary Table S1. Cognitive function in MCI and control groups  
 MCI (N=26) Control (N=26) p value 
Mnemonic Tests    
Rey complex fig. (delayed recall) 9.4 ± 4.8  18.1 ± 5.2 10-6 
Logical memory A 9.9 ± 3.5 11.7 ± 3 0.02 
Logical memory B  8.4 ± 3.4 10.2 ± 3.1 0.04 
Easy-word pair learning 8.1 ± 1.3 8.6± 0.7 0.06 
Hard-word pair learning 3 ± 2.4 5.7 ± 2.5 1.7 x 10-5 
Nonmnemonic Tests    
Rey complex fig. (copy) 31 ± 5.5 32.7 ± 4.4 0.16 
Attentive matrices 40.9 ± 10 44. 9 ± 9.7 0.07 
Token test 32.5 ± 3.1 33.5 ± 2 0.07 
Verbal fluency 9.1 ± 3.6 10 ± 2.9 0.18 
Digit span (forward) 5.6 ± 1.2 5.9 ± 1 0.16 
Digit span (backward) 4.5 ± 0.8 4.9 ± 0.9 0.07 
Trail Making A 42.7 ± 7.6 39.4 ± 4.7 0.08 
Trail Making B 117.1 ± 22.2 107.9 ± 14.5 0.08 
Data shown as mean ± S.D. Differences between groups were tested using ANCOVA, modeling 
group as a categorical independent variable and controlling for age, gender and level of 







Supplementary Figure S1.  Global CBF in the control and MCI groups in the two conditions: 
basal and under the acetazolamide (ACZ) challenge. Both groups responded similarly to the 
















Supplementary Table S2. Brain regions with significant CBF increase due to ACZ challenge in 
MCI and control groups.   
Group p-value Extent (voxels) Brain regions 
Control    
 0.002 1457 Right frontal lobe: precentral, superior (medial, 
dorsolateral and orbital), middle (including orbital) and 
inferior (opercular and triangular) gyri; rolandic 
operculum.  Right postcentral and supplementary motor 
area.         
 0.012 1028 Left frontal lobe: precentral, superior (medial and 
dorsolateral) and middle (including orbital) gyri. Left 
supplementary motor area   
MCI    
 10-3 2470 Right frontal lobe: precentral, superior (medial and 
dorsolateral), middle and inferior (triangular) gyri; and 
supplementary motor area.  Right postcentral gyrus. 
Right insula.    
 0.012 1027 Left frontal lobe: precentral, superior (medial and 
dorsolateral) and middle gyri; and supplementary motor 
area.  





Supplementary Table S3. Brain regions with significant CBF decrease in the MCI group as 
compared to the control group at baseline and ACZ conditions.         
Condition p-value Extent (voxels) Brain regions 
Basal    
 0.01 3435 Right temporoparietal cortices. Bilateral 
precuneus and posterior cingulate. Adjacent part 
of right occipital lobe and lateral temporal 
cortex. 
 0.015 851 Left temporoparietal cortices. Adjacent parts of 
left occipital and temporal cortex. Left insula.               
ACZ    
 0.013 1022 Bilateral precuneus and posterior cingulate. Left 
temporoparietal cortices.            













Supplementary Figure S2. Differences in the global clustering coefficient (Cglobal) across the 
range of sparsity degree. In red, the differences, the dashed line indicates the null hypothesis and 






   
Supplementary Figure S3. Brain regions with a significant grey matter volume decrease in the 













Supplementary Table S4. Brain regions with a significant gray matter volume decrease in the 
MCI group as compared to the control group.        
p-value  Extent (voxels) Brain regions 
0.02 1265 Left medial temporal lobe (hippocampus, 
parahippocampal and amygdala).   
0.04  1026 Left lateral temporal lobe (superior, middle and 
inferior gyri) and fusiform gyrus. Left temporal 
pole.  
0.01 1659 Right medial temporal lobe (hippocampus, 
parahippocampal and amygdala). Right lateral 
temporal lobe (superior, middle and inferior 
gyri) and fusiform gyrus. Right temporal pole.      
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